<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/5668914#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Evidence rdf:ID="Evidence170">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence171">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence174">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway140">
 <bp:pathwayOrder rdf:resource="#PathwayStep301" />
 <bp:pathwayOrder rdf:resource="#PathwayStep303" />
 <bp:pathwayOrder rdf:resource="#PathwayStep302" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction163" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction164" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence301" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 causes CMO-1 deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 11B2, mitochondrial (CYP11B2 aka aldosterone hydroxylase) is an enzyme necessary for aldosterone biosynthesis via corticosterone (CORST) and 18-hydroxycorticosterone (18HCORST). Defects in CYP11B2 results in disorders of aldosterone synthesis. Corticosterone methyloxidase 1 and 2 deficiencies (CMO-1; MIM:203400 and CMO-2 deficiency; MIM:61060) are autosomal recessive disorders of aldosterone biosynthesis (Mitsuuchi et al. 1993, Bureik et al. 2002). In CMO-1 deficiency, aldosterone is undetectable in plasma, while its immediate precursor, 18HCORST, is low or normal. In CMO-2 deficiency, aldosterone can be low or normal, but at the expense of increased secretion of 18HCORST. Patients with CMO-2 deficiency have elevated plasma 18-hydroxycorticosterone/aldosterone ratios.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence175">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway141">
 <bp:pathwayOrder rdf:resource="#PathwayStep305" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction165" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence305" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP2U1 causes SPG56</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 2U1 (CYP2U1) catalyses the hydroxylation of arachidonic acid, docosahexaenoic acid and other long chain fatty acids, generating bioactive eicosanoid derivatives which may play an important physiological role in fatty acid signaling processes. Defects in CYP2U1 can cause Spastic paraplegia 56, autosomal recessive (SPG56; MIM:615030), a neurodegenerative disorder characterised by a slow, gradual, progressive weakness and spasticity of the lower limbs (Tesson et al. 2012, Fink 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence172">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway142">
 <bp:pathwayOrder rdf:resource="#PathwayStep307" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction166" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence307" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP24A1 causes HCAI</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Catabolic inactivation of the active, hormonal form of vitamin D3 (calcitriol, CALTOL, 1,25-dihydroxyvitamin D3) is initially carried out by 24-hydroxylation, mediated by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). The product formed is eventually transformed to calcitroic acid, the major water-soluble metabolite that can be excreted in bile. Defects in CYP24A1 can cause hypercalcemia infantile (HCAI; MIM:143880), a disorder characterised by abnormally high level of calcium in the blood, failure to thrive, vomiting, dehydration, and nephrocalcinosis (Schlingmann et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence173">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway143">
 <bp:pathwayOrder rdf:resource="#PathwayStep309" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction167" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence309" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP21A2 causes AH3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Steroid 21-hydroxylase (CYP21A2) specifically catalyses the 21-hydroxylation of steroids which is required for the adrenal synthesis of mineralocorticoids and glucocorticoids. Defects in CYP21A2 can cause adrenal hyperplasia 3 (AH3; MIM:201910), a form of congenital adrenal hyperplasia (CAH) where cortisol synthesis is defective. This results in increased ACTH levels, causing overproduction and accumulation of cortisol precursors, particularly 17-hydroxyprogesterone (17HPROG). The resultant excessive production of androgens causes virilization. 21-hydroxylase deficiency accounts for more than 90% of CAH cases and ranges from mild to complete loss of activity (White et al. 2000, White    Bachega 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction123">
 <bp:evidence rdf:resource="#Evidence231" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC26A2 does not cotransport extracellular SO4(2-), H+ to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction124">
 <bp:evidence rdf:resource="#Evidence233" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction125">
 <bp:evidence rdf:resource="#Evidence234" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction126">
 <bp:evidence rdf:resource="#Evidence235" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcNAc to the terminal GlcA residue</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction127">
 <bp:evidence rdf:resource="#Evidence236" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcNAc to the heparan chain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction128">
 <bp:evidence rdf:resource="#Evidence238" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAPSS2 does not transfer SO4(2-) group to ATP to form APS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction129">
 <bp:evidence rdf:resource="#Evidence239" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAPSS2 does not transfer PO4(2-) group from ATP to APS to form PAPS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence167">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway133">
 <bp:pathwayOrder rdf:resource="#PathwayStep287" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction155" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence287" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11A1 causes AICSR</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) normally catalyses the side-chain cleavage of cholesterol to form pregnenolone. Defects in CYP11A1 can cause Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR; MIM:613743). This is a rare disorder that can present as acute adrenal insufficiency in infancy with elevated ACTH and plasma renin activity and low or absent adrenal steroids. The severest phenotype is loss-of-function mutations associated with prematurity, complete under-androgenisation and severe, early-onset adrenal failure (Kim et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence168">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway134">
 <bp:pathwayOrder rdf:resource="#PathwayStep289" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction156" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence289" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 in aflatoxin detoxification causes GLUTH</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">To be excreted in urine, glutathione conjugates undergo several hydrolysis steps to form mercapturic acids which are readily excreted. The first step is the hydrolysis of a gamma-glutamyl residue from the conjugate catalysed by gamma-glutamyltransferases (GGTs). These are membrane-bound, heterodimeric enzymes composed of light and heavy peptide chains. Extracellular glutathione (GSH) or its conjugates can be hydrolysed to give cysteinylglycine (CG, or CG conjugates) and free glutamate (L-Glu). Hydrolysis of GSH provides cells with a local cysteine supply and contributes to intracellular GSH levels (Heisterkamp et al. 2008). Defects in GGT1 can cause glutathionuria (GLUTH; MIM:231950), an autosomal recessive disorder characterised by increased GSH concentration in the plasma and urine. Mutations that cause GLUTH can occur in both chains of the GGT1 dimer (Heisterkamp et al. 2008, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence165">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway135">
 <bp:pathwayOrder rdf:resource="#PathwayStep291" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction157" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence291" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TBXAS1 causes GHDD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Thromboxane-A synthase (TBXAS1), an enzyme of the arachidonic acid cascade, produces thromboxane A2 (TXA2) from prostaglandin H2 (PGH2). Together with prostacyclin (PGI2), TXA2 plays a key role in the maintenance of haemostasis. It is also a constrictor of vascular and respiratory smooth muscle and implicated in the induction of osteoclast differentiation and activation. Defects in TBXAS1 can cause Ghosal hematodiaphyseal dysplasia (GHDD; MIM:231095), a rare autosomal recessive disorder characterised by increased bone density with predominant diaphyseal involvement and aregenerative anemia, a bone marrow failure where functional marrow cells are regenerated slowly or not at all (Genevieve et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence166">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway136">
 <bp:pathwayOrder rdf:resource="#PathwayStep293" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction158" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence293" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP7B1 causes SPG5A and CBAS3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Bile acids are synthesised from cholesterol via two pathways - a classic neutral pathway involving cholesterol 7-alpha-hydroxylase (CYP7A1), and an acidic pathway involving 25-hydroxycholesterol 7-alpha-hydroxylase (CYP7B1). Defects in CYP7B1 can cause spastic paraplegia 5A (SPG5A), a neurodegenerative disorder characterised by a slow, gradual, progressive weakness and spasticity of the lower limbs (Tsaousidou et al. 2008).  Defects in CYP7B1 can also cause Congenital bile acid synthesis defect 3 (CBAS3; MIM:613812), a disorder resulting in severe cholestasis, cirrhosis and liver synthetic failure. Hepatic CYP7B1 activity is undetectable (Setchell et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway137">
 <bp:pathwayOrder rdf:resource="#PathwayStep295" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction159" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence295" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAOA causes BRUNS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Amine oxidase (flavin-containing) A (MAOA) catalyses the oxidative deamination of biogenic and dietary amines, the regulation of which is critical for mental state homeostasis. MAOA, located on the mitochondrial outer membrane and requiring FAD as cofactor (Weyler 1989), preferentially oxidises biogenic amines such as 5-hydroxytryptamine (5HT), dopamine, noradrenaline and adrenaline. Defects in MAOA can cause Brunner syndrome (BRUNS; MIM:300615), a form of X-linked non-dysmorphic mild mental retardation. Male patients are affected by mild mental retardation and exhibit abnormal behaviour, including impulsive aggression (Brunner et al. 1993, Shih et al. 1999, Shih 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction120">
 <bp:evidence rdf:resource="#Evidence227" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB does not cleave the terminal GalNAc from DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway138">
 <bp:pathwayOrder rdf:resource="#PathwayStep297" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction160" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence297" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26B1 causes RHFCA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinoic acid (RA) is a biologically active analogue of vitamin A (retinol). RA plays an important role in regulating cell growth and differentiation.CYP26A1 and B1 are involved in the metabolic breakdown of RA by 4-hydroxylation. High expression levels of CYP26B1 in the cerebellum and pons of human brain suggests a protective role of specific tissues against retinoid damage (White et al. 2000). Defects in CYP26B1 can cause radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA; MIM:614416), a disease characterised by craniofacial malformations and multiple skeletal anomalies (Laue et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence169">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction121">
 <bp:evidence rdf:resource="#Evidence228" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB does not cleave the terminal GalNAc from HA fragments</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway139">
 <bp:pathwayOrder rdf:resource="#PathwayStep299" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction161" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence299" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27B1 causes VDDR1A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vitamin D3 (cholecalciferol), synthesised in human skin by ultraviolet radiation action on 7-dehydrocholesterol, does not possess any biological activity. Vitamin D hormonal activity requires hydroxylation at the 25 and 1-alpha positions by cytochrome P450 enzymes CYP2R1 and CYP27B1 respectively. Vitamin D 25-hydroxylase (CYP2R1) catalyses the hydroxylation of vitamin D3 to calcidiol (CDL). Subsequent 1-alpha-hydroxylation of CDL by CYP27B1 produces calcitriol (CTL). CTL binds and activates the nuclear vitamin D receptor, with subsequent regulation of physiologic events such as calcium homeostasis, cellular differentiation and proliferation.  Defects in CYP27B1 can cause rickets, vitamin D-dependent 1A (VDDR1A; MIM:264700), a disorder caused by deficiency of the active form of vitamin D (CTL) resulting in defective bone mineralization and clinical features of rickets. To date, 47 mutations have been identified, the majority of them (28) being missense mutations (Kim 2011, Cui et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction122">
 <bp:evidence rdf:resource="#Evidence229" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB does not cleave the terminal GalNAc from keratan sulfate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence181">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence182">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence180">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway150">
 <bp:pathwayOrder rdf:resource="#PathwayStep325" />
 <bp:pathwayOrder rdf:resource="#PathwayStep324" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction175" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction176" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence324" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27A1 causes CTX</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CYP27A1, a mitochondrial matrix sterol hydroxylase, catalyses the 27-hydroxylation of side-chains of sterol intermediates (Cali et al. 1991). In the bile acid synthesis pathway, CYP27A1 catalyses the first step in the oxidation of the side chain of sterol intermediates such as cholestane-triols (Pikuleva et al. 1998). Defects in CYP27A1 can cause Cerebrotendinous xanthomatosis (CTX; MIM:213700), a rare sterol storage disorder. Decreased bile acid production results in the accumulation of sterol intermediates in many tissues, including brain. The disorder is characterised by progressive neurologic dysfunction, premature atherosclerosis and cataracts (Gallus et al. 2006).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence185">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway151">
 <bp:pathwayOrder rdf:resource="#PathwayStep327" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction177" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence327" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GCLC causes HAGGSD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In mammalian cells, many antioxidant defence systems exist which protect cells from subsequent exposure to oxidant stresses. One antioxidant is glutathione (GSH), a tripeptide present in virtually all cells that regulates the intracellular redox state and protects cells from oxidative injury. It is metabolised via the gamma-glutamyl cycle, which is catalysed by six enzymes. In man, hereditary deficiencies have been found in five of the six enzymes. Gamma-glutamylcysteine ligase (GCL) catalyses the first and rate-limiting step in GSH biosynthesis. GCL is a heterodimer of a catalytic heavy chain (GCLC) and a regulatory light chain (GCLM). Defects in the catalytic GCLC can cause hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD; MIM:230450), a disease characterised by hemolytic anemia, glutathione deficiency, myopathy, late-onset spinocerebellar degeneration, and peripheral neuropathy (Ristoff    Larsson 2007, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence186">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway152">
 <bp:pathwayOrder rdf:resource="#PathwayStep329" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction178" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence329" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPLAH causes OPLAHD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The gamma-glutamyl cycle is a six-enzyme cycle that represents the primary pathway for glutathione synthesis and degradation. One step is the cleavage of 5-oxo-L-proline (OPRO) to form L-glutamate, coupled to the hydrolysis of ATP. This is catalysed by 5-oxoprolinase (OPLAH) is a homodimeric, cytosolic protein. Defects in OPLAH can cause 5-oxoprolinase deficiency (OPLAHD; MIM:260005), an extremely rare disorder of the gamma-glutamyl cycle about which debate continues as to whether it is a disorder or just a biochemical condition with no adverse clinical effects apart from 5-oxoprolinuria (Calpena et al. 2013, Almaghlouth et al. 2012, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence183">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway153">
 <bp:pathwayOrder rdf:resource="#PathwayStep331" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction179" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence331" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TPMT causes TPMT deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Methylation is a major biotransformation route of thiopurine drugs such as 6-mercaptopurine (6MP), used in the treatment of inflammatory diseases such as rheumatoid arthritis and childhood acute lymphoblastic leukemia. 6MP and its thioguanine nucleotide metabolites are principally inactivated by thiopurine methyltransferase (TPMT)-catalysed S-methylation.  Defects in TPMT can cause thiopurine S-methyltransferase deficiency (TPMT deficiency; MIM:610460). Patients with intermediate or no TPMT activity are at risk of toxicity such as myelosuppression after receiving standard doses of thiopurine drugs. Inter individual differences in response to these drugs are largely determined by genetic variation at the TPMT locus. TPMT exhibits an autosomal co dominant phenotype: About one in 300 people in Caucasian, African, African-American, and Asian populations are TPMT deficient. Approximately 6-10% of people in these populations inherit intermediate TPMT activity and are heterozygous at the TPMT locus. The rest are homozygous for the wild type allele and have high levels of TPMT activity. (Remy 1963, Weinshilboum et al. 1999, Couldhard    Hogarth 2005, Al Hadithy et al. 2005, Azimi et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence184">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway154">
 <bp:pathwayOrder rdf:resource="#PathwayStep333" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction180" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence333" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP4F22 causes ARCI5</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 4F22 (CYP4F22) is thought to 20-hydroxylate trioxilin A3 (TrXA3), an intermediary metabolite from the 12(R)-lipoxygenase pathway. This pathway is implicated in proliferative skin diseases. The major products of arachidonic acid in keratinocytes are 12- and 15-HETE which undergo biotransformation to products involved in skin hydration. CYP4F22 mutations can lead to autosomal recessive congenital ichthyosis 5 (ARCI5) (Lefevre et al. 2006, Lugassy et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep194">
 <bp:stepProcess rdf:resource="#Pathway94" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep193">
 <bp:stepProcess rdf:resource="#BiochemicalReaction101" />
 <bp:stepProcess rdf:resource="#Catalysis91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep192">
 <bp:stepProcess rdf:resource="#Pathway93" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep191">
 <bp:stepProcess rdf:resource="#Catalysis90" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction100" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep190">
 <bp:stepProcess rdf:resource="#Pathway92" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction134">
 <bp:evidence rdf:resource="#Evidence248" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PMM2 does not isomerise Man6P to Man1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction135">
 <bp:evidence rdf:resource="#Evidence250" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM2 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction136">
 <bp:evidence rdf:resource="#Evidence252" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM1 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep199">
 <bp:stepProcess rdf:resource="#BiochemicalReaction104" />
 <bp:stepProcess rdf:resource="#Catalysis94" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction137">
 <bp:evidence rdf:resource="#Evidence254" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DOLK does not phosphorylate DCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep198">
 <bp:stepProcess rdf:resource="#Pathway96" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction138">
 <bp:evidence rdf:resource="#Evidence256" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SRD5A3 does not reduce pPNOL to DCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep197">
 <bp:stepProcess rdf:resource="#BiochemicalReaction103" />
 <bp:stepProcess rdf:resource="#Catalysis93" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction139">
 <bp:evidence rdf:resource="#Evidence258" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPI does not  isomerize Fru6P to Man6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep196">
 <bp:stepProcess rdf:resource="#Pathway95" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep195">
 <bp:stepProcess rdf:resource="#BiochemicalReaction102" />
 <bp:stepProcess rdf:resource="#Catalysis92" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence178">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway144">
 <bp:pathwayOrder rdf:resource="#PathwayStep311" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction168" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence311" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35D1 causes SCHBCKD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter (SLC35D1) is an ER membrane-spanning protein that transports nucleotide-sugars from the cytosol into the ER lumen. SLC35D1 transports UDP-GlcUA and UDP-GalNAc, which are substrates for the synthesis of chondroitin sulfate disaccharide repeats, suggesting a role in chondroitin sulfate biosynthesis. Mutations in SLC35D1 can cause Schneckenbecken dysplasia (SCHBCKD; MIM:269250), a rare, autosomal recessive, lethal short-limbed skeletal dysplasia affecting cartilage and skeletal development (Liu et al. 2010, Liu    Hirschberg 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence179">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway145">
 <bp:pathwayOrder rdf:resource="#PathwayStep313" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction169" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence313" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 causes GLUTH</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">To be excreted in urine, glutathione conjugates undergo several hydrolysis steps to form mercapturic acids which are readily excreted. The first step is the hydrolysis of a gamma-glutamyl residue from the conjugate catalysed by gamma-glutamyltransferases (GGTs). These are membrane-bound, heterodimeric enzymes composed of light and heavy peptide chains. Extracellular glutathione (GSH) or its conjugates can be hydrolysed to give cysteinylglycine (CG, or CG conjugates) and free glutamate (L-Glu). Hydrolysis of GSH provides cells with a local cysteine supply and contributes to intracellular GSH levels (Heisterkamp et al. 2008). Defects in GGT1 can cause glutathionuria (GLUTH; MIM:231950), an autosomal recessive disorder characterised by increased GSH concentration in the plasma and urine. Mutations that cause GLUTH can occur in both chains of the GGT1 dimer (Heisterkamp et al. 2008, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence176">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway146">
 <bp:pathwayOrder rdf:resource="#PathwayStep315" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction170" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence315" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B1 causes AH4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 11B1, mitochondrial (CYP11B1) possesses steroid 11-beta-hydroxylase activity which can convert 11-deoxycortisol to cortisol. 11-beta-hydroxylase deficiency is one of the main causes of congenital adrenal hyperplasia (CAH) (5-8%), second only to 21-hydroxylase deficiency which accounts for more than 90% of CAH (Zhao et al. 2008). Defects in CYP11B1 can cause Adrenal hyperplasia 4 (AH4; MIM:202010), a form of congenital adrenal hyperplasia which is a common recessive disease due to failure to convert 11-deoxycortisol to cortisol. This impaired corticosteroid biosynthesis results in androgen excess, virilization and hypertension (White et al. 1991). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence177">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway147">
 <bp:pathwayOrder rdf:resource="#PathwayStep318" />
 <bp:pathwayOrder rdf:resource="#PathwayStep317" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction171" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction172" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence317" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A4 causes hyperbilirubinemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-glucuronosyltransferases (UGTs) play a major role in the conjugation and therefore elimination of potentially toxic xenobiotics and endogenous compounds. The 1-4 isoform UGT1A4 is able to act upon lipophilic bilirubin, the end product of heme breakdown. Defects in UGT1A4 can cause hyperbilirubinemia syndromes ranging from mild forms such as Gilbert syndrome (GILBS; MIM:143500) to the more severe Crigler-Najjar syndromes 1 and 2 (CN1, CN2; MIM:218800 and MIM:606785) (Sticova    Jirsa 2013, Strassburg 2010, Udomuksorn et al. 2007, Costa 2006, Maruo et al. 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction130">
 <bp:evidence rdf:resource="#Evidence241" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ST3GAL3 does not transfer SA to keratan</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway148">
 <bp:pathwayOrder rdf:resource="#PathwayStep320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction173" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence320" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective FMO3 causes TMAU</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trimethylamine (TMA) is present in the diet (in fish) but primarily formed in vivo from the breakdown of choline. It is N-oxidised by FMO3 in the liver, the major isoform active towards TMA. Trimethylaminuria (TMAU; MIM:602079, fish-odour syndrome) is a human genetic disorder characterised by an impaired ability to convert the malodourous TMA to its odourless N-oxide. Patients emit a foul odour, which resembles that of rotting fish and can be a psychologically disabling condition (Messenger et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction131">
 <bp:evidence rdf:resource="#Evidence243" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not transfer Gal to a branch of keratan</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway149">
 <bp:pathwayOrder rdf:resource="#PathwayStep322" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction174" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence322" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AHCY causes HMAHCHD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Adenosylhomocysteinase (AHCY) is a tetrameric, NAD+-bound, cytosolic protein that regulates all adenosylmethionine (AdoMet) dependent transmethylations by hydrolysing the feedback inhibitor adenosylhomocysteine (AdoHcy) to homocysteine (HCYS) and adenosine (Ade-Rib). Defects in AHCY cause Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD; MIM:613752), a metabolic disorder characterised by hypermethioninemia associated with failure to thrive, psychomotor retardation, facial dysmorphism with abnormal hair and teeth and myocardiopathy (Baric et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction132">
 <bp:evidence rdf:resource="#Evidence244" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not transfer Gal to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction133">
 <bp:evidence rdf:resource="#Evidence245" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not transfer Gal to the keratan chain</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence152">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence153">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence150">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway120">
 <bp:pathwayOrder rdf:resource="#PathwayStep259" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction140" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence259" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DHDDS causes RP59</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ER membrane-associated enzyme dehydrodolichyl diphosphate synthase (DHDDS) (Endo et al. 2003) normally mediates the sequential head-to-tail cis addition of multiple isopentyl pyrophosphate (IPP) molecules to farnesyl pyrophosphate (E,E-FPP) to produce polyprenol pyrophosphate (pPPP) (Shridas et al. 2003). Dolichol in humans contain homologues ranging from 17-23 isoprene units, the most common homologues contain 19 or 20 isoprene units (Freeman et al. 1980). Dolichol is an important substrate in the N-glycosylation of proteins, including rhodopsin.  Defects in DHDDS cause retinitis pigmentosa 59 (RP59; MIM:613861), a pigment retinopathy, characterised by retinal pigment deposits (visible on fundus examination) and primary loss of rod photoreceptors followed by secondary loss of cone photoreceptors. Sufferers typically have night vision blindness and loss of mid to peripheral vision. As the condition progresses, they lose far peripheral vision and eventually central vision (Zuchner et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence151">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway121">
 <bp:pathwayOrder rdf:resource="#PathwayStep261" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction141" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence261" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALT can cause GALCT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Galactose-1-phosphate uridylyltransferase (GALT) is one of the enzymes involved in galactose metabolism in the Leloir pathway. GALT catalyses the transfer of uridine monophosphate (UMP) from UDP-glucose (UDP-Glc) to galactose-1-phosphate (Gal1P) to form UDP-galactose (UDP-Gal) and glucose 1-phosphate. Defects in GALT can cause Galactosemia (GALCT; MIM:230400), an autosomal recessive disorder of galactose metabolism presenting in neonatals that causes jaundice, cataracts and mental retardation (Bosch 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction109">
 <bp:evidence rdf:resource="#Evidence208" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA does not cleave the terminall GalNAc from small HA fragments</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction101">
 <bp:evidence rdf:resource="#Evidence194" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT3 does not transfer GalNAc to mucins</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway119">
 <bp:pathwayOrder rdf:resource="#PathwayStep257" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction139" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence257" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPI causes MPI-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mannose 6-phosphate isomerase (MPI) normally isomerises fructose 6-phosphate (Fru6P) to mannose 6-phosphate (Man6P) in the cytosol. Man6P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for mannosyl transfer reactions in the N-glycosylation of proteins. Defects in MPI cause congenital disorder of glycosylation 1b (MPI-CDG, previously known as CDG1b,; MIM:602579), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Schollen et al. 2000). Unlike PMM2-CDG (CDG1a), there is no neurological involvement with MPI-CDG. Instead, patients present predominantly with diarrhoea, failure to thrive and protein-losing enteropathy (Pelletier et al. 1986). MPI-CDG is one of two CDGs that can be treated with oral mannose supplementation, but can be fatal if left untreated (Marquardt    Denecke 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction102">
 <bp:evidence rdf:resource="#Evidence196" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LFNG does not transfer GlcNAc to Pre-NOTCH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction103">
 <bp:evidence rdf:resource="#Evidence198" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMGNT1 does not transfer GlcNAc from UDP-GlcNAc to Man-O-Ser-DAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction104">
 <bp:evidence rdf:resource="#Evidence200" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT2 does not transfer Man from Dol-P-Man to DAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction105">
 <bp:evidence rdf:resource="#Evidence203" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHSY1 does not transfer GalNAc to chondroitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction106">
 <bp:evidence rdf:resource="#Evidence204" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHSY1 does not transfer GlcA to chondroitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction107">
 <bp:evidence rdf:resource="#Evidence206" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA does not cleave the terminal GalNAc from DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction108">
 <bp:evidence rdf:resource="#Evidence207" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA does not cleave the terminal GalNAc from keratan sulfate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence145">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway111">
 <bp:pathwayOrder rdf:resource="#PathwayStep240" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction130" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence240" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ST3GAL3 causes MCT12 and EIEE15</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase (ST3GAL3) mediates the transfer of sialic acid from CMP-sialic acid to galactose-containing glycoproteins and forms the sialyl Lewis a epitope on proteins which are required for attaining and/or maintaining higher cognitive functions. Some defects in ST3GAL3 result in mental retardation, autosomal recessive 12 (MRT12; MIM:611090), a disorder characterised by below average general intellectual function and impaired adaptive behaviour (Najmabadi et al. 2007,  Hu et al. 2011). Another defect of ST3GAL3 can cause early infantile epileptic encephalopathy-15 (EIEE15: MIM:615006), resulting in severe mental retardation (Edvardson et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence146">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway112">
 <bp:pathwayOrder rdf:resource="#PathwayStep244" />
 <bp:pathwayOrder rdf:resource="#PathwayStep243" />
 <bp:pathwayOrder rdf:resource="#PathwayStep242" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction132" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction133" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence242" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation (CDG, previously called carbohydrate-deficient glycoprotein syndromes, CDGSs), are a group of hereditary multisystem disorders. They are characterized biochemically by hypoglycosylation of glycoproteins, diagnosed by isoelectric focusing (IEF) of serum transferrin. There are two types of CDG, types I and II. Type I CDG has defects in the assembly of lipid-linked oligosaccharides or their transfer onto nascent glycoproteins, whereas type II CDG comprises defects of trimming, elongation, and processing of protein-bound glycans. Clinical symptoms are dominated by severe psychomotor and mental retardation, as well as blood coagulation abnormalities (Jaeken 2013). B4GALT1-CDG (CDG type IId) is a multisystem disease, characterized by dysmorphic features, hydrocephalus, hypotonia and blood clotting abnormalities (Hansske et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence143">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway113">
 <bp:pathwayOrder rdf:resource="#PathwayStep260" />
 <bp:pathwayOrder rdf:resource="#PathwayStep271" />
 <bp:pathwayOrder rdf:resource="#PathwayStep246" />
 <bp:pathwayOrder rdf:resource="#PathwayStep256" />
 <bp:pathwayOrder rdf:resource="#PathwayStep267" />
 <bp:pathwayOrder rdf:resource="#PathwayStep254" />
 <bp:pathwayOrder rdf:resource="#PathwayStep265" />
 <bp:pathwayOrder rdf:resource="#PathwayStep252" />
 <bp:pathwayOrder rdf:resource="#PathwayStep262" />
 <bp:pathwayOrder rdf:resource="#PathwayStep273" />
 <bp:pathwayOrder rdf:resource="#PathwayStep250" />
 <bp:pathwayOrder rdf:resource="#PathwayStep248" />
 <bp:pathwayOrder rdf:resource="#PathwayStep258" />
 <bp:pathwayOrder rdf:resource="#PathwayStep269" />
 <bp:pathwayComponent rdf:resource="#Pathway120" />
 <bp:pathwayComponent rdf:resource="#Pathway121" />
 <bp:pathwayComponent rdf:resource="#Pathway119" />
 <bp:pathwayComponent rdf:resource="#Pathway122" />
 <bp:pathwayComponent rdf:resource="#Pathway123" />
 <bp:pathwayComponent rdf:resource="#Pathway124" />
 <bp:pathwayComponent rdf:resource="#Pathway114" />
 <bp:pathwayComponent rdf:resource="#Pathway125" />
 <bp:pathwayComponent rdf:resource="#Pathway115" />
 <bp:pathwayComponent rdf:resource="#Pathway126" />
 <bp:pathwayComponent rdf:resource="#Pathway116" />
 <bp:pathwayComponent rdf:resource="#Pathway127" />
 <bp:pathwayComponent rdf:resource="#Pathway117" />
 <bp:pathwayComponent rdf:resource="#Pathway118" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence246" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with glycosylation precursor biosynthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation diseases associated with the enzymes that mediate the biosynthesis of glycosylation precursors are curated in this section (Jaeken    Matthijs 2007, Freeze et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence144">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway114">
 <bp:pathwayOrder rdf:resource="#PathwayStep247" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction134" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence247" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PMM2 causes PMM2-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphomannomutase 2 (PMM2) normally catalyses the isomerisation of mannose 6-phosphate (Man6P) to mannose 1-phosphate (Man1P) in the cytosol of cells. Man1P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for critical mannosyl transfer reactions in the N-glycosylation of proteins. Mutations in the PMM2 gene are one of the causes of Jaeken syndrome, a congenital disorder of glycosylation type 1a (PMM2-CDG, previously CDG-1a) (Matthijs et al. 1997). PMM2-CDG was first described in Belgian identical twin sisters, characterized by psychomotor retardation and multiple serum glycoprotein abnormalities. Serum and CSF transferrin were found to be deficient in sialic acid (Jaeken et al. 1984). PMM2-CDG is the most common CDG disease subtype.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence149">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway115">
 <bp:pathwayOrder rdf:resource="#PathwayStep249" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction135" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence249" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM2 causes DPM2-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM2 can cause congenital disorder of glycosylation 1u (DPM2-CDG, CDG1u; MIM:615042), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Barone et al. 2012). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway116">
 <bp:pathwayOrder rdf:resource="#PathwayStep251" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction136" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence251" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM1 causes DPM1-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM1 can cause congenital disorder of glycosylation 1e (DPM1-CDG, CDG-1e; MIM:608799), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Kim et al. 2000, Imbach et al. 2000, Garcia-Silva et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence147">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway117">
 <bp:pathwayOrder rdf:resource="#PathwayStep253" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction137" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence253" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DOLK causes DOLK-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichol kinase (DOLK, TMEM15) normally mediates the phosphorylation of dolichol (DCHOL) to form dolichyl phosphate (DOLP) in the ER membrane (Fernandez et al. 2002). DOLP is an important substrate in the synthesis of N- and O-glycosylated proteins and GPI anchors. Defects in DOLK cause congenital disorder of glycosylation type 1m (DOLK-CDG, CDG1m, also known as dolichol kinase deficiency; MIM:610768), a severe mutisystem disorder characterised by under-glycosylated serum glycoproteins. This disorder has a very severe phenotype and death can occur in early life (Kranz et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence148">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction100">
 <bp:evidence rdf:resource="#Evidence192" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LARGE does not transfer Xyl from UDP-Xyl to GlcA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway118">
 <bp:pathwayOrder rdf:resource="#PathwayStep255" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction138" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence255" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SRD5A3 causes SRD5A3-CDG, KHRZ</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyprenol reductase (SRD5A3), resident on the endoplasmic reticulum membrane, normally mediates the reduction of the alpha-isoprene unit of polyprenol (pPNOL) to form dolichol (DCHOL) in a NADPH-dependent manner (Cantagrel et al. 2010). DCHOLs are substrates required for the synthesis of the lipid-linked oligosaccharide (LLO) precursor used for N-glycosylation. Defects in SRD5A3 cause congenital disorder of glycosylation 1q (SRD5A3-CDG, CDG1q; MIM:612379), a neurodevelopmental disorder characterised by under-glycosylated serum glycoproteins resulting in nervous system development, psychomotor retardation, hypotonia, coagulation disorders and immunodeficiency (Cantagrel et al. 2010, Kasapkara et al. 2012). Defects in SRD5A3 can also cause Kahrizi syndrome (KHRZ; MIM:612713), a neurodevelopmental disorder characterised by mental retardation, cataracts, holes in eye structures, pathological curvature of the spine, and coarse facial features (Kahrizi et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence160">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence163">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence164">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway130">
 <bp:pathwayOrder rdf:resource="#PathwayStep281" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction152" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence281" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP19A1 causes AEXS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aromatase (CYP19A1) catalyses the conversion of androstenedione (ANDST) to estrone (E1). Defects in CYP19A1 can cause aromatase excess syndrome (AEXS; MIM:139300) and aromatase deficiency (AROD; MIM:613546). Affected individuals cannot synthesise endogenous estrogens. In females the lack of estrogen leads to pseudohermaphroditism and progressive virilization at puberty, whereas in males pubertal development is normal (Bulun 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence161">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway131">
 <bp:pathwayOrder rdf:resource="#PathwayStep283" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction153" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence283" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAT1A causes MATD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S-adenosylmethionine (AdoMet, SAM) is an important methyl donor in most transmethylation reactions. S-adenosylmethionine synthase isoform type-1 (MAT1A) catalyses the formation of AdoMet from methionine and ATP. Defects in MAT1A can cause methionine adenosyltransferase deficiency (MATD; MIM:250850), an inborn error of metabolism resulting in hypermethioninemia. In this condition, methionine accumulates because its conversion to AdoMet is impaired (Furujo et al. 2012, Mudd 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence162">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway132">
 <bp:pathwayOrder rdf:resource="#PathwayStep285" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction154" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence285" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27B1 causes VDDR1B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vitamin D3 (cholecalciferol), synthesised in human skin by ultraviolet radiation action on 7-dehydrocholesterol, does not possess any biological activity. Vitamin D hormonal activity requires hydroxylation at the 25 and 1-alpha positions by cytochrome P450 enzymes CYP2R1 and CYP27B1 respectively. Vitamin D 25-hydroxylase (CYP2R1) catalyses the hydroxylation of vitamin D3 to calcidiol (CDL). Subsequent 1-alpha-hydroxylation of CDL produces calcitriol (CTL). CTL binds and activates the nuclear vitamin D receptor, with subsequent regulation of physiologic events such as calcium homeostasis, cellular differentiation and proliferation.  Defects in CYP2R1 can cause rickets, vitamin D-dependent 1B (VDDR1B; MIM:600081), a disorder caused by a selective deficiency of the active form of vitamin D (CTL) resulting in defective bone mineralization and clinical features of rickets (Pikuleva et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction112">
 <bp:evidence rdf:resource="#Evidence212" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcNAc to the heparan chain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction113">
 <bp:evidence rdf:resource="#Evidence213" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction114">
 <bp:evidence rdf:resource="#Evidence215" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT7 does not transfer Gal to xylosyl-unit of the tetrasaccharide linker</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction115">
 <bp:evidence rdf:resource="#Evidence217" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GAT3 does not transfer GlcA to tetrasaccharide linker</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction116">
 <bp:evidence rdf:resource="#Evidence219" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST6 does not transfer SO4(2-) to GlcNAc residues on keratan-PG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction117">
 <bp:evidence rdf:resource="#Evidence221" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST3 does not transfer SO4(2-) to chondroitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction118">
 <bp:evidence rdf:resource="#Evidence223" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST14 does not transfer SO4(2-) to GalNAc in dermatan or DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction119">
 <bp:evidence rdf:resource="#Evidence225" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALT6 does not transfer Gal to the tetrasaccharide linker</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence156">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway122">
 <bp:pathwayOrder rdf:resource="#PathwayStep264" />
 <bp:pathwayOrder rdf:resource="#PathwayStep263" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction143" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence263" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE causes sialuria, NK and IBM2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sialuria (MIM:269921) is caused by a metabolic defect where the UDP?N?acetylglucosamine 2?epimerase, N?acetylmannosamine kinase (GNE) gene lacks feedback inhibition resulting in constitutive overproduction of free sialic acid (Neu5Ac) (Montreuil et al. 1968, Fontaine et al. 1968). Sialuria is characterised by a large cytoplasmic accumulation and urinary excretion of Neu5Ac (Kamerling et al. 1979). Sialurias differ from sialidoses, in which there is storage and excretion of &apos;bound&apos; Neu5Ac. Defects in GNE also cause Nonaka myopathy (NK; MIM:605820), an early adult-onset disorder characterised by muscle weakness and wasting of distal muscles, especially the anterior tibial muscles (Nonaka et al. 1981, Asaka et al. 2001). Defects in GNE also cause inclusion body myopathy 2 (IBM2; MIM:600737), an autosomal recessive disorder with a similar phenotype to Nonaka myopathy (NK). IBM2 is an adult-onset, proximal and distal muscle weakness and wasting disorder. Muscle biospsy reveals from sufferers shows a rimmed vacuole myopathy and the degenerating muscle fibers contained abnormal amounts of beta-amyloid protein such as that found in neurodegenerative diorders. However, there is no neurological symptoms in these patients (Argov    Yarom 1984).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence157">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway123">
 <bp:pathwayOrder rdf:resource="#PathwayStep266" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction144" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence266" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALK1 causes GALCT2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic galactokinase (GALK1) catalyses the first committed step in the Leloir pathway of galactose metabolism. GALK1 catalyses the phosphorylation of D-galactose (Gal) to form D-galactose 1-phosphate (Gal1P). Defects in GALK1 can cause type II galactosemia (GALCT2; MIM:230200), an autosomal recessive deficiency characterised by congenital cataracts during infancy and presenile cataracts in the adult population. Galactitol accumulation in the lens is the cause of these cataracts (Bosch et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence154">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway124">
 <bp:pathwayOrder rdf:resource="#PathwayStep268" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction145" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence268" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALE causes EDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic UDP-galactose 4&apos;-epimerase (GALE) catalyses the reversible interconversion of UDP-D-galactose (UDP-Gal) and UDP-glucose (UDP-Glc), the third reacton in the Leloir pathway of galactose metabolism. GALE can also catalyse the epimerisation of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The active form of the enzyme is a homodimer with one molecule of bound NAD per monomer (GALE:NAD+ dimer). Defects in GALE can cause Epimerase-deficiency galactosemia (EDG; MIM:230350), or type III galactosemia (diseases of galactose metabolism) whose clinical features include early-onset cataracts, liver damage, deafness and mental retardation. Historically, it was considered that there were two forms of GALE deficidency; a benign (&quot;peripheral&quot;) form where there is no GALE activity in red blood cells and characterised by mild symptoms (Gitzelmann 1972) and a rarer &quot;generalised&quot; form with no detectable GALE activity in all tissues resulting in more severe symptoms (Holton et al. 1981). The disease is now considered to be a continuum (Openo et al. 2006).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence155">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway125">
 <bp:pathwayOrder rdf:resource="#PathwayStep270" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction146" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence270" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM3 causes DPM3-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM3 can cause congenital disorder of glycosylation 1o (DPM3-CDG, CDG1o; MIM:612937), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Lefeber et al. 2009).  Four biosynthetic pathways depend on DOLPman; N-glycosylation, O-mannosylation, C-Mannosylation and GPI-anchor biosynthesis. A defect in DPM3 strongly reduces O-mannosylation of alpha-dystroglycan, explaining the clinical phenotype of muscular dystrophy and linking the congenital disorders of glycosylation with the dystroglycanopathies (Lefeber et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway126">
 <bp:pathwayOrder rdf:resource="#PathwayStep272" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction147" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence272" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PGM1 causes PGM1-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphoglucomutases 1 and 2 (PGM1, 2) are involved in the cytosolic biosynthesis of nucleotide sugars needed for glycan biosynthesis, specifically, the isomerisation of glucose-6-phosphate (G6P) into glucose-1-phosphate (G1P). Defects in PGM1 can cause congenital disorder of glycosylation 1t (CDG1t, now known as PGM1-CDG; MIM:614921), a broad spectrum disorder characterised by under-glycosylated serum glycoproteins (Timal et al. 2012, Tegtmeyer et al. 2014). CDGs result in a wide variety of clinical features such as defects in nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway127">
 <bp:pathwayOrder rdf:resource="#PathwayStep274" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction148" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence274" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GFPT1 causes CMSTA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucosamine-fructose 6-phosphate aminotransferases 1 and 2 (GFPT1,2) are the first and rate-limiting enzymes in the hexosamine synthesis pathway, and thus formation of hexosamines like N-acetylglucosamine (GlcNAc). These enzymes probably play a role in limiting the availability of substrates for the N- and O-linked glycosylation of proteins. GFPT1 and 2 are required for normal functioning of neuromuscular synaptic transmission. Defects in GFPT1 lead to myasthenia, congenital, with tubular aggregates 1 (CMSTA1; MIM:610542), characterised by altered muscle fibre morphology and impaired neuromuscular junction development. Sufferers of CMSTA1 show a good response to acetylcholinesterase inhibitors (Senderek et al. 2011). The missense mutations observed do not always result in significant reduction in enzyme activity, but biopsies show reduced amounts of GFPT1 protein suggesting increased turnover or defective translation (Senderek et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence158">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction110">
 <bp:evidence rdf:resource="#Evidence210" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway128">
 <bp:pathwayOrder rdf:resource="#PathwayStep282" />
 <bp:pathwayOrder rdf:resource="#PathwayStep280" />
 <bp:pathwayOrder rdf:resource="#PathwayStep323" />
 <bp:pathwayOrder rdf:resource="#PathwayStep300" />
 <bp:pathwayOrder rdf:resource="#PathwayStep288" />
 <bp:pathwayOrder rdf:resource="#PathwayStep321" />
 <bp:pathwayOrder rdf:resource="#PathwayStep342" />
 <bp:pathwayOrder rdf:resource="#PathwayStep286" />
 <bp:pathwayOrder rdf:resource="#PathwayStep340" />
 <bp:pathwayOrder rdf:resource="#PathwayStep284" />
 <bp:pathwayOrder rdf:resource="#PathwayStep308" />
 <bp:pathwayOrder rdf:resource="#PathwayStep306" />
 <bp:pathwayOrder rdf:resource="#PathwayStep328" />
 <bp:pathwayOrder rdf:resource="#PathwayStep304" />
 <bp:pathwayOrder rdf:resource="#PathwayStep326" />
 <bp:pathwayOrder rdf:resource="#PathwayStep292" />
 <bp:pathwayOrder rdf:resource="#PathwayStep290" />
 <bp:pathwayOrder rdf:resource="#PathwayStep312" />
 <bp:pathwayOrder rdf:resource="#PathwayStep334" />
 <bp:pathwayOrder rdf:resource="#PathwayStep310" />
 <bp:pathwayOrder rdf:resource="#PathwayStep332" />
 <bp:pathwayOrder rdf:resource="#PathwayStep276" />
 <bp:pathwayOrder rdf:resource="#PathwayStep298" />
 <bp:pathwayOrder rdf:resource="#PathwayStep330" />
 <bp:pathwayOrder rdf:resource="#PathwayStep296" />
 <bp:pathwayOrder rdf:resource="#PathwayStep294" />
 <bp:pathwayOrder rdf:resource="#PathwayStep319" />
 <bp:pathwayOrder rdf:resource="#PathwayStep316" />
 <bp:pathwayOrder rdf:resource="#PathwayStep338" />
 <bp:pathwayOrder rdf:resource="#PathwayStep314" />
 <bp:pathwayOrder rdf:resource="#PathwayStep336" />
 <bp:pathwayComponent rdf:resource="#Pathway140" />
 <bp:pathwayComponent rdf:resource="#Pathway141" />
 <bp:pathwayComponent rdf:resource="#Pathway142" />
 <bp:pathwayComponent rdf:resource="#Pathway143" />
 <bp:pathwayComponent rdf:resource="#Pathway133" />
 <bp:pathwayComponent rdf:resource="#Pathway155" />
 <bp:pathwayComponent rdf:resource="#Pathway134" />
 <bp:pathwayComponent rdf:resource="#Pathway156" />
 <bp:pathwayComponent rdf:resource="#Pathway135" />
 <bp:pathwayComponent rdf:resource="#Pathway157" />
 <bp:pathwayComponent rdf:resource="#Pathway136" />
 <bp:pathwayComponent rdf:resource="#Pathway158" />
 <bp:pathwayComponent rdf:resource="#Pathway137" />
 <bp:pathwayComponent rdf:resource="#Pathway159" />
 <bp:pathwayComponent rdf:resource="#Pathway138" />
 <bp:pathwayComponent rdf:resource="#Pathway139" />
 <bp:pathwayComponent rdf:resource="#Pathway150" />
 <bp:pathwayComponent rdf:resource="#Pathway151" />
 <bp:pathwayComponent rdf:resource="#Pathway130" />
 <bp:pathwayComponent rdf:resource="#Pathway152" />
 <bp:pathwayComponent rdf:resource="#Pathway131" />
 <bp:pathwayComponent rdf:resource="#Pathway153" />
 <bp:pathwayComponent rdf:resource="#Pathway132" />
 <bp:pathwayComponent rdf:resource="#Pathway154" />
 <bp:pathwayComponent rdf:resource="#Pathway144" />
 <bp:pathwayComponent rdf:resource="#Pathway145" />
 <bp:pathwayComponent rdf:resource="#Pathway146" />
 <bp:pathwayComponent rdf:resource="#Pathway147" />
 <bp:pathwayComponent rdf:resource="#Pathway148" />
 <bp:pathwayComponent rdf:resource="#Pathway149" />
 <bp:pathwayComponent rdf:resource="#Pathway129" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence276" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Metabolic disorders of biological oxidation enzymes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ability to process xenobiotica and many endogenous compounds is called biotransformation and is catalysed by enzymes mainly in the liver of higher organisms but also a number of other organs such as kidneys, gut and lungs. Metabolism occurs in two stages; phase 1 functionalisation and phase 2 conjugation. Defects in enzymes in these two phases can lead to disease (Nebert et al. 2013, Pikuleva    Waterman 2013, Zanger    Schwab 2013, Mudd 2013, Messenger et al. 2013, Aoyama    Nakaki 2013, Shih 2004, Millington 2013, Azimi et al. 2014, Sticova    Jirsa 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence159">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction111">
 <bp:evidence rdf:resource="#Evidence211" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcNAc to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway129">
 <bp:pathwayOrder rdf:resource="#PathwayStep279" />
 <bp:pathwayOrder rdf:resource="#PathwayStep278" />
 <bp:pathwayOrder rdf:resource="#PathwayStep277" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction149" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction151" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence277" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 causes AH5</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) mediates both 17-alpha-hydroxylase and 17,20-lyase activity, allowing the adrenal glands and gonads to synthesise both 17-alpha-hydroxylated glucocorticoids and sex steroids respectively (Kagimoto et al. 1998). Defects in CYP17A1 can cause Adrenal hyperplasia 5 (AH5), a form of congenital adrenal hyperplasia (CAH), a common recessive disease due to defective synthesis of cortisol and sex steroids. Common symptoms include mild hypocortisolism, ambiguous genitalia in genetic males or failure of the ovaries to function at puberty in genetic females, metabolic alkalosis due to hypokalemia and low-renin hypertension. CYP17A1 can have defects in either or both of 17-alpha-hydroxylase and 17,20-lyase activities thus patients can show combined partial 17-alpha-hydroxylase/17,20-lyase deficiency or isolated 17,20-lyase deficiency traits (Yanase et al. 1992, Kater    Biglieri 1994, Fluck    Miller 2006, Miller 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence130">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence372">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence131">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence373">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence370">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence371">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep161">
 <bp:stepProcess rdf:resource="#Pathway77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep160">
 <bp:stepProcess rdf:resource="#Catalysis75" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep169">
 <bp:stepProcess rdf:resource="#Pathway81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep168">
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
 <bp:stepProcess rdf:resource="#Catalysis79" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence129">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep167">
 <bp:stepProcess rdf:resource="#Pathway80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep166">
 <bp:stepProcess rdf:resource="#Catalysis78" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep165">
 <bp:stepProcess rdf:resource="#Pathway79" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep164">
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
 <bp:stepProcess rdf:resource="#Catalysis77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep163">
 <bp:stepProcess rdf:resource="#Pathway78" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep162">
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
 <bp:stepProcess rdf:resource="#Catalysis76" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence123">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence365">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence124">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence366">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence121">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence363">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence122">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence364">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence127">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence369">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence125">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence367">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence126">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence368">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence380">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence141">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence142">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence381">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence140">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway110">
 <bp:pathwayOrder rdf:resource="#PathwayStep238" />
 <bp:pathwayOrder rdf:resource="#PathwayStep237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction129" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence237" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAPSS2 causes SEMD-PA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in PAPSS2 cause spondyloepimetaphyseal dysplasia Pakistani type (SEMD-PA; MIM:612847), a bone disease characterized by epiphyseal dysplasia with mild metaphyseal abnormalities. Clinical features include short stature from birth, short and bowed lower limbs, mild brachydactyly, kyphoscoliosis, abnormal gait and enlarged knee joints. Some patients may manifest premature pubarche and hyperandrogenism (Ahmed et al. 1998, Noordam et al. 2009, Miyake et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence382">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep150">
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
 <bp:stepProcess rdf:resource="#Catalysis68" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep158">
 <bp:stepProcess rdf:resource="#Catalysis74" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway108">
 <bp:pathwayOrder rdf:resource="#PathwayStep230" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction123" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence230" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC26A2 causes chondrodysplasias</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SLC26A1 and 2 genes encode sulfate transporter proteins that facilitate sulfate uptake into cells, critical in cartilage for sulfation of proteoglycans and extracellular matrix organization. Defects in SLC26A2 result in impaired SO4(2-) transport leading to insufficient sulfation of cartilage proteoglycans. Defective SLC26A2 is implicated in the pathogenesis of a spectrum of autosomal recessive human chondrodysplasias. Severity of symptoms range from mild (diastrophic dysplasia; MIM:222600), intermediate (atelosteogenesis type II; MIM256050) to severe (achondrogenesis type 1B; MIM:600972) (Superti-Furga et al. 1996, Dwyer et al. 2010, Dawson    Markovich 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep157">
 <bp:stepProcess rdf:resource="#Catalysis73" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway109">
 <bp:pathwayOrder rdf:resource="#PathwayStep235" />
 <bp:pathwayOrder rdf:resource="#PathwayStep234" />
 <bp:pathwayOrder rdf:resource="#PathwayStep233" />
 <bp:pathwayOrder rdf:resource="#PathwayStep232" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction124" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction126" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction127" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence232" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 causes exostoses 1, TRPS2 and CHDS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Heparan sulfate (HS) is involved in regulating various body functions functions during development, homeostasis and pathology including blood clotting, angiogenesis and metastasis of cancer cells. Exostosin 1 and 2 (EXT1 and 2) glycosyltransferases are required to form HS. They are able to transfer N-acetylglucosamine (GlcNAc) and glucuronate (GlcA) to HS during its synthesis. The functional form of these enzymes appears to be a complex of the two located on the Golgi membrane. Defects in either EXT1 or EXT2 can cause hereditary multiple exostoses 1 (Petersen 1989) and 2 (McGaughran et al. 1995) respectively (MIM:133700 and MIM:133701), autosomal dominant disorders characterized by multiple projections of bone capped by cartilage resulting in deformed legs, forearms and hands. Trichorhinophalangeal syndrome, type II (TRPS2 aka Langer-Giedion syndrome, LGS) is a disorder that combines the clinical features of trichorhinophalangeal syndrome type I (TRPS1, MIM:190350) and multiple exostoses type I, caused by mutations in the TRPS1 and EXT1 genes, respectively (Langer et al. 1984, Ludecke et al. 1995). Defects in EXT1 may also be responsible for chondrosarcoma (CHDS; MIM:215300) (Schajowicz    Bessone 1967, Hecht et al. 1995).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep156">
 <bp:stepProcess rdf:resource="#Pathway75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep155">
 <bp:stepProcess rdf:resource="#Catalysis72" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep154">
 <bp:stepProcess rdf:resource="#Pathway74" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep153">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
 <bp:stepProcess rdf:resource="#Catalysis71" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep152">
 <bp:stepProcess rdf:resource="#Catalysis70" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep151">
 <bp:stepProcess rdf:resource="#Catalysis69" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence134">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway100">
 <bp:pathwayOrder rdf:resource="#PathwayStep212" />
 <bp:pathwayOrder rdf:resource="#PathwayStep211" />
 <bp:pathwayOrder rdf:resource="#PathwayStep210" />
 <bp:pathwayOrder rdf:resource="#PathwayStep209" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction113" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction111" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence209" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 causes exostoses 2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Heparan sulfate (HS) is involved in regulating various body functions during development, homeostasis and pathology including blood clotting, angiogenesis and metastasis of cancer cells. Exostosin 1 and 2 (EXT1 and 2) glycosyltransferases are required to form HS. They are able to transfer N-acetylglucosamine (GlcNAc) and glucuronate (GlcA) to HS during its synthesis. The functional form of these enzymes appears to be a complex of the two located on the Golgi membrane. Defects in either EXT1 or EXT2 can cause hereditary multiple exostoses 1 (Petersen 1989) and 2 (McGaughran et al. 1995) respectively (MIM:133700 and MIM:133701), autosomal dominant disorders characterised by multiple projections of bone capped by cartilage resulting in deformed legs, forearms and hands.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence376">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence135">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway101">
 <bp:pathwayOrder rdf:resource="#PathwayStep214" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction114" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence214" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT7 causes EDS, progeroid type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ehlers&#8211;Danlos syndrome (EDS) is a group of inherited connective tissue disorders, caused by a defect in the synthesis of collagen types I or III. Abnormal collagen renders connective tissues more elastic. The severity of the mutation can vary from mild to life-threatening. There is no cure and treatment is supportive, including close monitoring of the digestive, excretory and particularly the cardiovascular systems. Defective B4GALT7, a galactosyltransferase important in proteoglycan synthesis, causes the progeroid variant of EDS (MIM:130070). Features include an aged appearance, developmental delay, short stature, generalized osteopenia, defective wound healing, hypermobile joints, hypotonic muscles, and loose but elastic skin (Okajima et al. 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence377">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence132">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway102">
 <bp:pathwayOrder rdf:resource="#PathwayStep216" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction115" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence216" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GAT3 causes JDSSDHD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferases1, 2 and 3 (B3GAT1-3) are involved in forming the linker tetrasaccharide present in heparan sulfate and chondroitin sulfate. Defects in B3GAT3 cause multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects (JDSSDHD; MIM:245600). This is an autosomal recessive disease characterized by dysmorphic facies, elbow, hip and knee dislocations, clubfeet, short stature and cardiovascular defects (Steel    Kohl 1972, Bonaventure et al. 1992, Baasanjav et al. 2011). JDSSDHD has phenotypic similarities to Larsen syndrome (Larsen et al. 1950).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence374">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence133">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway103">
 <bp:pathwayOrder rdf:resource="#PathwayStep218" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction116" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence218" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST6 causes MCDC1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbohydrate sulfotransferase 6 (CHST6) catalyzes the transfer of sulfate to position 6 of non-reducing ends of N-acetylglucosamine (GlcNAc) residues on keratan sulfate (KS). KS plays a central role in maintaining corneal transparency. Defective CHST6 (Nakazawa et al. 1984) results in unsulfated keratan deposited within the intracellular space and the extracellular corneal stroma leading to macular dystrophy, corneal type I (MCDC1; MIM:217800). MCDC1 is an early-onset, ocular disease characterized by bilateral, progressive corneal opacification, and reduced corneal sensitivity (Jones    Zimmerman 1961). MCD can be subdivided into 2 types on the basis of immunohistochemical studies and serum analysis for keratan sulfate; MCD type I, in which there is a virtual absence of sulfated KS-specific antibody response in the serum and cornea and MCD type II, in which the normal KS-specific antibody response is present in cornea and serum (Yang et al. 1988).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence375">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence138">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway104">
 <bp:pathwayOrder rdf:resource="#PathwayStep220" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction117" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence220" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST3 causes SEDCJD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbohydrate sulfotransferase 3 (CHST3) transfers sulfate (SO4(2-)) to position 6 of N-acetylgalactosamine (GalNAc) residues of chondroitin-containg proteins resulting in chondroitin sulfate (CS), the predominant glycosaminoglycan present in cartilage. Defects in CHST3 result in spondyloepiphyseal dysplasia with congenital joint dislocations (SEDCJD; MIM:143095), a bone dysplasia clinically characterized by severe progressive kyphoscoliosis (abnormal curvature of the spine), arthritic changes with joint dislocations and short stature in adulthood (Unger et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence139">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway105">
 <bp:pathwayOrder rdf:resource="#PathwayStep222" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction118" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence222" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST14 causes EDS, musculocontractural type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbohydrate sulfotransferase 14 (CHST14 also known as D4ST-1) mediates the transfer of sulfate to position 4 of further N-acetylgalactosamine (GalNAc) residues of dermatan sulfate (DS). Defects in CHST14 cause Ehlers-Danlos syndrome, musculocontractural type (MIM:601776). The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders that share common features such as  skin hyperextensibility, articular hypermobility and tissue fragility (Beighton et al. 1998). The musculocontractural form of EDS (MIM:601776) include distinctive characteristics such as craniofacial dysmorphism, congenital contractures of fingers and thumbs, clubfeet, severe kyphoscoliosis and muscular hypotonia (Malfait et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence136">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway106">
 <bp:pathwayOrder rdf:resource="#PathwayStep224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction119" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence224" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALT6 causes EDSP2 and SEMDJL1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The biosynthesis of dermatan sulfate/chondroitin sulfate and heparin/heparan sulfate glycosaminoglycans (GAGs) starts with the formation of a tetrasaccharide linker sequence attached to the core protein. Beta-1,3-galactosyltransferase 6 (B3GALT6) is one of the critical enzymes involved in the formation of this linker sequence. Defects in B3GALT6 causes Ehlers-Danlos syndrome progeroid type 2 (EDSP2; MIM:615349), a severe disorder resulting in a broad spectrum of skeletal, connective tissue and wound healing problems. Defects in B3GALT6 can also cause spondyloepimetaphyseal dysplasia with joint laxity type 1 (SEMDJL1; MIM:271640), characterised by spinal deformaty and lax joints, especially of the hands and respiratory compromise resulting in early death (Nakajima et al. 2013, Malfait et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence378">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence137">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep159">
 <bp:stepProcess rdf:resource="#Pathway76" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway107">
 <bp:pathwayOrder rdf:resource="#PathwayStep228" />
 <bp:pathwayOrder rdf:resource="#PathwayStep227" />
 <bp:pathwayOrder rdf:resource="#PathwayStep226" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction120" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction122" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence226" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB causes GM2G2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-hexosaminidase (HEX) cleaves the terminal N-acetyl galactosamine (GalNAc) from glycosaminoglycans (GAGs) and any other molecules containing a terminal GalNAc. There are two forms of HEX; HEXA and B. The A form is a trimer of the subunits alpha, beta A and beta B. The B form is a tetramer of 2 beta A and 2 beta B subunits (O&apos;Dowd et al. 1988). Defects in the two subunits cause lysosomal storage diseases marked by the accumulation of GM2 gangliosides in neuronal cells.  Defects in the beta subunits are the cause of GM2-gangliosidosis type 2 (GM2G2; MIM:268800), also known as Sandhoff disease (Sandhoff et al. 1968, Banerjee et al. 1991). Sandhoff disease is an autosomal recessive lysosomal storage disease clinically indistinguishable from GM2-gangliosidosis type 1, presenting early blindness with cherry-red spots on the macula, progressive motor and mental deterioration and macrocephaly. Death usually occurs by the age of 3 years.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence379">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence350">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence351">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep183">
 <bp:stepProcess rdf:resource="#Catalysis86" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction96" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep182">
 <bp:stepProcess rdf:resource="#Pathway88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep181">
 <bp:stepProcess rdf:resource="#Pathway87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep180">
 <bp:stepProcess rdf:resource="#Catalysis85" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction95" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence109">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence107">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep189">
 <bp:stepProcess rdf:resource="#Catalysis89" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction99" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence349">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence108">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep188">
 <bp:stepProcess rdf:resource="#Pathway91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep187">
 <bp:stepProcess rdf:resource="#BiochemicalReaction98" />
 <bp:stepProcess rdf:resource="#Catalysis88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep186">
 <bp:stepProcess rdf:resource="#Pathway90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep185">
 <bp:stepProcess rdf:resource="#BiochemicalReaction97" />
 <bp:stepProcess rdf:resource="#Catalysis87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep184">
 <bp:stepProcess rdf:resource="#Pathway89" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence343">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence344">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence341">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence342">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence347">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence106">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence348">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence345">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence346">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence361">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence120">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence362">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence360">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep172">
 <bp:stepProcess rdf:resource="#Catalysis81" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep171">
 <bp:stepProcess rdf:resource="#Pathway82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep170">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
 <bp:stepProcess rdf:resource="#Catalysis80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep179">
 <bp:stepProcess rdf:resource="#Pathway86" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence118">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep178">
 <bp:stepProcess rdf:resource="#Catalysis84" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction94" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence119">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep177">
 <bp:stepProcess rdf:resource="#Pathway85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep176">
 <bp:stepProcess rdf:resource="#Catalysis83" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep175">
 <bp:stepProcess rdf:resource="#Pathway84" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep174">
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
 <bp:stepProcess rdf:resource="#Catalysis82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep173">
 <bp:stepProcess rdf:resource="#Pathway83" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence354">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence355">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence352">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence353">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence116">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence358">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence359">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence356">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence357">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DBT loss-of-function mutants don&apos;t synthesize BCAA-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep125">
 <bp:stepProcess rdf:resource="#Pathway61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep367">
 <bp:stepProcess rdf:resource="#BiochemicalReaction197" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACAT1 mutants don&apos;t synthesize propionyl-CoA or acetyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep124">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
 <bp:stepProcess rdf:resource="#Catalysis60" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep366">
 <bp:stepProcess rdf:resource="#Pathway171" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function DLD mutants don&apos;t dehydrogenate dihydrolipoyl DBT</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep123">
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
 <bp:stepProcess rdf:resource="#Catalysis59" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep365">
 <bp:stepProcess rdf:resource="#BiochemicalReaction196" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H139Hfs13* PPM1K does not dephosphorylate BCKDH</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep122">
 <bp:stepProcess rdf:resource="#Pathway60" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep364">
 <bp:stepProcess rdf:resource="#Pathway170" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MCCC mutants don&apos;t synthesize beta-methylglutaconyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep121">
 <bp:stepProcess rdf:resource="#Pathway59" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep363">
 <bp:stepProcess rdf:resource="#BiochemicalReaction195" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCKDHA or BCKDHB loss-of-function mutants don&apos;t synthesize BCAA-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep120">
 <bp:stepProcess rdf:resource="#Pathway58" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep362">
 <bp:stepProcess rdf:resource="#Pathway169" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep361">
 <bp:stepProcess rdf:resource="#BiochemicalReaction194" />
</bp:PathwayStep>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ECHS1 mutants don&apos;t synthesize beta-hydroxyisobutyryl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep360">
 <bp:stepProcess rdf:resource="#Pathway168" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GBE1 does not catalyze branch formation in growing glycogen chains (liver)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep129">
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
 <bp:stepProcess rdf:resource="#Catalysis62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep128">
 <bp:stepProcess rdf:resource="#Pathway63" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective G6PC does not hydrolyze glucose 6-phosphate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep127">
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
 <bp:stepProcess rdf:resource="#Catalysis61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep369">
 <bp:stepProcess rdf:resource="#BiochemicalReaction198" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GYS1 does not transfer glucose to growing glycogen chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep126">
 <bp:stepProcess rdf:resource="#Pathway62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep368">
 <bp:stepProcess rdf:resource="#Pathway172" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep114">
 <bp:stepProcess rdf:resource="#Pathway55" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PNP does not convert (deoxy)guanosine to guanine and (deoxy)ribose</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep356">
 <bp:stepProcess rdf:resource="#Pathway166" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep113">
 <bp:stepProcess rdf:resource="#Catalysis55" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PNP does not convert (deoxy)inosine to hypoxanthine and (deoxy)ribose</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep355">
 <bp:stepProcess rdf:resource="#BiochemicalReaction191" />
 <bp:stepProcess rdf:resource="#Catalysis176" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep112">
 <bp:stepProcess rdf:resource="#Pathway54" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ADA does not deaminate (deoxy)adenosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep354">
 <bp:stepProcess rdf:resource="#Pathway165" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep111">
 <bp:stepProcess rdf:resource="#Catalysis54" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HPRT1 does not convert guanine or hypoxanthine to GMP or IMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep353">
 <bp:stepProcess rdf:resource="#BiochemicalReaction190" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep110">
 <bp:stepProcess rdf:resource="#Pathway53" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAH does not hydroxylate L-Phe to L-Tyr</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep352">
 <bp:stepProcess rdf:resource="#Pathway164" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective APRT does not convert adenine to AMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep351">
 <bp:stepProcess rdf:resource="#BiochemicalReaction189" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep350">
 <bp:stepProcess rdf:resource="#BiochemicalReaction188" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep119">
 <bp:stepProcess rdf:resource="#Catalysis58" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIBCH mutants don&apos;t synthesize beta-hydroxyisobutyrate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep118">
 <bp:stepProcess rdf:resource="#Pathway57" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCKDK loss-of-function mutations do not phosphorylate BCKDH</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep117">
 <bp:stepProcess rdf:resource="#Catalysis57" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep359">
 <bp:stepProcess rdf:resource="#BiochemicalReaction193" />
 <bp:stepProcess rdf:resource="#Catalysis177" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep116">
 <bp:stepProcess rdf:resource="#Pathway56" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IVD mutants don&apos;t synthesize beta-methylcrotonyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep358">
 <bp:stepProcess rdf:resource="#Pathway167" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep115">
 <bp:stepProcess rdf:resource="#Catalysis56" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AUH mutants don&apos;t synthesize 3-hydroxy-methylglutaryl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep357">
 <bp:stepProcess rdf:resource="#BiochemicalReaction192" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis180">
 <bp:controlled rdf:resource="#BiochemicalReaction203" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis182">
 <bp:controlled rdf:resource="#BiochemicalReaction205" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis181">
 <bp:controlled rdf:resource="#BiochemicalReaction204" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep381">
 <bp:stepProcess rdf:resource="#BiochemicalReaction206" />
 <bp:stepProcess rdf:resource="#Catalysis183" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SGSH does not hydrolyse Heparan sulfate chain(2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep380">
 <bp:stepProcess rdf:resource="#BiochemicalReaction205" />
 <bp:stepProcess rdf:resource="#Catalysis182" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GUSB does not hydrolyse GlcA-&#946;1,3-GlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep147">
 <bp:stepProcess rdf:resource="#Pathway72" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GUSB does not hydrolyse CS/HS precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep146">
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
 <bp:stepProcess rdf:resource="#Catalysis66" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GLB1 does not hydrolyse a glycosaminoglycan</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep145">
 <bp:stepProcess rdf:resource="#Pathway71" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GUSB does not hydrolyse (HA)2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep144">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNS does not hydrolyse sulfate from Gal6S in keratan sulfate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep143">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GLB1 does not hydrolyse linker chain(2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep142">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HGSNAT does not acetylate Heparan sulfate chain(3)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep141">
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HGSNAT does not acetylate Heparan chain(1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep140">
 <bp:stepProcess rdf:resource="#Pathway70" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis173">
 <bp:controlled rdf:resource="#BiochemicalReaction184" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis172">
 <bp:controlled rdf:resource="#BiochemicalReaction183" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis175">
 <bp:controlled rdf:resource="#BiochemicalReaction186" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis174">
 <bp:controlled rdf:resource="#BiochemicalReaction185" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis177">
 <bp:controlled rdf:resource="#BiochemicalReaction193" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis176">
 <bp:controlled rdf:resource="#BiochemicalReaction191" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDS does not hydrolyse dermatan sulfate (Chebi:63517 chain)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep149">
 <bp:stepProcess rdf:resource="#Pathway73" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis179">
 <bp:controlled rdf:resource="#BiochemicalReaction202" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep148">
 <bp:stepProcess rdf:resource="#Catalysis67" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis178">
 <bp:controlled rdf:resource="#BiochemicalReaction201" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep370">
 <bp:stepProcess rdf:resource="#BiochemicalReaction199" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GYG1 is not autoglucosyolated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep136">
 <bp:stepProcess rdf:resource="#Pathway67" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep378">
 <bp:stepProcess rdf:resource="#BiochemicalReaction203" />
 <bp:stepProcess rdf:resource="#Catalysis180" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DCXR does not reduce L-xylulose to xylitol</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep135">
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep377">
 <bp:stepProcess rdf:resource="#Pathway176" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EPM2A does not dephosphorylate phosphoglycogen (type 2A disease)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep134">
 <bp:stepProcess rdf:resource="#Pathway66" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep376">
 <bp:stepProcess rdf:resource="#BiochemicalReaction202" />
 <bp:stepProcess rdf:resource="#Catalysis179" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GYS2 does not transfer glucose to growing glycogen chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep133">
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
 <bp:stepProcess rdf:resource="#Catalysis64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep375">
 <bp:stepProcess rdf:resource="#BiochemicalReaction201" />
 <bp:stepProcess rdf:resource="#Catalysis178" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC37A4 does not exchange G6P and Pi across the ER membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep132">
 <bp:stepProcess rdf:resource="#Pathway65" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep374">
 <bp:stepProcess rdf:resource="#Pathway175" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NHLRC1 does not ubiquitinate EPM2A (laforin) and PPP1R3C (PTG) (type 2B disease)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep131">
 <bp:stepProcess rdf:resource="#Catalysis63" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep373">
 <bp:stepProcess rdf:resource="#Pathway174" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GAA does not hydrolyze lysosomal glycogen</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep130">
 <bp:stepProcess rdf:resource="#Pathway64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep372">
 <bp:stepProcess rdf:resource="#BiochemicalReaction200" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective G6PC3 does not hydrolyze glucose 6-phosphate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep371">
 <bp:stepProcess rdf:resource="#Pathway173" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis183">
 <bp:controlled rdf:resource="#BiochemicalReaction206" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep139">
 <bp:stepProcess rdf:resource="#Pathway69" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNS does not hydrolyse 6-sulfate from GlcNAc6S</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep138">
 <bp:stepProcess rdf:resource="#Pathway68" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SGSH does not hydrolyse Heparan sulfate chain(7)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep137">
 <bp:stepProcess rdf:resource="#Catalysis65" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep379">
 <bp:stepProcess rdf:resource="#BiochemicalReaction204" />
 <bp:stepProcess rdf:resource="#Catalysis181" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hereditary fructose intolerance</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deficiencies in aldolase B arising from mutations in the aldolase B gene (ALDOB) prevent the cleavage of fructose 1-phosphate to glyceraldehyde (GA) and dihydroxyacetone phosphate (DHAP), leading to hereditary fructose intolerance (HFI). This autosomal recessive disorder is potentially fatal, but can be managed by exclusion of fructose from the diet (Cox et al. 1988; Tolan 1995).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction98">
 <bp:evidence rdf:resource="#Evidence188" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT1 does not transfer Man from Dol-P-Man to DAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep323">
 <bp:stepProcess rdf:resource="#Pathway150" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in transaldolase 1 (TALDO1), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of D-fructose 6-phosphate and D-erythrose 4-phosphate to form sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate, have been associated with congenital liver disease (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction97">
 <bp:evidence rdf:resource="#Evidence186" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective C1GALT1C1 does not bind C1GALT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep322">
 <bp:stepProcess rdf:resource="#Catalysis163" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction174" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep321">
 <bp:stepProcess rdf:resource="#Pathway149" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction99">
 <bp:evidence rdf:resource="#Evidence190" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT12 does not transfer GalNAc to mucins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep320">
 <bp:stepProcess rdf:resource="#Catalysis162" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction173" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RA does not bind SFTPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA3 does not transport PC, PG from ER membrane to lamellar body</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of propionyl-CoA catabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Propionyl-CoA catabolism is the aspect of mitochondrial beta-oxidation affected by the one disease of this process annotated in Reactome.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence171" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPAGT1 does not transfer GlcNAc to DOLP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SFTPA2 does not translocate from ER membrane to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of mitochondrial beta oxidation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Of the array of known defects of mitochondrial lipid metabolism, one is annotated in Reactome, methylmalonic acidurioa due to deficiencies of the MMUT (Methylmalonyl-CoA mutase, mitochondrial) enzyme (Worgan et al. 2006)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A2 does not cotransport HPO4(2-), 3Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#Pathway20" />
 <bp:pathwayComponent rdf:resource="#Pathway22" />
 <bp:pathwayComponent rdf:resource="#Pathway21" />
 <bp:pathwayComponent rdf:resource="#Pathway35" />
 <bp:pathwayComponent rdf:resource="#Pathway34" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of carbohydrate metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The processes by which dietary carbohydrate is digested to monosaccharides and these are taken up from the gut lumen into cells where they are oxidized to yield energy or consumed in biosynthetic processes are a central part of human metabolism and defects in them can lead to serious disease. Defects annotated here affect saccharide digestion in the gut lumen, fructose metabolism, and the pentose phosphate pathway. In addition, the defect in glucuronate catabolism that leads to essential pentosuria, a benign phenotype that is one of Garrod&apos;s original four inborn errors of metabolism, is annotated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence175" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NEU1 does not hydrolyse Neu5Ac from glycoconjugates</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep329">
 <bp:stepProcess rdf:resource="#BiochemicalReaction178" />
 <bp:stepProcess rdf:resource="#Catalysis167" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPB does not translocate from ER membrane to multivesicle body</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUT causes MMAM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MUT cause methylmalonic aciduria, mut type (MMAM; MIM:251000), an often fatal disorder of organic acid metabolism (Worgan et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence173" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not add Gal to N-glycan</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep328">
 <bp:stepProcess rdf:resource="#Pathway152" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPC does not translocate from ER membrane to multivesicle body</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RPIA deficiency: failed conversion of R5P to RU5P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A mutation in ribose-5-phosphate isomerase (RPIA), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of  ribose 5-phosphate and D-ribulose 5-phosphate, has been associated with a slowly progressive leukoencephalopathy (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction94">
 <bp:evidence rdf:resource="#Evidence179" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG1 does not transfer the first Man to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep327">
 <bp:stepProcess rdf:resource="#Catalysis166" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction177" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RB does not bind SFTPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pentose phosphate pathway disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant forms of two enzymes of the pentose phosphate pathway have been associated with disease in humans. A mutation in ribose-5-phosphate isomerase (RPIA), which normally mediates the reversible interconversion of D-ribulose-5-phosphate and ribose-5-phosphate, has been associated with a slowly progressive leukoencephalopathy, and mutations in transaldolase 1 (TALDO1), which normally mediates the reversible interconversion of D-fructose 6-phosphate and D-erythrose-4-phosphate to form sedoheptulose-7-phosphate and D-glyceraldehyde-3-phosphate, have been associated with congenital liver disease (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence177" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG12 does not add mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep326">
 <bp:stepProcess rdf:resource="#Pathway151" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RPIA does not isomerize R5P to RU5P</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RPIA deficiency: failed conversion of RU5P to R5P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A mutation in ribose-5-phosphate isomerase (RPIA), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of   D-ribulose 5-phosphate and ribose 5-phosphate, has been associated with a slowly progressive leukoencephalopathy (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction96">
 <bp:evidence rdf:resource="#Evidence184" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALTL does not transfer glucose to O-fucosyl-proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep325">
 <bp:stepProcess rdf:resource="#Catalysis165" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction176" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUT does not isomerise L-MM-CoA to SUCC-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in transaldolase 1 (TALDO1), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate to form D-fructose 6-phosphate and D-erythrose 4-phosphate, have been associated with congenital liver disease (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction95">
 <bp:evidence rdf:resource="#Evidence181" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG2 does not transfer a second Man to N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep324">
 <bp:stepProcess rdf:resource="#Catalysis164" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction175" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway20">
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Intestinal saccharidase deficiencies</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in in two enzymes required for intestinal digestion of dietary carbohydrate, lactase (LCT, a domain of lactase-phlorizin hydrolase protein) and sucrase-isomaltase (SI), are annotated here. The first affects nursing infants; the second affects individuals after weaning. The disaccharide lactose is a major constituent of human breast milk. To be taken up from the gut in the nursing infant, this sugar must first be hydrolyzed by LCT present on the external face of enterocytes in microvilli of the small intestine. Mutations that disrupt LCT activity are associated with acute illness in newborn children as lactose fermentation by gut bacteria leads to severe diarrhea. The condition is effectively treated by feeding affected infants a lactose-free formula. This congenital disease is distinct from the down-regulation of LCT expression after weaning in many human populations that is associated with a milder form of lactose intolerance in adults (Jarvela et al. 2009). The starch in a post-weaning diet is digested by amylases to di- and oligosaccharides that must be further digested to monosaccharides in order to be taken up from the lumen of the small intestine into endothelial cells of the intestinal brush border. If they are not digested, a process in which enterocyte-associated SI plays a central role, they remain in the gut lumen and are fermented by gut bacteria, leading to osmotic and fermentative diarrhea (Naim et al. 2012; Van Beers et al. 1995).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep312">
 <bp:stepProcess rdf:resource="#Pathway145" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway29">
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IV - Morquio syndrome B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in beta-galactosidase (GLB1; MIM:611458) can result in GM1 gangliosidosis (GM1; MIM:230500) (Nishimoto et al. 1991) (not described here), with several phenotypes indicating mental deterioration, as well as in mucopolysaccharidosis IVB, a characteristic mucopolysaccharidosis with no neurological symptoms (Callahan 1999).  Mucopolysaccharidosis IVB (MPS IVB, Morquio&apos;s syndrome B; MIM:253010) is a rare, autosomal recessive mucopolysaccharide storage disease characterized by intracellular accumulation of keratan sulfate (KS), skeletal dysplasia and corneal clouding. There is no central nervous system involvement, intelligence is normal and there is increased KS excretion in urine (Suzuki et al. &quot;Beta-galactosidase deficiency (beta-galactosidosis): GM1 gangliosidosis and Morquio B disease&quot;, p3775-3809 in Stryer et al. 2001). MPSIVB is caused by a defect in betagalactosidase (GLB1), which normally cleaves terminal galactosyl residues from glycosaminoglycans, gangliosides and glycoproteins. The GLB1 gene spans 62.5 kb and contains 16 exons (Oshima et al.1988, Santamaria et al. 2007) and maps to chromosome 3p21.33 (Takano    Yamanouchi 1993).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep311">
 <bp:stepProcess rdf:resource="#BiochemicalReaction168" />
 <bp:stepProcess rdf:resource="#Catalysis157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep310">
 <bp:stepProcess rdf:resource="#Pathway144" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway22">
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayComponent rdf:resource="#Pathway29" />
 <bp:pathwayComponent rdf:resource="#Pathway31" />
 <bp:pathwayComponent rdf:resource="#Pathway30" />
 <bp:pathwayComponent rdf:resource="#Pathway33" />
 <bp:pathwayComponent rdf:resource="#Pathway32" />
 <bp:pathwayComponent rdf:resource="#Pathway24" />
 <bp:pathwayComponent rdf:resource="#Pathway23" />
 <bp:pathwayComponent rdf:resource="#Pathway26" />
 <bp:pathwayComponent rdf:resource="#Pathway25" />
 <bp:pathwayComponent rdf:resource="#Pathway28" />
 <bp:pathwayComponent rdf:resource="#Pathway27" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidoses</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mucopolysaccharidoses (MPS) are a group of rare, inherited lysosomal storage disorders caused by deficiencies of enzymes catalyzing the stepwise degradation of glycosaminoglycans (GAGs, originally called mucopolysaccharides) (Neufeld    Muenzer in Scriver et al. 2001). Catabolism of the GAGs dermatan sulfate, heparan sulfate, heparin, keratan sulfate, chondroitin sulfate or hyaluronan may be blocked at one or more steps, resulting in lysosomal accumulation of GAG fragments of varying size. Over time these collect in the cells, blood and connective tissues ultimately resulting in progressive irreversible cellular damage which affects appearance, physical abilities, organ and system function, vision, and usually mental development (Lehman et al. 2011, Ashworth et al. 2006). Life expectancy is also reduced. There are 11 known enzyme deficiencies that give rise to 7 distinct MPS. These disorders are biochemically characterized by elevated levels of partially or undegraded GAGs in lysosomes, blood, urine and cerebro-spinal fluid (Muenzer 2011, Coutinho et al. 2012). The MPS are part of the lysosomal storage disease family, a group of about 50 genetic disorders caused by deficient lysosomal proteins (Ballabio    Gieselmann 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway21">
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Essential fructosuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deficiencies in KHK (ketohexokinase) are associated with essential fructosuria (Bonthron et al. 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep319">
 <bp:stepProcess rdf:resource="#Pathway148" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway24">
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS VI - Maroteaux-Lamy syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome, polydystrophic dwarfism; MIM:253200) is an autosomal recessive lysosomal storage disorder caused by a deficiency in arylsulfatase B (ARSB, N-acetyl-galactosamine 4-sulfatase; MIM:611542). It is named after two French physicians, Pierre Maroteaux and Maurice Emil Joseph Lamy. Maroteaux first described this disorder as a novel dysostosis associated with increased urinary excretion of chondroitin sulfate (CS; Maroteaux et al. 1963). The gene encoding ARSB is mapped to chromosome 5q11-q13 (Fidzianska et al. 1984) and contains 8 exons spanning about 206 kb (Karangeorgos et al. 2007). Defective ARSB results in build up of dermatan sulfate (DS) and chondroitin sulfate (CS) in soft tissues causing compression and blockages in blood vessels, nerves, trachea, corneal clouding and disrupting normal bone development. Symptoms are similar to MPS I but with normal intelligence generally (Rapini et al. 2007, Valayannopoulos et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep318">
 <bp:stepProcess rdf:resource="#Catalysis161" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction172" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway23">
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS I - Hurler syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type I (MPS I, Hurler syndrome, Hurler&apos;s disease, gargoylism, Scheie, Hirler-Scheie syndrome;  MIM:607014, 607015 and 607016) is an autosomal recessive genetic disorder where there is a deficiency of alpha-L iduronidase (IDUA, MIM:252800), a glycosidase that removes non-reducing terminal alpha-L-iduronide residues during the lysosomal degradation of the glycosaminoglycans heparan sulphate and dermatan sulphate (McKusick 1959). In 1992, Scott and colleagues were able to clone and purify the gene that encodes this enzyme, IDUA, demonstrating that it spans approximately 19 kb and contains 14 exons (Scott et al. 1992). Hurler syndrome is named after a German paediatrician Gertrud Hurler (1919, no reference available). The result is build up of heparan sulfate and dermatan sulfate in the body and increased urinary excretion of these GAGs. Symptoms and signs include hepatosplenomegaly, dwarfism, unique facial features, corneal clouding, retinopathy, progressive mental retardation appears during childhood and early death can occur due to organ damage (Campos    Monaga 2012). MPS I is divided into three subtypes, ranging from severe to mild phenotypes; Mucopolysaccharidosis type IH (MPSIH, Hurler syndrome, MIM:607014), mucopolysaccharidosis type IH/S (MPSIH/S, HurlerScheie syndrome, MIM: 607015) and mucopolysaccharidosis type IS (MPSIS, Scheie syndrome, MIM: 607016) respectively (McKusick 1972).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep317">
 <bp:stepProcess rdf:resource="#Catalysis160" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction171" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway26">
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IX - Natowicz syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type IX (MPS IX, Natowicz syndrome, Hyaluronidase deficiency, MIM:601492) is a rare lysosomal storage disease characterized by high hyaluronan (HA) concentration in the serum resulting from deficiency in hyaluronidase 1 (HYAL1, MIM:607071) which normally hydrolyses 1-4 linkages between N-acetylglucosamine (GlcNAc) and D-glucuronate (GlcA) residues. Symptoms of MPS IX are periodically painful soft tissue masses around the joints, acquired short stature and erosion of the hip joint, although joint movement and intelligence are normal (Natowicz et al. 1996, Triggs-Raine et al. 1999). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep316">
 <bp:stepProcess rdf:resource="#Pathway147" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway25">
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIIB - Sanfilippo syndrome B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837838, 1963, no reference). MPS IIIB (Mucopolysaccharidosis type IIIB, MPS IIIB, Sanfilippo syndrome type B; MIM:252920) is an autosomal recessive genetic disorder due to loss of function of alpha-N-acetylglucosaminidase (NAGLU; MIM:609701), involved in the hydrolysis of terminal non-reducing N-acetylglucosamine residues in heparan sulfate (HS) The gene encoding NAGLU was cloned in 1996 by Zhao and colleagues. It contains 6 exons and spans 8.3 kb on chromosome 17q21 (Zhao et al. 1996). MPSIIIB is characterized by severe CNS retardation but only mild somatic disease and death usually occurs in the second or third decade of life (Zhao et al. 1996, Yogalingam    Hopwood 2001, de Ruijter et al. 2011). MPS IIIB shows extensive molecular heterogeneity (Schmidtchen et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep315">
 <bp:stepProcess rdf:resource="#Catalysis159" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction170" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway28">
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS VII - Sly syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type VII (MPS VII, Sly syndrome, beta-glucuronidase deficiency; MIM:253220) is an autosomal recessive lysosomal storage disease characterized by a deficiency of the enzyme beta-glucuronidase (GUSB; MIM:611499) which would normally cleave glucuronide residues from dematan sulphate, keratan sulphate and chondroitin sulphate, resulting in build up of these GAGs in cells and tissues (Sly et al. 1973). The gene encoding GUSB is 21 kb long, contains 12 exons and gives rise to two different types of cDNAs, through an alternate splicing mechanism (Miller et al. 1990). It maps to 7q11.21-q11.22 (Speleman et al. 1996). The phenotype is highly variable, ranging from severe causing death, non-immune hydrops fetalis (Vervoort et al. 1996) to mild forms with survival into adulthood (Storch et al. 2003). Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment (Shipley et al. 1993, Tomatsu et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep314">
 <bp:stepProcess rdf:resource="#Pathway146" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway27">
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS II - Hunter syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis II (MPS II, Hunter syndrome, MIM:309900) is an X-linked, recessive genetic disorder which therefore primarily affects males. MPS II was first described in 1917, by Major Charles Hunter (Hunter 1917) and is caused by a deficiency (or absence) of iduronate-2-sulfatase (IDS, MIM:300823), which would normally hydrolyse the 2-sulfate groups of the L-iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and heparin. Without IDS, these GAGs accumulate in the body and are excessively excreted in urine. Although the disease was known since the early 1970s, being the first MPS to be defined clinically in humans, it wasn&apos;t until the 1990s that IDS was cloned. It is now known to be localized to Xq28 (Wilson et al. 1991) and contain 9 exons (Flomen et al. 1993) spanning approximately 24 kb (Wilson et al. 1993). Build up can occur in the liver and spleen as well as in the walls and valves of the heart (reduced hepatic and cardiac function, liver/spleen hepatosplenomegaly), airways (leading to obstructive airway disease), all major joints and bones (joint stiffness and skeletal deformities) and in brain (severe mental retardation). The rate of progression and degree of severity of the disorder can be different for each person with MPS II. Severe forms of the disorder can result in death in childhood whereas those with a &quot;milder&quot; form can expect to live to their 20&apos;s or 30&apos;s.   Some patients even survive into their fifth and sixth decades of life (Wraith et al. 2008, Beck 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep313">
 <bp:stepProcess rdf:resource="#Catalysis158" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction169" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence192">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence193">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence190">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway160">
 <bp:pathwayOrder rdf:resource="#PathwayStep373" />
 <bp:pathwayOrder rdf:resource="#PathwayStep346" />
 <bp:pathwayComponent rdf:resource="#Pathway161" />
 <bp:pathwayComponent rdf:resource="#Pathway174" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence346" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in vitamin and cofactor metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vitamins are essential nutrients, required in small amounts from the diet for the normal growth and development of a multicellular organism. Where there is vitamin deficiency, either by poor diet or a defect in metabolic conversion, diseases called Avitaminoses occur. Currently, cobalamin (Cbl, vitamin B12) metabolic defects are described below (Chapter 155 in The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver et al. 2001)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence191">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway161">
 <bp:pathwayOrder rdf:resource="#PathwayStep356" />
 <bp:pathwayOrder rdf:resource="#PathwayStep366" />
 <bp:pathwayOrder rdf:resource="#PathwayStep354" />
 <bp:pathwayOrder rdf:resource="#PathwayStep364" />
 <bp:pathwayOrder rdf:resource="#PathwayStep352" />
 <bp:pathwayOrder rdf:resource="#PathwayStep362" />
 <bp:pathwayOrder rdf:resource="#PathwayStep360" />
 <bp:pathwayOrder rdf:resource="#PathwayStep371" />
 <bp:pathwayOrder rdf:resource="#PathwayStep349" />
 <bp:pathwayOrder rdf:resource="#PathwayStep347" />
 <bp:pathwayOrder rdf:resource="#PathwayStep358" />
 <bp:pathwayOrder rdf:resource="#PathwayStep368" />
 <bp:pathwayComponent rdf:resource="#Pathway170" />
 <bp:pathwayComponent rdf:resource="#Pathway171" />
 <bp:pathwayComponent rdf:resource="#Pathway172" />
 <bp:pathwayComponent rdf:resource="#Pathway162" />
 <bp:pathwayComponent rdf:resource="#Pathway173" />
 <bp:pathwayComponent rdf:resource="#Pathway163" />
 <bp:pathwayComponent rdf:resource="#Pathway164" />
 <bp:pathwayComponent rdf:resource="#Pathway165" />
 <bp:pathwayComponent rdf:resource="#Pathway166" />
 <bp:pathwayComponent rdf:resource="#Pathway167" />
 <bp:pathwayComponent rdf:resource="#Pathway168" />
 <bp:pathwayComponent rdf:resource="#Pathway169" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence347" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in cobalamin (B12) metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cobalamin (Cbl, vitamin B12) is a nutrient essential for normal functioning of the brain and nervous system and for the formation of blood. Cbl-dependent methionine synthase (MTR) is required for conversion of 5-methyltetrahydrofolate (metTHF) to tetrahydrofolate (THF), in addition to its role in conversion of homocysteine to methionine. In Cbl deficiency, and in inborn errors of Cbl metabolism that affect function of methionine synthase, inability to regenerate THF from metTHF results in decreased function of folate-dependent reactions that are involved in 2 steps of purine biosynthesis and thymidylate synthesis. Cbl deficiency results in hyperhomocysteinemia (due to defects in the conversion of homocysteine to methionine which requires Cbl as a cofactor) and increased levels of methylmalonic acid (MMA). Methionine is used in myelin production, protein, neurotransmitter, fatty acid and phospholipid production and DNA methylation. Symptoms of Cbl deficiency are bone marrow promegaloblastosis (megaloblastic anemia) due to the inhibition of DNA synthesis (specifically purines and thymidine) and neurological symptoms. The defective genes involved in Cbl deficiencies are described below (Froese    Gravel 2010, Nielsen et al. 2012, Whitehead 2006, Watkins    Rosenblatt 2011, Fowler 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence196">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway162">
 <bp:pathwayOrder rdf:resource="#PathwayStep348" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction187" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence348" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CD320 causes MMATC</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in CD320 cause methylmalonic aciduria type TCblR (MMATC aka methylmalonic aciduria; MIM:613646) resulting in elevated methylmalonic acid (MMA) and homocysteine (HCYS) in newborns (Quadros et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence197">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway163">
 <bp:pathwayOrder rdf:resource="#PathwayStep351" />
 <bp:pathwayOrder rdf:resource="#PathwayStep350" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction188" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence350" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTR causes HMAG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MTR cause methylcobalamin deficiency type G (cblG; MIM:250940), an autosomal recessive inherited disease that causes mental retardation, macrocytic anemia, and homocystinuria (Leclerc et al. 1996, Gulati et al. 1996, Watkins et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence194">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway164">
 <bp:pathwayOrder rdf:resource="#PathwayStep353" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction190" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence353" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TCN2 causes TCN2 deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective transcobalamin II (produced by the TCN2 gene) results in TCN2 deficiency (MIM:275350), an autosomal recessive disorder with early-onset in infancy characterized by failure to thrive, megaloblastic anemia, and pancytopenia. If left untreated, the disorder can result in mental retardation and neurologic abnormalities (Haberle et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence195">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway165">
 <bp:pathwayOrder rdf:resource="#PathwayStep355" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction191" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence355" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAB causes MMA, cblB type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMAB cause methylmalonic aciduria type cblB (cblB aka methylmalonic aciduria type B or vitamin B12 responsive methylmalonicaciduria of cblB complementation type; MIM:251110). Affected individuals have methylmalonic aciduria and episodes of metabolic ketoacidosis, despite a functional methylmalonyl CoA mutase. In severe cases, newborns become severely acidotic and may die if acidosis is not treated promptly (Dobson et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
 <bp:stepProcess rdf:resource="#Catalysis50" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence147" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG11 does not transfer Man to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep345">
 <bp:stepProcess rdf:resource="#Pathway160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#Pathway49" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence145" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to (GlcNAc)2 (Man)5 (PP-Dol)1 by ALG3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep344">
 <bp:stepProcess rdf:resource="#Catalysis175" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction186" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
 <bp:stepProcess rdf:resource="#Catalysis49" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence151" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse 1,2-linked mannose (c branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep343">
 <bp:stepProcess rdf:resource="#Catalysis174" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction185" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#Pathway48" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence149" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG14 does not transfer GlcNAc from UDP-GlcNAc to GlcNAcDOLP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep342">
 <bp:stepProcess rdf:resource="#Pathway159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep341">
 <bp:stepProcess rdf:resource="#Catalysis173" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction184" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence152" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse 1,2-linked mannose (a branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep340">
 <bp:stepProcess rdf:resource="#Pathway158" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence189">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway155">
 <bp:pathwayOrder rdf:resource="#PathwayStep335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction181" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence335" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26C1 causes FFDD4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinoic acid (RA) is a biologically active analogue of vitamin A (retinol). RA plays an important role in regulating cell growth and differentiation. CYP26C1 is involved in the metabolic breakdown of RA by 4-hydroxylation. While CYP26C1 can hydroxylate the trans form, it is unique in hydroxylating the 9-cis isomer of RA (9cRA) (Taimi et al. 2004). Defects in CYP26C1 can cause focal facial dermal dysplasia 4 (FFDD4; MIM:614974), a rare syndrome characterised by facial lesions.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway156">
 <bp:pathwayOrder rdf:resource="#PathwayStep337" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction182" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence337" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACY1 causes encephalopathy</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aminoacylase 1 (ACY1) is a cytosolic, homodimeric zinc-binding metalloenzyme with a wide range of tissue expression. It hydrolyses acylated L-amino acids (except L-aspartate) into L-amino acids and an acyl group. It can also hydrolyse N-acetylcysteine-S-conjugates. Defects in ACY1 can cause aminoacylase-1 deficiency (ACY1D; MIM:609924) resulting in encephalopathy, delay in psychomotor development, seizures and increased urinary excretion of several N-acetylated amino acids (Sass et al. 2006, Sass et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep109">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
 <bp:stepProcess rdf:resource="#Catalysis53" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACTH does not bind MCR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence187">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway157">
 <bp:pathwayOrder rdf:resource="#PathwayStep339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction183" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence339" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GSS causes GSS deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In mammalian cells, many antioxidant defence systems exist which protect cells from subsequent exposure to oxidant stresses. One antioxidant is glutathione (GSH), a tripeptide present in virtually all cells that regulates the intracellular redox state and protects cells from oxidative injury. It is metabolised via the gamma-glutamyl cycle, which is catalysed by six enzymes. In man, hereditary deficiencies have been found in five of the six enzymes. Glutathione synthetase deficiency is the most frequently recognised disorder. Defects in GSS can cause glutathione synthetase deficiency (GSSD aka 5-oxoprolinase deficiency, MIM:266130), a severe autosomal recessive disorder characterised by an increased rate of haemolysis, 5-oxoprolinuria, CNS damage and recurrent bacterial infections. In this condition, decreased levels of cellular glutathione result in overstimulation of gamma-glutamylcysteine synthesis and its subsequent conversion to 5-oxoproline. Glutathione synthetase deficiency can be classed as mild, moderate or severe (Ristoff    Larsson 2007, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep108">
 <bp:stepProcess rdf:resource="#Pathway52" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence188">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway158">
 <bp:pathwayOrder rdf:resource="#PathwayStep341" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction184" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence341" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP1B1 causes Glaucoma</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 1B1 (CYP1B1) can oxidise a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics as well as activating a range of procarcinogens. A specific substrate is the female sex hormone estradiol-17beta (EST17b) which is 4-hydroxylated to 4-hydroxyestradiol-17beta 4OH-EST17b). Defects in CYP1B1 can cause glaucoma disorders such as Glaucoma 3, primary congenital, A (GLC3A; MIM:231300), Glaucoma, primary open angle (POAG; MIM:137760), Glaucoma 1, open angle, A (GLC1A; MIM:137750) and Peters anomaly (PAN; MIM:604229). These disorders cause a progressive optic neuropathy characterised by visual field defects that ultimately lead to irreversible blindness (Li et al. 2011, Sarfarazi et al. 2003, Vincent et al. 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep107">
 <bp:stepProcess rdf:resource="#Catalysis52" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to (GlcNAc)2 (Man)8 (PP-Dol)1 by ALG9</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway159">
 <bp:pathwayOrder rdf:resource="#PathwayStep344" />
 <bp:pathwayOrder rdf:resource="#PathwayStep343" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction185" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction186" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence343" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A1 causes hyperbilirubinemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-glucuronosyltransferases (UGTs) play a major role in the conjugation and therefore elimination of potentially toxic xenobiotics and endogenous compounds. The 1-1 isoform UGT1A1 is able to act upon lipophilic bilirubin, the end product of heme breakdown. Defects in UGT1A1 can cause hyperbilirubinemia syndromes ranging from mild forms such as Gilbert syndrome (GILBS; MIM:143500) and transient familial neonatal hyperbilirubinemia (HBLRTFN; MIM:237900) to the more severe Crigler-Najjar syndromes 1 and 2 (CN1, CN2; MIM:218800 and MIM:606785) (Sticova    Jirsa 2013, Strassburg 2010, Udomuksorn et al. 2007, Costa 2006, Maruo et al. 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep349">
 <bp:stepProcess rdf:resource="#Pathway163" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep106">
 <bp:stepProcess rdf:resource="#Pathway51" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">2-oxoglutarate + NADPH + H+ =&gt; (R)-2-hydroxyglutarate + NADP+ [mutant IDH1]</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep348">
 <bp:stepProcess rdf:resource="#BiochemicalReaction187" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep105">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
 <bp:stepProcess rdf:resource="#Catalysis51" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence144" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to N-glycan precursor (GlcNAc)2 (Man)7 (PP-Dol)1 by ALG12</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep347">
 <bp:stepProcess rdf:resource="#Pathway162" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep104">
 <bp:stepProcess rdf:resource="#Pathway50" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence143" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to (GlcNAc)2 (Man)6 (PP-Dol)1 by ALG9</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep346">
 <bp:stepProcess rdf:resource="#Pathway161" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway170">
 <bp:pathwayOrder rdf:resource="#PathwayStep365" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction196" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence365" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMADHC causes MMAHCD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMADHC cause methylmalonic aciduria and homocystinuria type cblD (MMAHCD; MIM:277410), a disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl) (Coelho et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway171">
 <bp:pathwayOrder rdf:resource="#PathwayStep367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction197" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence367" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CBLIF causes IFD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in cobalamin binding intrinsic factor CBLIF, aka gastric intrinsic factor GIF) cause hereditary intrinsic factor deficiency (IFD, aka congenital pernicious anemia; MIM:261000). IFD is an autosomal recessive disorder characterized by megaloblastic anemia (Tanner et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway172">
 <bp:pathwayOrder rdf:resource="#PathwayStep370" />
 <bp:pathwayOrder rdf:resource="#PathwayStep369" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction198" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction199" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence369" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMACHC causes MAHCC</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMACHC cause methylmalonic aciduria and homocystinuria type cblC (MMAHCC; MIM:277400). MMAHCC is the most common disorder of cobalamin metabolism and is characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Affected individuals may have developmental, haematologic, neurologic, metabolic, ophthalmologic, and dermatologic clinical findings (Lerner-Ellis et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway173">
 <bp:pathwayOrder rdf:resource="#PathwayStep372" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction200" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence372" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAA causes MMA, cblA type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMAA cause methylmalonic aciduria type cblA (cblA aka methylmalonic aciduria type A or vitamin B12-responsive methylmalonic aciduria of cblA complementation type; MIM:251100). Affected individuals accumulate methylmalonic acid in the blood and urine and are prone to potentially life threatening acidotic crises in infancy or early childhood (Dobson et al. 2002, Lerner-Ellis et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway174">
 <bp:pathwayOrder rdf:resource="#PathwayStep377" />
 <bp:pathwayOrder rdf:resource="#PathwayStep374" />
 <bp:pathwayComponent rdf:resource="#Pathway175" />
 <bp:pathwayComponent rdf:resource="#Pathway176" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence374" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in biotin (Btn) metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Biotin (Btn, vitamin B7, vitamin H, coenzyme R) is an essential cofactor for five biotin-dependent carboxylase enzymes, involved in the synthesis of fatty acids, isoleucine, valine and in gluconeogenesis. Thus, Btn is necessary for cell growth, fatty acid synthesis and the metabolism of fats and amino acids. Inherited metabolic disorders characterized by deficient activities of all five biotin dependent carboxylases are termed multiple carboxylase deficiencies. Two congenital defects in biotin metabolism leading to multiple carboxylase deficiency are known, holocarboxylase synthetase deficiency (MIM 609018) and biotinidase deficiency (MIM 253260). In both scenarios symptoms include ketolactic acidosis, organic aciduria, hyperammonemia, skin rashes, hypotonia, seizures, developmental delay, alopecia, and coma. As humans are auxotrophic for Btn, the micronutrient must be obtained from external soures such as intestinal microflora and dietary forms. Accordingly, severe malnutrition can also give rise to biotin deficiency and multiple carboxylase deficiency. Biotin deficiency can also be induced by the excessive consumption of raw egg white that contains the biotin-binding protein avidin. Holocarboxylase synthetase deficiency arises when all five biotin-dependent enzymes are not biotinylated leading to their reduced activities. The defective genes causing these conditions are described here (Pendini et al. 2008, Suzuki et al. 2005). Biotinidase deficiency is caused by defects in the recycling of Btn. General symptoms include decreased appetite and growth, dermatitis and perosis. The defective genes causing these conditions are described here (Procter et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway175">
 <bp:pathwayOrder rdf:resource="#PathwayStep376" />
 <bp:pathwayOrder rdf:resource="#PathwayStep375" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction201" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction202" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence375" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective BTD causes biotidinase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BTD deficiency is an autosomal recessive disorder in which the body is unable to recycle and reuse biotin (Btn). This results in a secondary Btn deficiency that leads to juvenile-onset multiple carboxylase deficiency (MIM:253260) (Wolf 2012, Wolf et al. 1983). Patients present with neurological and cutaneous symptoms, including seizures, hypotonia, skin rash, and alopecia, usually between the second and fifth months of life (Wolf 2010). Children with profound BTD deficiency are treated with pharmacological doses of biotin (5-20 mg daily). Neonatal screening for BTD deficiency is performed in most states of the United States and many other countries.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway176">
 <bp:pathwayOrder rdf:resource="#PathwayStep378" />
 <bp:pathwayOrder rdf:resource="#PathwayStep381" />
 <bp:pathwayOrder rdf:resource="#PathwayStep380" />
 <bp:pathwayOrder rdf:resource="#PathwayStep379" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction203" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction204" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction205" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction206" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence378" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS causes multiple carboxylase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in HLCS causes holocarboxylase synthetase deficiency (HLCS deficiency aka early onset multiple carboxylase deficiency; MIM:253270). HLCS deficiency is an autosomal recessive disorder whereby deficient HLCS activity results in reduced activity of all five biotin-dependent carboxylases. Symptoms include metabolic acidosis, organic aciduria, lethargy, hypotonia, convulsions and dermatitis (Suzuki et al. 2005). Patients can present symptoms shortly after birth to up to early childhood and will be prescribed oral biotin supplements, typically 10-20 mg daily. Two classes of HLCS deficiency have been reported depending on whether patients respond to biotin therapy. Most patients respond favourably to treatment and show complete reversal of biochemical and clinical symptoms (Morrone et al. 2002, Dupuis et al. 1999). Here mutations in the HLCS active site cause a reduced affinity for biotin that can be overcome by pharmacological doses of the vitamin (Pendini et al. 2008). Patients who display incomplete responsiveness to biotin therapy have a poor long-term prognosis (Bailey et al. 2008).  Here mutations that reside outside of the enzyme&apos;s active site have no effect on biotin binding but do compromise the protein-protein interaction between the HLCS and its substrates, resulting in reduced biotinylation of all five carboxylases thus reducing their enzymatic activity (Mayende et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence165" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MOGS does not cleave glucose from an N-glycosylated protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep334">
 <bp:stepProcess rdf:resource="#Pathway155" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence163" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG8 does not add glucose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep333">
 <bp:stepProcess rdf:resource="#Catalysis169" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction180" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence169" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG6 does not add glucose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep332">
 <bp:stepProcess rdf:resource="#Pathway154" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence167" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MGAT2 does not transfer GlcNAc to N-glycans</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep331">
 <bp:stepProcess rdf:resource="#BiochemicalReaction179" />
 <bp:stepProcess rdf:resource="#Catalysis168" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep330">
 <bp:stepProcess rdf:resource="#Pathway153" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway166">
 <bp:pathwayOrder rdf:resource="#PathwayStep357" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction192" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence357" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTRR causes HMAE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MTRR cause methylcobalamin deficiency type E (cblE; methionine synthase reductase deficiency; MIM:236270) (Wilson et al. 1999). Patients with cblE exhibit megaloblastic anemia and hyperhomocysteinemia. SAM is used as a methyl donor in many biological reactions and demethylation of SAM produces S-adenosylhomocysteine, which is deadenosylated to form homocysteine. Homocysteine remethylation is carried out by MTR, which requires MTRR to maintain enzyme-bound cobalamin (Cbl) in its active form; but in cblE patients, MTR becomes inactivated and thus homocysteine accumulates.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway167">
 <bp:pathwayOrder rdf:resource="#PathwayStep359" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction193" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence359" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCD4 causes MAHCJ</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family D member 4 (ABCD4) is thought to mediate the lysosomal export of cobalamin (Cbl aka vitamin B12) into the cytosol, making it available for the production of Cbl cofactors. Cbl is an important cofactor for correct haematological and neurological functions. Defects in ABCD4 can cause methylmalonic aciduria and homocystinuria, cblJ type (MAHCJ; MIM:614857), a genetically heterogeneous metabolic disorder of Cbl metabolism characterised by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Clinically, symptoms include feeding difficulties, poor growth, hypotonia, lethargy, anaemia and delayed development (Coelho et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence154" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse a second 1,2-linked mannose (a branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence198">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway168">
 <bp:pathwayOrder rdf:resource="#PathwayStep361" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction194" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence361" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AMN causes MGA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in AMN cause recessive hereditary megaloblastic anemia 1 (RH-MGA1 aka MGA1 Norwegian type or Imerslund-Grasbeck syndrome, I-GS; MIM:261100). The Norwegian cases described by Imerslund were due to defects in AMN (Imerslund 1960). The resultant malabsorption of Cbl (vitamin B12) leads to impaired B12-dependent folate metabolism and ultimately impaired thymine synthesis and DNA replication.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence153" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse 1,2-linked mannose (b branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence199">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep339">
 <bp:stepProcess rdf:resource="#Catalysis172" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction183" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway169">
 <bp:pathwayOrder rdf:resource="#PathwayStep363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction195" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence363" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CUBN causes MGA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in the CUBN gene cause recessive hereditary megaloblastic anemia 1 (RH-MGA1 aka MGA1 Finnish type or Imerslund-Grasbeck syndrome, I-GS; MIM:261100). The Finnish cases described by Grasbeck et al. were caused by defects in CUBN (Grasbeck et al. 1960). The resultant malabsorption of Cbl (cobalamin, vitamin B12) leads to impaired B12-dependent folate metabolism and ultimately impaired thymine synthesis and DNA replication.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence158" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG9 does not add the seventh mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep338">
 <bp:stepProcess rdf:resource="#Pathway157" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence156" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG3 does not add mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep337">
 <bp:stepProcess rdf:resource="#Catalysis171" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction182" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence161" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RFT1 does not flip the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep336">
 <bp:stepProcess rdf:resource="#Pathway156" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence159" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG9 does not add the last mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep335">
 <bp:stepProcess rdf:resource="#Catalysis170" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction181" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway51">
 <bp:pathwayOrder rdf:resource="#PathwayStep107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in either of the protein subunits of the E1 decarboxylase subcomplex of BCKDH are associated with Maple Syrup Urine Disease 1 (MSUD1). Mutations of residues in BCKDHA that participate in subunit associations or that form part of the hydrophobic core destabilize the overall assembly of BCKDH and are associated with classic Maple Syrup Urine Disease 1A (Aevarsson et al, 2000; reviewed in Straus et al, 2020; Biswas et al, 2019). Mutations of BCKDHA with less drastic effects on structural  stability of the overall BCKDH complex are generally associated with intermediate or intermittent forms of MSUD, and are not annotated in this pathway (reviewed in Strauss et al, 2020)  Mutations in BCKDHB appear to be causative in 35% of MSUD cases(reviewed in Strauss et al, 2020). Classic Maple Syrup Disease 1B is associated with severe loss-of-function mutations in BCKDHB that destabilize the protein interaction interfaces and compromise structural integrity of the complex (reviewed in Straus et al, 2020; Biswas et al, 2019).  Less detrimental mutations in BCKDHB are not annotated in this pathway and are generally associated with intermediate or intermittent forms of MSUD (reviewed in Strauss et al, 2020).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway50">
 <bp:pathwayOrder rdf:resource="#PathwayStep105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DLD cause MSUD3/DLDD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the dihydrolipoyl dehydrogenase (DLD) gene are associated with dihydrolipoyl dehydrogenase deficiency (DLDD), an autosomal recessive disorder characterized by lactic acidosis and neurological deterioration (reviewed in Quinonez et al, 2021). DLDD is sometimes referred to as Maple Syrup Urine Disease 3 due to its effects on BCKDH function, but the phenotype is distinct due to the involvement of DLD in multiple protein complexes (reviewed in Strauss et al, 2020). DLD encodes the shared E3 component of the multiprotein mitochondrial enzymes BCKDH (branched-chain amino acid dehydrogenase), KGDH (alpha-ketoglutarate deydrogenase) and PDH (pyruvate dehydrogenase). In consequence mutations in DLD have pleiotropic effects and manifest with a range of clinical outcomes, including increased urinary excretion of alpha-keto acids and accumulation of pyruvate and plasma branched-chain amino acids in plasma (reviewed in Quinonez and Thoene, 2021). Mutations in DLD often occur as compound heterozygotes complicating the assignment of pathogenic effect. Moreover, the severity of phenotypic effects displayed in vivo does not correlate linearly with the extent of residual DLD enzymatic activity in vitro (Shany et al, 1999; Cameron et al, 2006; Quinonez et al, 2013; reviewed in Quinonez and Thoene, 2021).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway53">
 <bp:pathwayOrder rdf:resource="#PathwayStep111" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mitochondrial short-chain enoyl-CoA hydratase deficiency 1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ECHS1 (short-chain enoyl-CoA hydratase, also known as SCEH) is a mitochondrial enzyme that plays roles in fatty acid oxidation and valine metabolism (Yamada et al, 2015). In the branched-chain amino acid catabolism pathway, ECHS1 has specificity for the valine derivative methylacrylyl-CoA, but can also act on the leucine derivative 3-methylcrotonyl-CoA. ECHS1 binds to the isoleucine derivative tiglyl-CoA, but does not appreciably catalyze its hydration (Yamada et al, 2015; Ferdinandusse et al, 2015). Homozygous mutations in ECHS1 are associated with a severe Leigh-like disorder, characterized by cardiac aberrations, encephalopathy and epilepsy and severe developmental and neurological delays, likely arising at least in large measure from the accumulation of toxic levels of methylacrylyl-CoA (Peters et al, 2014; Haack et al, 2015; Yamada et al, 2015; Ferinandusse et al, 2015; Sakai et al, 2015; Tetreault et al, 2015; Kohda et al, 2016; Fitzsimmons et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway52">
 <bp:pathwayOrder rdf:resource="#PathwayStep109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-Methylcrotonyl-CoA carboxylase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-methylcrotonyl-CoA carboxylase catalyzes the reversible conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, the fourth step in the catabolism of leucine (Chu et al, 2007; Son et al, 2020). MCCC is composed of two subunits encoded by MCCC1 and MCCC2. MCCC1 protein is covalently attached to a biotin moiety that is essential for the ATP dependent carboxylation activity, while MCCC2 contributes carboxyltransferase activity (Holzinger et al, 2001; Lau et al, 1979; Gallardo et al, 2001; Baumgartner et al, 2001). Mutations in either subunit of the enzyme, MCCC1 and MCCC2, are associated with 3-methylcrotonyl-CoA carboxylase deficiency (MCCD), also known as 3-methylcrotonylglycinuria, an autosomal recessive inborn error of metabolism characterized by accumulation and excretion of 3-hydroxyvaleric acid and 3-methylcrotonylglycine (Bannwart et al, 1992; Lehnert et al, 1996; Baumgartner et al, 2005). MCCD is the most prevalent organic aciduria with frequencies ~ 1:50,000 but has variable clinical phenotypes. 1-2% of affected individuals are at risk of a severe adverse effect that manifests during the neonatal period with severe neurological impairment while ~10% of affected individuals develop only minor symptoms (Baumgartner et al, 2001; Gallardo et al, 2001; Gruenert et al, 2012). Mutations in MCCC1 and MCCC2 have been identified that affect the stability or activity of the alpha or beta subunit, occasionally by compromising the essential biotinylation of the protein (Gallardo et al, 2001; Grunert et al, 2012; Fonseca et al, 2016; Dantas et al, 2005 ; Steen et al, 1999; Morscher et al, 2012 ; Baumgartner et al, 2001; 2004; Uematsu et al, 2007; Holzinger et al, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis115">
 <bp:controlled rdf:resource="#BiochemicalReaction125" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis114">
 <bp:controlled rdf:resource="#BiochemicalReaction124" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis117">
 <bp:controlled rdf:resource="#BiochemicalReaction127" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis116">
 <bp:controlled rdf:resource="#BiochemicalReaction126" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis119">
 <bp:controlled rdf:resource="#BiochemicalReaction129" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis118">
 <bp:controlled rdf:resource="#BiochemicalReaction128" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway55">
 <bp:pathwayOrder rdf:resource="#PathwayStep115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-hydroxyisobutyryl-CoA hydrolase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-hydroxyisobutyryl-CoA hydrolase deficiency is an autosomal recessive inborn error of metabolism caused by mutations in HIBCH, a mitochondrial enzyme that catalyzes the fifth step of the valine catabolic pathway (Hawes et al, 1996; Brown et al, 1982; Loupatty et al, 2007). Like mutations in ECHS1, the enzyme that catalyzes the third step of valine metabolism, HIBCH mutations result in accumulation of toxic metabolic intermediates and manifest clinically with severe psychomotor and developmental delays, neurodegeneration and brain lesions, characteristic of a Leigh-like syndrome (Brown et al, 1982; Loupatty et al, 2007; Ferdinandusse et al, 2013; Peters et al, 2015; Reuter et al, 2014; D&apos;Gama et al, 2020; reviewed in Rahman et al, 2023).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway54">
 <bp:pathwayOrder rdf:resource="#PathwayStep113" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branched-chain ketoacid dehydrogenase kinase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branched-chain ketoacid dehydrogenase kinase deficiency (BCKDKD) is a neurological disorder that arises due to mutations in branched-chain ketoacid dehydrogenase kinase (BCKDK) (Joshi et al 2006; Novarino et al, 2012; Garcia-Cazorla et al, 2014; Tangeraas et al, 2023). BCKDK is a negative regulator of the branched-chain ketoacid dehydrogenase complex (BCKDH), the enzyme responsible for oxidative decarboxylation of branched-chain amino acid derivatives. BCKDK-dependent phosphorylation of serine residues in the E1 alpha subunit of the enzyme BCKDHA inactivates the BCKDH (Popov et al, 1992; Li et al, 2004; Wynn et al, 2004). Inactivating mutations of BCKDK are associated with impaired intellectual development, microencephaly and autism (Joshi et al 2006; Novarino et al, 2012; Garcia-Cazorla et al, 2014; Tangeraas et al, 2023). Consistent with the role of BCKDK in inhibiting BCKDH activity, inactivating mutations in BCKDK result in higher levels of BCKDH activity and reduced BCAAs in plasma, tissues and urine in mouse models, patients and cell lines (Joshi et al, 2006; Novarino et al, 2012). Symptoms of BCKDK deficiency are alleviated in mouse models by dietary supplementation with a BCAA-enriched diet (Joshi et al, 2006; Novarino et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway57">
 <bp:pathwayOrder rdf:resource="#PathwayStep119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Isovaleric acidemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Isovaleric acidemia is an inborn error of metabolism that arises due to mutations in isovaleryl-CoA dehydrogenase (IVD), a mitochondrial enzyme that catalyzes the third step in the catabolic pathway for leucine, the conversion of isovaleryl-CoA and FAD to  beta-methylcrotonyl-CoA and FADH2 (Tanaka et al, 1966; Finocchiaro et al. 1978; Rhead and Tanaka 1980). Isovaleric acidemia has variable clinical presentation and lacks a clear correspondence between genotypic alterations and phenotypic outcome (Vockley and Ensenauer, 2006). Symptoms include vomiting, seizures, low energy, and a characteristic sweaty foot odor due to presence of isovaleric acid, 3-hydroxyisovaleric acid, isovarleryl-glycine and isovaleryl-carnitine in blood and urine (Vockley et al, 1991; Mohsen et al, 1998; Zaki et al, 2017; Dercksen et al, 2012; D&apos;Annibale et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway56">
 <bp:pathwayOrder rdf:resource="#PathwayStep117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-methylglutaconic aciduria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in AUH are associated with 3-methylglutaconic aciduria, a rare autosomal recessive disorder. AUH catalyzes the fifth step in the catabolism of leucine, the conversion of 3-methylglutaconyl-CoA to 3-hydroxy-methylglutaryl-CoA (Iljst et al, 2002; Ly et al, 2003; Mack et al, 2006). Mutations that affect AUH stability or function result in accumulation of metabolic intermediates such as 3-methylglutaconic acid, 3-methylglutaric acid and 3-hydroxyisovaleric acid that are excreted in urine (Duran et al, 1982; Ly et al, 2002; Mack et al, 2006; Nardecchia et al, 2022). The clinical presentation of 3-methylglutaconic aciduria is variable ranging from no-to-mild symptoms to severe encephalopathy, metabolic acidosis and coma (Nardecchia et al, 2022). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway59">
 <bp:pathwayOrder rdf:resource="#PathwayStep122" />
 <bp:pathwayComponent rdf:resource="#Pathway60" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleotide catabolism defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Purine nucleotide phosphorylase defects (Aust et al. 1992, Williams et al. 1987) are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis111">
 <bp:controlled rdf:resource="#BiochemicalReaction121" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway58">
 <bp:pathwayOrder rdf:resource="#PathwayStep125" />
 <bp:pathwayOrder rdf:resource="#PathwayStep121" />
 <bp:pathwayComponent rdf:resource="#Pathway61" />
 <bp:pathwayComponent rdf:resource="#Pathway59" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of nucleotide metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Metabolic reactions disrupted by deficiencies of ADA, APRT, HPRT1, and PNP are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis110">
 <bp:controlled rdf:resource="#BiochemicalReaction120" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis113">
 <bp:controlled rdf:resource="#BiochemicalReaction123" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis112">
 <bp:controlled rdf:resource="#BiochemicalReaction122" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction17" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction16" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction19" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway60">
 <bp:pathwayOrder rdf:resource="#PathwayStep124" />
 <bp:pathwayOrder rdf:resource="#PathwayStep123" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, PNP (purine nucleotide phosphorylase) catalyzes the conversion of (deoxy)guanosine and (deoxy)inosine to guanine and hypoxanthine, respectively. In the absence of PNP activity, however, these purine nucleosides accumulate, disrupting lymphoid cell function and leading to severe immunodeficiency (Aust et al. 1992; Williams et al. 1987).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction18" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway62">
 <bp:pathwayOrder rdf:resource="#PathwayStep127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HPRT1 disrupts guanine and hypoxanthine salvage</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, guanine and hypoxanthine can be salvaged by conversion to GMP and IMP, catalyzed by HPRT1 (hypoxanthine guanine phosphoribosyltransferase). In the absence of HPRT1 activity, however, accumulated guanine and hypoxanthine are catabolized by XDH (xanthine dehydrogenase / oxidase) to urate (Fu    Jinnah 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway61">
 <bp:pathwayOrder rdf:resource="#PathwayStep130" />
 <bp:pathwayOrder rdf:resource="#PathwayStep128" />
 <bp:pathwayOrder rdf:resource="#PathwayStep126" />
 <bp:pathwayComponent rdf:resource="#Pathway62" />
 <bp:pathwayComponent rdf:resource="#Pathway64" />
 <bp:pathwayComponent rdf:resource="#Pathway63" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleotide salvage defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in APRT and HGPRT lead to synthesis of 2,8-dioxo-adenine and overproduction of uric acid, respectively, associated with kidney damage and other symptoms (Boll&#233;e et al. 2012; Fu    Jinnah 2012). Defects in ADA lead to accumulation of (deoxy)adenosine and consequent severe combined immunodeficiency (Akeson et al. 1988).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction15" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway64">
 <bp:pathwayOrder rdf:resource="#PathwayStep131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective APRT disrupts adenine salvage</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, adenine formed in processes such as polyamine biosynthesis can be salvaged by conversion to AMP, catalyzed by APRT (adenine phosphoribosyltransferase). In the absence of APRT activity, however, accumulated adenine is instead converted to 2,8-dioxo-adenine. Accumulation of insoluble crystals of 2,8-dioxo-adenine in the kidneys causes the kidney damage that is a major symptom of APRT deficiency in humans (Van Acker et al. 1977; Boll&#233;e et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
 <bp:stepProcess rdf:resource="#Catalysis1" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway63">
 <bp:pathwayOrder rdf:resource="#PathwayStep129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ADA disrupts (deoxy)adenosine deamination</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, adenosine and deoxyadenosine can be deaminated to inosine and deoxyinosine, catalyzed by ADA (adenosine deaminase). In the absence of ADA activity, however, accumulated nucleosides disrupt lymphoid cell function, leading to severe combined immunodeficiency (Hirschhorn et al. 1989, 1990).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis126">
 <bp:controlled rdf:resource="#BiochemicalReaction136" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis125">
 <bp:controlled rdf:resource="#BiochemicalReaction135" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis128">
 <bp:controlled rdf:resource="#BiochemicalReaction138" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis127">
 <bp:controlled rdf:resource="#BiochemicalReaction137" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis129">
 <bp:controlled rdf:resource="#BiochemicalReaction139" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway66">
 <bp:pathwayOrder rdf:resource="#PathwayStep135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACTH causes obesity and POMCD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The precursor peptide pro-opiomelanocortin (POMC) gives rise to many peptide hormones through cleavage. The cleavage products corticotropin (ACTH) and beta-lipotropin give rise to smaller peptides that have distinct biologic activities: alpha-melanotropin and corticotropin-like intermediate lobe peptide (CLIP) are formed from ACTH; gamma-LPH and beta-endorphin are formed from beta-LPH. ACTH (POMC(138-176) stimulates the adrenal glands to release cortisol, a glucocorticoid released in response to stress whose primary functions are to stimulate gluconeogenesis, suppress the immune system and aid metabolism of fats, proteins and carbohydrates.  Defects in ACTH can cause obesity (MIM:601665) resulting in excessive accumulation of body fat (Challis et al. 2002, Millington 2013). Defects in ACTH can also cause pro-opiomelanocortinin deficiency (POMCD; MIM:609734) where affected individuals present early-onset obesity, adrenal insufficiency and red hair (Krude et al. 1998, Krude et al. 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction24" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway65">
 <bp:pathwayOrder rdf:resource="#PathwayStep133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phenylketonuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phenylalanine hydroxylase (PAH) normally catalyzes the conversion of phenylalanine to tyrosine. In the absence of functional PAH, phenylalanine accumulates to high levels in the blood and is converted to phenylpyruvate and phenyllactate (Clemens et al. 1990; Langenbeck et al. 1992; Mitchell et al. 2011). The extent of these conversions is modulated by genetic factors distinct from PAH, as siblings with the identical PAH defect can produce different amounts of them (Treacy et al. 1996). Both L-amino acid oxidase (Boulland et al. 2004) and Kynurenine--oxoglutarate transaminase 3 (Han et al. 2004) can catalyze the conversion of phenylalanine to phenylpyruvate and lactate dehydrogenase can catalyze the conversion of the latter molecule to phenyllactate (Meister 1950), in reactions not annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway68">
 <bp:pathwayOrder rdf:resource="#PathwayStep245" />
 <bp:pathwayOrder rdf:resource="#PathwayStep200" />
 <bp:pathwayOrder rdf:resource="#PathwayStep181" />
 <bp:pathwayOrder rdf:resource="#PathwayStep139" />
 <bp:pathwayComponent rdf:resource="#Pathway97" />
 <bp:pathwayComponent rdf:resource="#Pathway87" />
 <bp:pathwayComponent rdf:resource="#Pathway113" />
 <bp:pathwayComponent rdf:resource="#Pathway69" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of glycosylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of glycosylation, usually referred to as congenital disorders of glycosylation (CDG), are rare inherited disorders ascribing defects of nucleotide-sugar biosynthesis and transport, glycosyl transfer events and vesicular transport. Most CDGs cause neurological impairment ranging from severe psychomotor retardation to mild intellectual disability. Defects in N-glycosylation are the main cause of CDGs (Marquardt    Denecke 2003, Grunewald et al. 2002, Hennet 2012, Goreta et al. 2012) and can be identified by a characteristic abnormal isoelectric focusing profile of plasma transferrin (Jaeken et al. 1984, Stibler    Jaeken 1990). Disorders of O-glycosylation, glycosaminoglycan and glycolipid metabolism have recently been discovered and, together with N-glycosylation, represent the major pathways affected by glycan biosynthetic disorders (Freeze 2006, Jaeken 2011). In addition, glycosylation diseases associated with the enzymes that mediate the biosynthesis of glycosylation precursors are described in this section. As the number of these disorders has increased, nomenclature has been simplified so that now, the name of the mutant gene is followed by the abbreviation CDG (Jaeken et al. 2009). Effective therapies for most types of CDGs are so far not available (Thiel    Korner 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis120">
 <bp:controlled rdf:resource="#BiochemicalReaction130" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway67">
 <bp:pathwayOrder rdf:resource="#PathwayStep137" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Somatic mutations affecting arginine residue 132 of IDH1 (isocitrate dehydrogenase 1, a cytosolic enzyme that normally catalyzes the NADP+-dependent conversion of isocitrate to 2-oxoglutarate), are very commonly found in human glioblastomas (Parsons et al. 2008). These mutant proteins efficiently catalyze the NADPH-dependent reduction of 2-oxoglutarate to form 2-hydroxyglutarate. Cells expressing the mutant protein accumulate elevated levels of 2-hydroxyglutarate, probably in the cytosol as IDH1 is a cytosolic enzyme. The fate of the 2-hydroxyglutarate is unclear, but the high frequency with which the mutation is found in surveys of primary tumors is consistent with the possibility that it is advantageous to the tumor cells (Dang et al 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction21" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis122">
 <bp:controlled rdf:resource="#BiochemicalReaction132" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction20" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway69">
 <bp:pathwayOrder rdf:resource="#PathwayStep161" />
 <bp:pathwayOrder rdf:resource="#PathwayStep171" />
 <bp:pathwayOrder rdf:resource="#PathwayStep147" />
 <bp:pathwayOrder rdf:resource="#PathwayStep169" />
 <bp:pathwayOrder rdf:resource="#PathwayStep179" />
 <bp:pathwayOrder rdf:resource="#PathwayStep145" />
 <bp:pathwayOrder rdf:resource="#PathwayStep156" />
 <bp:pathwayOrder rdf:resource="#PathwayStep167" />
 <bp:pathwayOrder rdf:resource="#PathwayStep177" />
 <bp:pathwayOrder rdf:resource="#PathwayStep154" />
 <bp:pathwayOrder rdf:resource="#PathwayStep165" />
 <bp:pathwayOrder rdf:resource="#PathwayStep175" />
 <bp:pathwayOrder rdf:resource="#PathwayStep163" />
 <bp:pathwayOrder rdf:resource="#PathwayStep140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep173" />
 <bp:pathwayOrder rdf:resource="#PathwayStep149" />
 <bp:pathwayOrder rdf:resource="#PathwayStep159" />
 <bp:pathwayComponent rdf:resource="#Pathway80" />
 <bp:pathwayComponent rdf:resource="#Pathway71" />
 <bp:pathwayComponent rdf:resource="#Pathway82" />
 <bp:pathwayComponent rdf:resource="#Pathway70" />
 <bp:pathwayComponent rdf:resource="#Pathway81" />
 <bp:pathwayComponent rdf:resource="#Pathway73" />
 <bp:pathwayComponent rdf:resource="#Pathway84" />
 <bp:pathwayComponent rdf:resource="#Pathway72" />
 <bp:pathwayComponent rdf:resource="#Pathway83" />
 <bp:pathwayComponent rdf:resource="#Pathway75" />
 <bp:pathwayComponent rdf:resource="#Pathway86" />
 <bp:pathwayComponent rdf:resource="#Pathway74" />
 <bp:pathwayComponent rdf:resource="#Pathway85" />
 <bp:pathwayComponent rdf:resource="#Pathway77" />
 <bp:pathwayComponent rdf:resource="#Pathway76" />
 <bp:pathwayComponent rdf:resource="#Pathway79" />
 <bp:pathwayComponent rdf:resource="#Pathway78" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with N-glycosylation of proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation (CDGs) are a group of autosomal recessive disorders caused by enzymatic defects in the synthesis and processing of asparagine (N)-linked glycans or oligosaccharides on glycoproteins. These glycoconjugates play critical roles in processes such as metabolism, cell recognition and adhesion, cell migration, protease resistance, host defense, and antigenicity. CDGs are divided into 2 main groups: type I CDGs comprise defects in the assembly of the dolichol lipid-linked oligosaccharide (LLO) chain and its transfer to the nascent protein, whereas type II CDGs comprise defects in the trimming and processing of protein-bound glycans (Marquardt    Denecke 2003, Grunewald et al. 2002, Hennet 2012, Cylwik et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis121">
 <bp:controlled rdf:resource="#BiochemicalReaction131" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction23" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis124">
 <bp:controlled rdf:resource="#BiochemicalReaction134" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction22" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis123">
 <bp:controlled rdf:resource="#BiochemicalReaction133" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway31">
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIIC - Sanfilippo syndrome C</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837838, 1963, no reference). Mucopolysaccharidosis type IIIC (MPS IIIC, Sanfilippo syndrome C; MIM:252930) is an autosomal recessive genetic disorder due to the loss of heparan alpha-glucosaminide N-acetyltransferase (HGSNAT; MIM:610453) that normally acetylates the non-reducing terminal alpha-glucosamine residue of  heparan sulfate. The molecular defects underlying MPS IIIC remained unknown for almost three decades due to the low tissue content and instability of HGSNAT. But, during the last decade, the gene was cloned in parallel by two different groups and shown to contain 18 exons and span approximately 62Kb (Fan et al. 2006, Hrebicek et al. 2006). Loss of HGSNAT results in build up of this glycosaminglycan (GAG) in cells and tissues and is characterized by severe central nervous system degeneration but only with mild somatic disease and death occurs typically during the second or third decade of life (Kresse et al. 1978, Klein et al. 1978, Feldhammer et al. 2009, de Ruijter et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway30">
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IV - Morquio syndrome A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis IV A (MPS IVA, MPS4A, Morquio&apos;s syndrome, Morquio&apos;s; MIM:253000) is a rare, autosomal recessive mucopolysaccharide storage disease, first described simultaneously in 1929 by L Morquio (Morquio L, Sur une forme de distrophie familiale, Bull Soc Pediat, Paris, 27, 1929, 145-152) and JF Brailsford (Brailsford, JF, Chondro-osteo-dystrophy: roentgenographic and clinical features of child with dislocation of vertebrae,  Am j Surg, 7, 1929, 404-410). MPSIVA is caused by a deficiency in N-acetylgalactosamine 6-sulfatase (GALNS; MIM:612222) which normally hydrolyses 6-sulfate groups of N-acetylgalactosamine 6-sulfate units of chondroitin sulfate (CS) and of galactose 6-sulfate units of keratan sulfate (KS) (Matalon et al. 1974). The result is accumulation of KS/DS in cells and overexcretion in urine. Severe osteochondrodysplasia is a commonly seen phenotype for this disease. The severity of the disease is variable but severe cases limits lifespan to their 20&apos;s or 30&apos;s (Prat et al. 2008, Tomatsu et al. 2011). The gene coding for human GALNS was mapped to chromosome 16q24.3 (Masuno et al. 1993) and its structure described at the same time by two independent groups as comprising 14 exons and spanning approximately 40-50 kb (Nakashima et al.1994, Morris et al.1994). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep301">
 <bp:stepProcess rdf:resource="#Catalysis151" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction162" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep300">
 <bp:stepProcess rdf:resource="#Pathway140" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway33">
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIID - Sanfilippo syndrome D</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837-838, 1963, no reference). Mucopolysaccharidosis type IIID (MPS IIID, Sanfilippo syndrome D, MIM:252940) is an autosomal recessive genetic disorder due to the loss of N-acetyl-D-glucosamine 6-sulfatase (GNS; MIM:607664), that hydrolyses the 6-sulfate groups of the N-acetyl-D-glucosamine 6-sulfate units of the glycosaminoglycans (GAGs) heparan sulfate and keratan sulfate. GNS is localized to chromosome 12q14 and has 14 exons spanning 46 kb (Robertson et al. 1988, Mok et al. 2003). Loss of enzyme activity leads to lysosomal accumulation and urinary excretion of  heparan sulfate and N-acetylglucosamine 6-sulfate residues (Mok et al. 2003). Keratan sulphate does not accumulate in MPS IIID, as beta-linked N-acetyl-D-glucosamine 6-sulphate can be cleaved by beta-hexosaminidase A (Kresse et al. 1980). This disorder is characterized by progressive mental deterioration but only moderate physical abnormalities and death duing the second or third decade of life, presenting a phenotype similar to MPSIIIA (Jones et al. 1997, de Ruijter et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep309">
 <bp:stepProcess rdf:resource="#BiochemicalReaction167" />
 <bp:stepProcess rdf:resource="#Catalysis156" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway32">
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIIA - Sanfilippo syndrome A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (MPS III, Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837-838, 1963, no reference). Mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo syndrome A, MIM:252900) is a rare, autosomal recessive lysosomal storage disease characterised by severe CNS degeneration in early childhood leading to death between 10 and 20 years of age. A deficiency of the enzyme N-sulphoglucosamine sulphohydrolase (SGSH, MIM:605270), which normally hydrolyses the sulfate group from the terminal N-sulphoglucosamine residue of heparan sulfate (HS), leads to the build-up of HS in cells and tissues and its presence in urine (van de Kamp et al. 1981, Yogalingam    Hopwood 2001, de Ruijter et al. 2011). The gene encoding N-sulfoglucosamine sulfohydrolase, SGSH, was cloned in 1995 (Scott et al.1995) and, later, shown to contain 8 exons spanning approximately 11 kb (Karageorgos et al. 1996).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep308">
 <bp:stepProcess rdf:resource="#Pathway143" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway35">
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayComponent rdf:resource="#Pathway40" />
 <bp:pathwayComponent rdf:resource="#Pathway42" />
 <bp:pathwayComponent rdf:resource="#Pathway41" />
 <bp:pathwayComponent rdf:resource="#Pathway44" />
 <bp:pathwayComponent rdf:resource="#Pathway43" />
 <bp:pathwayComponent rdf:resource="#Pathway37" />
 <bp:pathwayComponent rdf:resource="#Pathway36" />
 <bp:pathwayComponent rdf:resource="#Pathway39" />
 <bp:pathwayComponent rdf:resource="#Pathway38" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage diseases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The regulated turnover of glycogen plays a central, tissue-specific role in the maintenance of blood glucose levels and in the provision of glucose to tissues such as muscle and brain in response to stress. Defects in the enzymes involved in glycogen turnover are associated with abnormal responses to fasting and exercise that can differ widely in their presentation and severity. Additional symptoms can be the result of accumulation of abnormal products of glycogen metabolism (Hauk et al. 1959; Hers 1964; Shin 2006). Annotations are provided here for diseases due to deficiencies of GYS1 and GYS1 (glycogen synthase 1 and 2; glycogen storage disease type 0 (GSD type 0), of G6PC (glucose-6-phosphatase, GSD type Ia) and the SLC37A4 transporter (GSD type Ib), of GAA (lysosomal acid alpha-glucosidase, GSD type II), of GBE1 (glycogen branching enzyme, GSD type IV), and of GYG1 (glycogenin 1, GSD XV). Two additional diseases, myoclonic epilepsy of Lafora (Roach et al. 2012) and severe congenital neutropenia type 4 (Boztug et al. 2009), are included as they are due to defects in enzymes of glycogen metabolism.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep307">
 <bp:stepProcess rdf:resource="#Catalysis155" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction166" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway34">
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Essential pentosuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Essential pentosuria, the excretion in the urine of high levels of L-xylulose, is a benign autosomal recessive trait found in Ashkenazi Jewish and Lebanese populations. It is due to mutations that inactivate DXCR (L-xylulose reductase) and thus prevent the conversion of L-xylulose to xylitol in the glucuronate pathway (Pierce et al. 2011; Wang    van Eys 1970).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep306">
 <bp:stepProcess rdf:resource="#Pathway142" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway37">
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type 0 (liver GYS2)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen synthase 2 (GYS2 &quot;liver&quot;) normally catalyzes the addition of glucose residues to a growing glycogen molecule. In its absence, glycogen synthesis fails. Expression of GYS2 is confined to the liver and its deficiency is most prominently associated with fasting hypoglycemia (Gitzelmann et al. 1996; Orho et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep305">
 <bp:stepProcess rdf:resource="#Catalysis154" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction165" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway36">
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type XV (GYG1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen synthesis is normally initiated by the autoglycosylation of glycogenin (GYG) to form oligo (1,4)-alpha-D-glucosyl GYG. A missense mutation of GYG1 yields a protein that cannot undergo glucosylation, leading to failure of glycogen synthesis, associated with muscle weakness and other abnormalities (Moslemi et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep304">
 <bp:stepProcess rdf:resource="#Pathway141" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway39">
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type Ib (SLC37A4)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SLC37A4 transport protein in the endoplasmic reticulum membrane normally mediates the exchange of cytosolic glucose-6-phosphate and orthophosphate from the endoplasmic reticulum lumen. Defects in this transporter are associated with glycogen storage disease type Ib (Gerin et al. 1997; Chen et al. 2008; Veiga-da-Cunha et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep303">
 <bp:stepProcess rdf:resource="#Catalysis153" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction164" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway38">
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Myoclonic epilepsy of Lafora</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lafora disease is a progressive neurodegenerative disorder with onset typically late in childhood, characterized by seizures and progressive neurological deterioration and death within ten years of onset. Recessive mutations in EPM2A (laforin) and NHLRC1 (malin) have been identified as causes of the disease. The disease is classified here as one of glycogen storage as EPM2A (laforin) and NHLRC1 (malin) regulate normal glycogen turnover and defects in either protein are associated with the formation of Lafora bodies, accumulations of abnormal, insoluble glycogen molecules in tissues including  brain, muscle, liver, and heart (Ramachandran et al. 2009; Roach et al. 2012). Consistent with a central role for glycogen accumulation in the disease, reduced (Turnbull et al. 2011) or absent (Pederson et al. 2013) glycogen synthase activity prevents Lafora Disease in mouse models. Type 2A disease. EPM2A (laforin) associated with cytosolic glycogen granules, normally catalyzes the removal of the phosphate groups added rarely but consistently to growing glycogen molecules (Tagliabracci et al. 2011). Defects in this catalytic activity lead to the formation of phosphorylated glycogen molecules that are insoluble and that show abnormal branching patterns (Minassian et al. 1998, Serratosa et al. 1999, Tagliabracci et al. 2011). Type 2B disease. NHLRC1 (malin) normally mediates polyubiquitination of EPM2A (laforin) and PPP1R3C (PTG). The two polyubiquitinated proteins are targeted for proteasome-mediated degradation, leaving a glycogen-glycogenin particle associated with glycogen synthase. In the absence of NHLRC1 activity, EPM2A and PPP1R3C proteins appear to persist,  associated with the formation of abnormal, stable glycogen granules (Lafora bodies) (Chan et al. 2003; Gentry et al. 2005). In NHLRC1 knockout mice PPP1R3C levels are unchanged rather than increased, suggesting that NHLRC1 does not target PPP1R3C for degradation.  However, EPM2A protein levels are increased in this knockout consistent with NHLRC1&apos;s proposed role (DePaoli-Roach et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep302">
 <bp:stepProcess rdf:resource="#Catalysis152" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction163" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway40">
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Severe congenital neutropenia type 4 (G6PC3)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucose-6-phosphatase 3 (G6PC3) associated with the endoplasmic reticulum membrane normally catalyzes the hydrolysis of glucose-6-phosphate to glucose and orthophosphate. In the body, this enzyme is ubiquitously expressed; mutations that inactivate it are associated with severe congenital neutropenia (but not with fasting hypoglycemia or lactic acidemia) (Boztug et al. 2009, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway42">
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type IV (GBE1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally, cytosolic glycogen branching enzyme (GBE1) associated with glycogen granules transfers terminal alpha(1,4) glucose blocks to form alpha(1,6) branches on growing glycogen molecules of both liver and muscle types. In the absence of GBE1 activity, abnormal amylopectin-like glycogen with longer alpha(1,4) chains and fewer branch points forms in all tissues where glycogen is normally found. Presentation of the disease is clinically heterogeneous: missense and nonsense mutations associated with little or no enzyme activity can lead to progressive liver disease or neuromuscuolar disease (Bao et al. 1996; Bruno et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway41">
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type II (GAA)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type II (GSD II - Pompe&apos;s disease) is caused by mutations that reduce or eliminate the activity of lysosomal alpha-glucosidase (GAA) (Hers 1963). The presentation of GSD II varies with the severity of the mutation: patients with little or no GAA activity are affected shortly after birth and multiple tissues are severely affected. Patients with higher levels of GAA activity present later in life, often with symptoms restricted tocardiac and  skeletal muscle (Leslie    Tinkle). At a cellular level, symptoms of the disease are due to accumulation of structurally normal glycogen in lysosomes. Glycogen, thought to enter lysosomes via autophagy, is fully degraded by GAA (Brown et al. 1970), but accumulates if the enzyme is absent or reduced in activity. The two mutant alleles annotated here are associated with near-complete loss of enzyme activity and early onset of disease (Hermans et al. 1991; Zhong et al. 1991). Many other mutant alleles have been described and their residual activities correlated with disease presentation (e.g., Kroos et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis104">
 <bp:controlled rdf:resource="#BiochemicalReaction114" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis103">
 <bp:controlled rdf:resource="#BiochemicalReaction113" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis106">
 <bp:controlled rdf:resource="#BiochemicalReaction116" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis105">
 <bp:controlled rdf:resource="#BiochemicalReaction115" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis108">
 <bp:controlled rdf:resource="#BiochemicalReaction118" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis107">
 <bp:controlled rdf:resource="#BiochemicalReaction117" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis109">
 <bp:controlled rdf:resource="#BiochemicalReaction119" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway44">
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type Ia (G6PC)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucose-6-phosphatase (G6PC) associated with the inner face of the endoplasmic reticulum membrane normally catalyzes the hydrolysis of glucose-6-phosphate to glucose and orthophosphate. Defects in glucose-6-phosphatase are the cause of glycogen storage disease type Ia (Lei et al. 1993, 1995, Chou and Mansfield 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway43">
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type 0 (muscle GYS1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen synthase 1 (GYS1 &quot;muscle&quot;) is widely expressed in the body. It normally catalyzes the addition of glucose residues to a growing glycogen molecule. In its absence, glycogen synthesis fails. This deficiency is most prominently associated with exercise intolerance and cardiomyopathy (Kolberg et al. 2007; Cameron et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway46">
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-ketothiolase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACAT1 is a mitochondrial enzyme that plays a role in metabolism of ketone bodies and isoleucine catabolism (Fukao et al, 1991; Haapalainen et al, 2007; reviewed in Fukao et al, 2019). As part of isoleucine catabolism in the mitochondria, ACAT1 catalyzes the thiolytic degradation of alpha-methylacetoacetyl-CoA to propionyl-CoA and acetyl-CoA (Fukao et al, 1991; Happalainen et al, 2007). Mutations in ACAT1 that affect protein stability and enzymatic activity are associated with beta-ketothiolase deficiency, also known as alpha-methylacetoacetic aciduria, an inborn error of metabolism that is identified by the presence of isoleucine intermediate metabolites in bodily fluids (Daum et al, 1973; Schutgens et al, 1982; Fukao et al, 1991; Fukao et al, 1992; Wakazono et al, 1995; Fukao et al, 1998; Sakurai et al, 2007; reviewed in Korman, 2006; Fukao et al, 2019). Neonatal onset is rare and most affected individuals present between 6 and 18 months with metabolic acidosis, lethargy, vomiting and sometimes coma (reviewed in Korman, 2006). As with other disorders of branched-chain metabolism, there is not a direct correlation between genotype and severity of phenotypic presentation (reviewed in Korman, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway45">
 <bp:pathwayOrder rdf:resource="#PathwayStep114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayOrder rdf:resource="#PathwayStep108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep118" />
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep116" />
 <bp:pathwayComponent rdf:resource="#Pathway53" />
 <bp:pathwayComponent rdf:resource="#Pathway52" />
 <bp:pathwayComponent rdf:resource="#Pathway55" />
 <bp:pathwayComponent rdf:resource="#Pathway54" />
 <bp:pathwayComponent rdf:resource="#Pathway46" />
 <bp:pathwayComponent rdf:resource="#Pathway57" />
 <bp:pathwayComponent rdf:resource="#Pathway56" />
 <bp:pathwayComponent rdf:resource="#Pathway47" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of branched-chain amino acid catabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the genes that encode enzymes responsible for the catabolism of the branched-chain amino acids leucine, isoleucine and valine give rise to a number of inborn errors of metabolism (IEMs). Although IEMs are individually rare, collectively they are relatively common with an estimated overall prevalence of ~1:800 live births (Mak et al, 2013). The frequency of particular IEMs is also highly variable across different populations, a result in part of founder effects in closed populations. For instance, although the overall frequency of Maple Syrup Urine disease is 1:185,000 live births (Strauss et al, 2020), the frequency rises to 1:380 in some Old Order Mennonite communities (Fisher et al, 1991). Accumulation of toxic intermediary metabolites causes a range of clinical phenotypes in patients with IEMs including metabolic acidosis, vomiting, seizures, psychomotor and developmental delays and death (reviewed in Schrier Vergano et al, 2022; Holo&#269;ek, 2018; Neinast et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway48">
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DBT cause MSUD2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DBT disrupt the integrity of the E2 subunit of BCKDH, resulting in MSUD2 (reviewed in Strauss et al, 2020; Biswas et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis100">
 <bp:controlled rdf:resource="#BiochemicalReaction110" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway47">
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayOrder rdf:resource="#PathwayStep106" />
 <bp:pathwayOrder rdf:resource="#PathwayStep104" />
 <bp:pathwayComponent rdf:resource="#Pathway51" />
 <bp:pathwayComponent rdf:resource="#Pathway50" />
 <bp:pathwayComponent rdf:resource="#Pathway48" />
 <bp:pathwayComponent rdf:resource="#Pathway49" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maple Syrup Urine Disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The branched-chain alpha ketoacid dehydrogenase complex (BCKDH) catalyzes the oxidative decarboxylation of branched-chain keto acids in the mitochondrial matrix as the second step in the degradation of branched-chain amino acids (BCAAs) leucine, valine and isoleucine, providing acetyl CoA and succinyl CoA intermediates for the Krebs Cycle (reviewed in Strauss et al, 2020; Zhang et al, 2023).  BCKDH is a multi-enzyme complex consisting of three sub-complexes, the E2 transacylase, the E1 decarboxylase and the E3 dehydrogenase. The core of BCKDH is the E2 transacylase domain, made up of 24 copies of Dihydrolipoamide Branched-chain Transacylase (DBT) arranged in octahedral symmetry. Surrounding the E2 core are 12 copies of the E1 decarboxylase tetramer (each of which consists of a dimer of BCKDHA and a dimer of BCKDHB) and six copies of the E3 dehydrogenase (each consisting of a dimer of Dihydrolipoyl Dehydrogenase (DLD)). The E3 subcomplex is not specific to BCKDH but is also a component of the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (alpha-KGDC) (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000; reviewed in Biswas et al, 2019; Strauss et al, 2020).  In addition to the E1, E2 and E3 components, the BCKDH complex also depends on other cofactors- lipoamide for the function of the E2 transacylase, thiamine diphosphate and potassium for the function of the E1 decarboxylase and FAD and NAD+ for the function of the E3 dehydrogenase (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000; reviewed in Biswas et al, 2019; Strauss et al, 2020).  The activity of BCKDH is regulated by the association of BCKD kinase (BCKDK) and protein phosphatase 1K (PPM1K) with the macromolecular complex (Reed et al, 1985). Phosphorylation of BCKDHB S342 by BCKDK inhibits the catalytic activity of BCKDH, while PPM1K-mediated dephosphorylation activates it (Li et al, 2004; Wynn et al, 2004; Wynn et al, 2012). BCKDK is itself negatively regulated by thiamine (Chuang et al, 2006).  Structures for each of the subcomplexes of human BCKDH have been solved, and the complex has a total molecular mass on the order of 4 million Da (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000).  Loss-of-function mutations in the BCKDHA, BCKDHB and DBT genes disrupt the stability and the activity of the BCKDH complex, causing an accumulation of branched-chain keto-acids that causes the characteristic odor associated with Maple Syrup Urine disease (MSUD), an inborn error of metabolism with a prevalence of 1:185,000 live births (reviewed in Strauss et al, 2020; Biswas et al, 2019). MSUD is an autosomal recessive disorder and in its classic neonatal form is characterized by a maple syrup odor to the urine, poor feeding, mental and physical retardation, lethargy, seizures, coma and death. Classic MSUD, like the intermediate, intermittent and thiamine-responsive forms described below, may arise as a result of mutations in any of BCKDHA, BCKDHB or DBT. Classic MSUD is characterized by the lowest (~0-3%) residual enzymatic activity of all the forms, and presents clinically during the neonatal period. An intermediate form (residual activity ~3-30%) manifests clinically many months after birth with signs of mental retardation and developmental delay. Patients with the intermittent form of MSUD have normal levels of BCAA and BCKA and normal development and physiology while healthy, but are triggered into manifesting symptoms of MSUD when stressed by, for instance, infection. The existence of a thiamine-responsive form of MSUD, in which symptoms are alleviated by dietary thiamine, is somewhat controversial, but may reflect the inhibitory effect of thiamine on BCKDK, relieving inhibition of BCKDH activity (Chaung et al, 2006; reviewed in Strauss et al, 2020, Biswas et al, 2019). Mandatory newborn screening programs include testing for MSUD, allowing for early intervention that is especially critical in cases of classic MSUD (Strauss et al, 2020)  Mutations in DLD, the E3 subunit shared with PDH and alpha-KGDH, affect the enzymatic activity of all three complexes and are responsible for a more severe disorder called dihydrolipoamide dehydrogenase deficiency (DLDD). DLLD generally results in death in infancy due to lactic acidosis (Taylor et al, 1978; reviewed in Ambrus, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis102">
 <bp:controlled rdf:resource="#BiochemicalReaction112" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway49">
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H139Hfs13* PPM1K causes a mild variant of  MSUD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPM1K is a mitochondrial protein phosphatase that removes the inhibitory phosphorylation from the E1 beta subunit of branched-chain ketoacid dehydrogenase (BCKDH) to restore BCKDH activity (Lu et al, 2007; Lu et al, 2009 a, b; Wynn et al, 2012; Zhou et al, 2012).  BCKDH is responsible for the oxidative decarboxylation of branched-chain amino acid (BCAA) derivatives of leucine, valine and isoleucine, providing acetyl CoA and succinyl CoA intermediates for the Krebs Cycle (reviewed in Strauss et al, 2020; Zhang et al, 2023). Loss-of-function mutations in subunits of BCKDH cause accumulation of toxic BCAAs in the urine, neurological defects and are the cause of Maple Syrup Urine disease (MSUD). More recently, a frameshift mutation in PPM1K was identified as the probable cause of a mild variant of MSUD (Oyarzabal et al, 2012). This frameshift introduces a stop codon at residue 151, destabilizing the protein, and transfection of PPM1K-deficient fibroblast lines with WT PPM1K restores BCKDH activity (Oyarzabal et al, 2012). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis101">
 <bp:controlled rdf:resource="#BiochemicalReaction111" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis45">
 <bp:controlled rdf:resource="#BiochemicalReaction50" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway91">
 <bp:pathwayOrder rdf:resource="#PathwayStep189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction99" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence189" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT12 causes CRCS1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The family of UDP GalNAc:polypeptide N acetylgalactosaminyltransferases (GalNAc transferases, GALNTs) carry out the addition of N acetylgalactosamine on serine, threonine or possibly tyrosine residues on a wide variety of proteins, and most commonly associated with mucins (Wandall et al. 1997). This reaction takes place in the Golgi apparatus (Rottger et al. 1998). There are 20 known members of the GALNT family, 15 of which have been characterised and 5 candidate members which are thought to belong to this family based on sequence similarity (Bennett et al. 2012). The GALNT-family is classified as belonging to CAZy family GT27. Defects in one of the GALNT family, GALNT12 (Guo et al. 2002) (MIM: 610290) can result in decreased glycosylation of mucins, mainly expressed in the digestive organs such as the stomach, small intestine and colon, and may play a role in colorectal cancer 1 (CRCS1; MIM:608812). CRCS1 is a complex disease characterised by malignant lesions arising from the inner walls of the colon and rectum (Guda et al. 2009, Clarke et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis44">
 <bp:controlled rdf:resource="#BiochemicalReaction49" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway90">
 <bp:pathwayOrder rdf:resource="#PathwayStep187" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction98" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence187" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Co-expression of both protein O-mannosyl-transferases 1 and 2 (POMT1 and POMT2; CAZy family GT39) is necessary for enzyme activity, that is mediating the transfer of mannosyl residues to the hydroxyl group of serine or threonine residues of proteins such as alpha-dystroglycan (DAG1; MIM:128239). DAG1 is a cell surface protein that plays an important role in the assembly of the extracellular matrix in muscle, brain, and peripheral nerves by linking the basal lamina to cytoskeletal proteins. Defects in POMT1 (MIM:607423) results in defective glycosylation of DAG1 and can cause severe congenital muscular dystrophy-dystroglycanopathies ranging from a severe type A, MDDGA1 (brain and eye abnormalities; MIM:236670), through a less severe type B, MDDGB1 (congenital form with mental retardation; MIM:613155) to a milder type C, MDDGC1 (limb girdle form; MIM:609308) (Bertini et al. 2011, Wells 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis47">
 <bp:controlled rdf:resource="#BiochemicalReaction52" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway93">
 <bp:pathwayOrder rdf:resource="#PathwayStep193" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction101" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence193" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT3 causes HFTC</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The family of UDP GalNAc:polypeptide N acetylgalactosaminyltransferases (GalNAc transferases, GALNTs) carry out the addition of N acetylgalactosamine (GalNAc) on serine, threonine or possibly tyrosine residues on a wide variety of proteins, most commonly associated with mucins.  This is the initial reaction in the biosynthesis of GalNAc-type O linked oligosaccharides (Wandall et al. 1997). This reaction takes place in the Golgi apparatus (Rottger et al. 1998). There are 20 known members of the GALNT family, 15 of which have been characterised and 5 candidate members which are thought to belong to this family based on sequence similarity (Bennett et al. 2012). The GALNT-family is classified as belonging to CAZy family GT27. Defects in one of the GALNT family genes, GALNT3 (MIM:601756), can cause familial hyperphosphatemic tumoral calcinosis (HFTC; MIM:211900). HFTC is a rare autosomal recessive severe metabolic disorder characterised by the progressive deposition of calcium phosphate crystals in the skin, soft tissues and sometimes bone (Chefetz et al. 2005). The biochemical observation is hyperphosphatemia, caused by increased renal absorption of phosphate (Chefetz et al. 2005, Ichikawa et al. 2005). Some patients manifest recurrent, transient, painful swellings of the long bones with radiological evidence of periosteal reaction and cortical hyperostosis (Frishberg et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis46">
 <bp:controlled rdf:resource="#BiochemicalReaction51" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway92">
 <bp:pathwayOrder rdf:resource="#PathwayStep191" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction100" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence191" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LARGE causes MDDGA6 and MDDGB6</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosyltransferase-like protein LARGE (MIM:603590) is a bifunctional glycosyltransferase with both xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the biosynthesis of a phosphorylated O-mannosyl trisaccharide, a structure present in alpha-dystroglycan (DAG1; MIM:128239) which plays a key role in skeletal muscle function and regeneration. LARGE contains two substrate-specific GT-domains and belongs to the CAZy glycosyltransferase families GT8 and GT49. Defects in LARGE result in hypoglycosylation of DAG1 and cause several congenital muscular dystrophies (CMDs). Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A6 (MDDGA6; MIM:613154) is associated with brain anomalies, eye malformations, profound mental retardation, and death usually in the first years of life (Clement et al. 2008, Mercuri et al. 2009). Muscular dystrophy-dystroglycanopathy congenital with mental retardation B6 (MDDGB6; MIM:608840) is associated with profound mental retardation, white matter changes and structural brain abnormalities (Longman et al. 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis41">
 <bp:controlled rdf:resource="#BiochemicalReaction46" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway95">
 <bp:pathwayOrder rdf:resource="#PathwayStep197" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction103" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence197" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGNT1; CAZy family GT61; MIM:606822) mediates the transfer of N-acetylglucosaminyl (GlcNAc) residues to mannosylated proteins such as mannose-O-serine-dystroglycan (man-O-Ser-DAG1). DAG1 is a cell surface protein that plays an important role in the assembly of the extracellular matrix in muscle, brain, and peripheral nerves by linking the basal lamina to cytoskeletal proteins. Defects in POMGNT1 (MIM:606822) result in disrupted glycosylation of DAG1 and can cause severe congenital muscular dystrophy-dystroglycanopathies ranging from a severe type A3 (MDDGA3; MIM:253280), through a less severe type B3 (MDDGB3; MIM:613151) to a milder type C3 (MDDGC3; MIM:613157) (Bertini et al. 2011, Wells 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis40">
 <bp:controlled rdf:resource="#BiochemicalReaction45" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway94">
 <bp:pathwayOrder rdf:resource="#PathwayStep195" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction102" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence195" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LFNG causes SCDO3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Fringe family (CAZy family GT31) of glycosyltransferases in mammals includes LFNG (lunatic fringe; MIM:602576), MFNG (manic fringe; MIM:602577) and RFNG (radical fringe; MIM:602578). Fringe enzymes function in the Golgi apparatus where they initiate the elongation of O-linked fucose on fucosylated peptides by the addition of a beta 1,3 N-acetylglucosaminyl group (GlcNAc) (Moloney et al. 2000). Fringe enzymes elongate conserved O fucosyl residues conjugated to EGF repeats of NOTCH, modulating NOTCH activity (Cohen et al. 1997, Johnston et al. 1997) by decreasing the affinity of NOTCH extracellular domain for JAG ligands (Bruckner et al. 2000).  The spondylocostal dysostoses (SCDs) are a group of disorders that arise during embryonic development by a disruption of somitogenesis. The Notch signalling pathway is essential for somitogenesis, the precursors of vertebra and associated musculature. Defects in one of the Fringe enzymes, beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (LFNG), can cause spondylocostal dysostosis, autosomal recessive 3 (SCDO3, MIM:609813), a condition of variable severity associated with vertebral and rib segmentation defects (Sparrow et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis43">
 <bp:controlled rdf:resource="#BiochemicalReaction48" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway97">
 <bp:pathwayOrder rdf:resource="#PathwayStep213" />
 <bp:pathwayOrder rdf:resource="#PathwayStep201" />
 <bp:pathwayOrder rdf:resource="#PathwayStep223" />
 <bp:pathwayOrder rdf:resource="#PathwayStep221" />
 <bp:pathwayOrder rdf:resource="#PathwayStep231" />
 <bp:pathwayOrder rdf:resource="#PathwayStep241" />
 <bp:pathwayOrder rdf:resource="#PathwayStep208" />
 <bp:pathwayOrder rdf:resource="#PathwayStep219" />
 <bp:pathwayOrder rdf:resource="#PathwayStep229" />
 <bp:pathwayOrder rdf:resource="#PathwayStep217" />
 <bp:pathwayOrder rdf:resource="#PathwayStep239" />
 <bp:pathwayOrder rdf:resource="#PathwayStep204" />
 <bp:pathwayOrder rdf:resource="#PathwayStep215" />
 <bp:pathwayOrder rdf:resource="#PathwayStep225" />
 <bp:pathwayOrder rdf:resource="#PathwayStep236" />
 <bp:pathwayComponent rdf:resource="#Pathway110" />
 <bp:pathwayComponent rdf:resource="#Pathway108" />
 <bp:pathwayComponent rdf:resource="#Pathway109" />
 <bp:pathwayComponent rdf:resource="#Pathway99" />
 <bp:pathwayComponent rdf:resource="#Pathway100" />
 <bp:pathwayComponent rdf:resource="#Pathway111" />
 <bp:pathwayComponent rdf:resource="#Pathway98" />
 <bp:pathwayComponent rdf:resource="#Pathway101" />
 <bp:pathwayComponent rdf:resource="#Pathway112" />
 <bp:pathwayComponent rdf:resource="#Pathway102" />
 <bp:pathwayComponent rdf:resource="#Pathway103" />
 <bp:pathwayComponent rdf:resource="#Pathway104" />
 <bp:pathwayComponent rdf:resource="#Pathway105" />
 <bp:pathwayComponent rdf:resource="#Pathway106" />
 <bp:pathwayComponent rdf:resource="#Pathway107" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence201" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with glycosaminoglycan metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of genetic disorders are caused by mutations in the genes encoding glycosyltransferases and sulfotransferases, enzymes responsible for the synthesis of  glycosaminoglycans (GAGs) as well as hexosaminidase degradation of GAGs (Mizumoto et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis160">
 <bp:controlled rdf:resource="#BiochemicalReaction171" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis42">
 <bp:controlled rdf:resource="#BiochemicalReaction47" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway96">
 <bp:pathwayOrder rdf:resource="#PathwayStep199" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction104" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence199" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Co-expression of both protein O-mannosyl-transferases 1 and 2 (POMT1 and POMT2; CAZy family GT39) is necessary for enzyme activity, that is mediating the transfer of mannosyl residues to the hydroxyl group of serine or threonine residues of proteins such as alpha-dystroglycan (DAG1; MIM:128239). DAG1 is a cell surface protein that plays an important role in the assembly of the extracellular matrix in muscle, brain, and peripheral nerves by linking the basal lamina to cytoskeletal proteins. Defects in POMT2 (MIM:607439) results in defective glycosylation of DAG1 and can cause severe congenital muscular dystrophy dystroglycanopathies ranging from a severe type A, MDDGA2 (brain and eye abnormalities; MIM:613150), through a less severe type B, MDDGB2 (congenital form with mental retardation; MIM:613156) to a milder type C, MDDGC2 (limb girdle form; MIM:603158) (Bertini et al. 2011, Wells 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze Suc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze iMal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective KHK does not phosphorylate beta-D-fructose</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TALDO1 does not transform SH7P, GA3P to Fru(6)P, E4P</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis159">
 <bp:controlled rdf:resource="#BiochemicalReaction170" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis158">
 <bp:controlled rdf:resource="#BiochemicalReaction169" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TALDO1 does not transform Fru(6)P, E4P to SH7P, GA3P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RPIA does not isomerize RU5P to R5P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze maltotriose</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALDOB does not cleave Fru 1-P to GA and DHAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze Mal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LCT does not hydrolyze Lac</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway99">
 <bp:pathwayOrder rdf:resource="#PathwayStep207" />
 <bp:pathwayOrder rdf:resource="#PathwayStep206" />
 <bp:pathwayOrder rdf:resource="#PathwayStep205" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction108" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction109" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence205" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA causes GM2G1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-hexosaminidase (HEX) cleaves the terminal N-acetyl galactosamine (GalNAc) from glycosaminoglycans (GAGs) and any other molecules containing a terminal GalNAc. There are two forms of HEX; HEXA and B. The A form is a trimer of the subunits alpha, beta A and beta B. The B form is a tetramer of 2 beta A and 2 beta B subunits (O&apos;Dowd et al. 1988). Defects in the two subunits cause lysosomal storage diseases marked by the accumulation of GM2 gangliosides in neuronal cells. Defects in the alpha subunits are the cause of GM2-gangliosidosis type 1 (GM2G1) (MIM:272800), also known as Tay-Sachs disease (Okada    O&apos;Brien 1969, Nakano et al. 1988). Classical Tay-Sachs disease is characterised by infant-onset neurodegeneration followed by paralysis, dementia and blindness, Death occurs by the age of 2 or 3 (Okada et al. 1971). The two other forms of Tay-Sachs disease, juvenile- and adult-onset, are less commom and severe than the infant-onset form (Suzuki et al. 1970, Johnson et al. 1982).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis151">
 <bp:controlled rdf:resource="#BiochemicalReaction162" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway98">
 <bp:pathwayOrder rdf:resource="#PathwayStep202" />
 <bp:pathwayOrder rdf:resource="#PathwayStep203" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction106" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence202" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHSY1 causes TPBS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Chondroitin sulfate synthases (CHSY) are involved in the synthesis of chondroitin sulfate, adding alternatingly glucuronate (GlcA) and N-acetylgalactosamine (GalNAc) to the growing chondroitin polymer (Mizumoto et al. 2013). Defects in CHSY1 cause temtamy preaxial brachydactyly syndrome (TPBS; MIM:605282), a syndrome characterized by multiple congenital anomalies, mental retardation, sensorineural deafness, growth retardation and bilateral symmetric digital anomalies mainly in the form of preaxial brachydactyly (literally, shortness of fingers and toes) and hyperphalangism (Temtamy et al. 1998, Race et al. 2010, Tian et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis150">
 <bp:controlled rdf:resource="#BiochemicalReaction161" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis153">
 <bp:controlled rdf:resource="#BiochemicalReaction164" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis152">
 <bp:controlled rdf:resource="#BiochemicalReaction163" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis49">
 <bp:controlled rdf:resource="#BiochemicalReaction54" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis155">
 <bp:controlled rdf:resource="#BiochemicalReaction166" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis48">
 <bp:controlled rdf:resource="#BiochemicalReaction53" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis154">
 <bp:controlled rdf:resource="#BiochemicalReaction165" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis157">
 <bp:controlled rdf:resource="#BiochemicalReaction168" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis156">
 <bp:controlled rdf:resource="#BiochemicalReaction167" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis56">
 <bp:controlled rdf:resource="#BiochemicalReaction61" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis55">
 <bp:controlled rdf:resource="#BiochemicalReaction60" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis58">
 <bp:controlled rdf:resource="#BiochemicalReaction63" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis57">
 <bp:controlled rdf:resource="#BiochemicalReaction62" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis52">
 <bp:controlled rdf:resource="#BiochemicalReaction57" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis51">
 <bp:controlled rdf:resource="#BiochemicalReaction56" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis54">
 <bp:controlled rdf:resource="#BiochemicalReaction59" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis171">
 <bp:controlled rdf:resource="#BiochemicalReaction182" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis53">
 <bp:controlled rdf:resource="#BiochemicalReaction58" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis170">
 <bp:controlled rdf:resource="#BiochemicalReaction181" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDS does not hydrolyse Heparan sulfate chain(5)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HYAL1 does not hydrolyse (HA)50</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis50">
 <bp:controlled rdf:resource="#BiochemicalReaction55" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDUA does not hydrolyse Heparan sulfate chain(6)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDUA does not hydrolyse Heparan sulfate chain(1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis169">
 <bp:controlled rdf:resource="#BiochemicalReaction180" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ARSB does not hydrolyse C4S/C6S chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDUA does not hydrolyse the unsulfated alpha-L-iduronosidic link in DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NAGLU does not hydrolyse heparan chain(2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ARSB does not hydrolyse DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HYAL1 does not hydrolyse Chondroitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NAGLU does not hydrolyse Heparan sulfate chain(4)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis162">
 <bp:controlled rdf:resource="#BiochemicalReaction173" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis161">
 <bp:controlled rdf:resource="#BiochemicalReaction172" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis164">
 <bp:controlled rdf:resource="#BiochemicalReaction175" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis163">
 <bp:controlled rdf:resource="#BiochemicalReaction174" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis166">
 <bp:controlled rdf:resource="#BiochemicalReaction177" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis59">
 <bp:controlled rdf:resource="#BiochemicalReaction64" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis165">
 <bp:controlled rdf:resource="#BiochemicalReaction176" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis168">
 <bp:controlled rdf:resource="#BiochemicalReaction179" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis167">
 <bp:controlled rdf:resource="#BiochemicalReaction178" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction28" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction27" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis25">
 <bp:controlled rdf:resource="#BiochemicalReaction30" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway71">
 <bp:pathwayOrder rdf:resource="#PathwayStep146" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence146" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG11 causes CDG-1p</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase (ALG11) transfers the fourth and fifth mannoses (Man) to the N-glycan precursor in an alpha-1,2 orientation. These additions are the last two on the cytosolic side of the ER membrane before the N-glycan is flipped to the luminal side of the membrane. Recently discovered defects in ALG11 have been linked to congential disorder of glycosylation, type 1p (ALG11-CDG, CGD1p) (Rind et al. 2010, Thiel et al. 2012). The disease is a multi-system disorder characterised by under-glycosylated serum glycoproteins. Early-onset developmental retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency are reported features of this disorder (Rind et al. 2010, Thiel et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis24">
 <bp:controlled rdf:resource="#BiochemicalReaction29" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway70">
 <bp:pathwayOrder rdf:resource="#PathwayStep144" />
 <bp:pathwayOrder rdf:resource="#PathwayStep143" />
 <bp:pathwayOrder rdf:resource="#PathwayStep142" />
 <bp:pathwayOrder rdf:resource="#PathwayStep141" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 causes CDG-1f</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mannose-P-dolichol utilisation defect 1 protein (MPDU1) is required for the efficient utilisation of the mannose donor dolichyl-phospho-mannose (DOLPman) in the synthesis of both lipid-linked oligosaccharides (LLOs) and glycosylphosphatidylinositols. Defects in MPDU1 can cause congenital disorder of glycosylation 1f (MPDU1-CDG, CDG-1f; MIM:609180), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide phenotypic spectrum, such as poor neurological development, psychomotor retardation, dysmorphic features, hypotonia, coagulation abnormalities and immunodeficiency. In this condition, DOLPman is no longer utilised in transferase reactions extending LLOs, even as substrate levels and transferase enzyme activities appear normal (Anand et al. 2001, Schenk et al. 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway73">
 <bp:pathwayOrder rdf:resource="#PathwayStep153" />
 <bp:pathwayOrder rdf:resource="#PathwayStep152" />
 <bp:pathwayOrder rdf:resource="#PathwayStep151" />
 <bp:pathwayOrder rdf:resource="#PathwayStep150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence150" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 causes MRT15</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (MAN1B1) normally trims single mannose residues from misfolded glycoproteins, targeting them for degradation and thus providing a quality control process for N-glycoyslated proteins. Defects in MAN1B1 can cause mental retardation, autosomal recessive 15 (MRT15; MIM:614202), a disorder resulting in nonsyndromic moderate to severe mental retardation. It is characterised by significantly below average intellectual functioning associated with impaired adaptative behaviour during the developmental period (Rafiq et al. 2010, Rafiq et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway72">
 <bp:pathwayOrder rdf:resource="#PathwayStep148" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence148" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG14 causes ALG14-CMS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-N-acetylglucosamine transferase subunit ALG14 homolog (ALG14) forms a complex with ALG13 protein and is required for the addition of the second N-acetylglucosamine (GlcNAc) to the lipid linked oligosaccharide (LLO) intermediate (GlcNAcDOLDP) (Gao et al. 2005). Defects in ALG14 can cause congenital myasthenic syndrome (ALG14-CMS), which is due to a defect in neuromuscular signal transmission (Cossins et al. 2013). The most commonly affected muscles include proximal limb muscles. Mutations causing ALG14-CMS include p.P65L and p.R104* (Cossins et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction26" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway75">
 <bp:pathwayOrder rdf:resource="#PathwayStep158" />
 <bp:pathwayOrder rdf:resource="#PathwayStep157" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence157" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG9 causes CDG-1l</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alpha-1,2-mannosyltransferase ALG9 (ALG9) normally catalyses the transfer of mannose to the lipid-linked oligosaccharide (LLO) precursor. It adds the 7th and 9th mannose moieties to LLO. Defects in ALG9 are associated with congenital disorder of glycosylation 1l (ALG9-CDG, CDG1l; MIM:608776), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Frank et al. 2004, Weinstein et al. 2005). The LLO profile showed accumulation of (GlcNAc)2 (Man)6 (PP-Dol)1 and (GlcNAc)2 (Man)8 (PP-Dol)1 fragments, suggesting a defect in ALG9 and correlating with the normal function of ALG9 in adding the 7th and 9th mannose moieties (Frank et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction25" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway74">
 <bp:pathwayOrder rdf:resource="#PathwayStep155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence155" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG3 causes CDG-1d</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase (ALG3) adds the sixth mannose (although the first to be derived from dolichyl-phosphate-mannose, DOLPman) to the lipid-linked oligosaccharide (LLO) intermediate GlcNAc(2) Man(5) (PPDol)1 (Korner et al. 1999). Defects in ALG3 are associated with congenital disorder of glycosylation 1d (ALG3-CDG, CDG1d; MIM:601110), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Sun et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis137">
 <bp:controlled rdf:resource="#BiochemicalReaction147" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis136">
 <bp:controlled rdf:resource="#BiochemicalReaction146" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis139">
 <bp:controlled rdf:resource="#BiochemicalReaction149" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis138">
 <bp:controlled rdf:resource="#BiochemicalReaction148" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway77">
 <bp:pathwayOrder rdf:resource="#PathwayStep162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence162" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG8 causes CDG-1h</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) (Stanchi et al. 2001, Chantret et al. 2003) normally adds the second glucose moiety to the lipid-linked oligosaccharide precursor (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG8 can cause congenital disorder of glycosylation 1h (ALG8-CDG, CDG-1h; MIM:608104), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Chantret et al. 2003, Schollen et al. 2004). ALG8 deficiency is accompanied by an accumulation of the N-glycan precursor (Glc)1 (GlcNAc)2 (Man)9 (PP-Dol)1. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway76">
 <bp:pathwayOrder rdf:resource="#PathwayStep160" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence160" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RFT1 causes CDG-1n</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The N-glycan precursor is flipped across the ER membrane, moving it from the cytosolic side to the ER lumenal side. The exact mechanism of this translocation is not well understood but protein RFT1 homolog (RFT1) is known to be involved  (Helenius et al. 2002). Defects in RFT1 are associated with congenital disorder of glycosylation 1n (RFT1-CDG, CDG-1n). The disease is a multi-system disorder characterised by under-glycosylated serum glycoproteins. Early-onset developmental retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency are reported features of this disorder (Haeuptle et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway79">
 <bp:pathwayOrder rdf:resource="#PathwayStep166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence166" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MGAT2 causes CDG-2a</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (MGAT2) normally catalyses the transfer of a GlcNAc moiety onto the alpha-1,6 mannose of an alpha-1,4 branch of oligomannose N-glycans to form complex N-glycans (Tan et al. 1995). Defects in MGAT2 are associated with congenital disorder of glycosylation type IIa (MGAT2-CDG, CDG-2a; MIM:212066), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Tan et al. 1996,  Cormier-Daire et al. 2000,  Alkuraya 2010, Alazami et al. 2012). Type II CDGs refer to defects in the trimming and processing of protein-bound glycans.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis131">
 <bp:controlled rdf:resource="#BiochemicalReaction141" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway78">
 <bp:pathwayOrder rdf:resource="#PathwayStep164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence164" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MOGS causes CDG-2b</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After the lipid-linked oligosaccharide (LLO) precursor is attached to the protein, the outer alpha-1,2-linked glucose is removed by by mannosyl-oligosaccharide glucosidase (MOGS). This is a mandatory step for protein folding control and glycan extension. Defects in MOGS are associated with congenital disorder of glycosylation type IIb (CDGIIb), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (De Praeter et al. 2000, Voelker et al. 2002). Type II CDGs refer to defects in the trimming and processing of protein-bound glycans.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis130">
 <bp:controlled rdf:resource="#BiochemicalReaction140" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis27">
 <bp:controlled rdf:resource="#BiochemicalReaction32" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis133">
 <bp:controlled rdf:resource="#BiochemicalReaction143" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis26">
 <bp:controlled rdf:resource="#BiochemicalReaction31" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis132">
 <bp:controlled rdf:resource="#BiochemicalReaction142" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis29">
 <bp:controlled rdf:resource="#BiochemicalReaction34" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis135">
 <bp:controlled rdf:resource="#BiochemicalReaction145" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis28">
 <bp:controlled rdf:resource="#BiochemicalReaction33" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis134">
 <bp:controlled rdf:resource="#BiochemicalReaction144" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis34">
 <bp:controlled rdf:resource="#BiochemicalReaction39" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway80">
 <bp:pathwayOrder rdf:resource="#PathwayStep168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence168" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG6 causes CDG-1c</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG6) normally adds the first glucose moiety to the lipid-linked oligosaccharide precursor (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins (Imbach et al. 1999). Defects in ALG6 can cause congenital disorder of glycosylation 1c (ALG6-CDG, CDG-1c; MIM:603147), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Imbach et al. 1999, Imbach et al. 2000, Westphal et al. 2000, Sun et al. 2005). ALG6 deficiency is accompanied by an accumulation of the N-glycan precursor (GlcNAc)2 (Man)9 (PP-Dol)1 and is the second most common CDG disease subtype after PMM2-CDG (CDG-1a) (Imbach et al. 1999). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis33">
 <bp:controlled rdf:resource="#BiochemicalReaction38" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis36">
 <bp:controlled rdf:resource="#BiochemicalReaction41" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway82">
 <bp:pathwayOrder rdf:resource="#PathwayStep172" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence172" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 causes CDG-2d</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation (CDG, previously called carbohydrate-deficient glycoprotein syndromes, CDGSs), are a group of hereditary multisystem disorders. They are characterized biochemically by hypoglycosylation of glycoproteins, diagnosed by isoelectric focusing (IEF) of serum transferrin. There are two types of CDG, types I and II. Type I CDG has defects in the assembly of lipid-linked oligosaccharides or their transfer onto nascent glycoproteins, whereas type II CDG comprises defects of trimming, elongation, and processing of protein-bound glycans. Clinical symptoms are dominated by severe psychomotor and mental retardation, as well as blood coagulation abnormalities (Jaeken 2013). B4GALT1-CDG (CDG type IId) is a multisystem disease, characterized by dysmorphic features, hydrocephalus, hypotonia and blood clotting abnormalities (Hansske et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis35">
 <bp:controlled rdf:resource="#BiochemicalReaction40" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway81">
 <bp:pathwayOrder rdf:resource="#PathwayStep170" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence170" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPAGT1 causes CDG-1j, CMSTA2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) catalyses the initial committed step in the biosynthesis of dolichyl pyrophosphate-oligosaccharides. Defects in DPAGT1 cause congenital disorder of glycosylation 1j (DPAGT1-CDG, previously known as CDG-1j; MIM:608093), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Wu et al. 2003, Timal et al. 2012). Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. Defects in DPAGT1 can also cause myasthenic syndrome, congenital, with tubular aggregates, 2 (CMSTA2; MIM:614750), characterised by muscle weakness of mainly the proximal limb muscles, with tubular aggregates present on muscle biopsy. Sufferers find walking difficult and fall frequently. Younger sufferers show hypotonia and poor head control. A disorder of neuromuscular transmission is detected on electromyography (Belaya et al. 2012, Finlayson et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis30">
 <bp:controlled rdf:resource="#BiochemicalReaction35" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway84">
 <bp:pathwayOrder rdf:resource="#PathwayStep176" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence176" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG12 causes CDG-1g</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase (ALG12) (Chantret et al. 2002) normally tranfers the 8th mannose moiety to the lipid-linked oligosaccharide (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG12 are associated with congenital disorder of glycosylation 1g (ALG12-CDG, CDG1g; MIM:607143), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Chantret et al. 2002, Grubenmann et al. 2002). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway83">
 <bp:pathwayOrder rdf:resource="#PathwayStep174" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence174" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NEU1 causes sialidosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sialidases have important roles in the degradation of glycoconjugates by removing terminal sialic acid residues. Defects in sialidase 1 (NEU1) cause sialidosis, a lysosomal storage disease characterised by the progressive lysosomal storage of sialidated glycopeptides and oligosaccharides and the accumulation and excretion of N-acetylneuraminic acid (Neu5Ac) covalently-linked (&apos;bound&apos;) glycoconjugates (Lowden    O&apos;Brien 1979). The sialidoses are distinct from the sialurias in which there is storage and excretion of &apos;free&apos; Neu5Ac. Sialidosis manifests into types I and II forms. Type I is the milder form, also known as the &apos;normosomatic&apos; type or the cherry red spot-myoclonus syndrome. Sialidosis type II is the more severe form with an earlier onset, and is also known as the &apos;dysmorphic&apos; type.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis32">
 <bp:controlled rdf:resource="#BiochemicalReaction37" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway86">
 <bp:pathwayOrder rdf:resource="#PathwayStep180" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction95" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence180" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG2 causes CDG-1i</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alpha 1,3/1,6 mannosyltransferase ALG2 (ALG2) is a bifunctional mannosyltransferase normally tranfers a mannose moiety to the lipid linked oligosaccharide (LLO aka N glycan precursor) which is required for subsequent N glycosylation of proteins. Defects in ALG2 can cause congenital disorder of glycosylation 1i (ALG2-CDG, previously known as CDG1i; MIM:607906), a multisystem disorder characterised by under glycosylated serum glycoproteins. CDG type 1 diseases result in a wide phenotypic spectrum, from poor neurological development, psychomotor retardation and dysmorphic features to hypotonia, coagulation abnormalities and immunodeficiency (Thiel et al. 2003). Defect in ALG2 can also cause congenital myasthenic syndrome (ALG2-CMS), which is due to a defect in neuromuscular signal transmission (Cossins et al. 2013). The most commonly affected muscles include proximal limb muscles. Mutations causing ALG2-CMS include p.V68G and p.72_75delinsSPR (Cossins et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis31">
 <bp:controlled rdf:resource="#BiochemicalReaction36" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway85">
 <bp:pathwayOrder rdf:resource="#PathwayStep178" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction94" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence178" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG1 causes CDG-1k</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Chitobiosyldiphosphodolichol beta-mannosyltransferase (ALG1) normally tranfers a mannose moiety to the lipid-linked oligosaccharide (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG1 can cause congenital disorder of glycosylation 1k (ALG1-CDG, previously known as CDG1k; MIM:608540), a multisystem disorder characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. Compared to other CDGs, ALG1-CDG has a very severe phenotype, which can result in an early death (Schwarz et al. 2004, Kranz et al. 2004, Dupre et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis148">
 <bp:controlled rdf:resource="#BiochemicalReaction159" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis147">
 <bp:controlled rdf:resource="#BiochemicalReaction158" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis149">
 <bp:controlled rdf:resource="#BiochemicalReaction160" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway88">
 <bp:pathwayOrder rdf:resource="#PathwayStep183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction96" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence183" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALTL causes PpS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human beta-1,3-glucosyltransferase like protein (B3GALTL, HGNC Approved Gene Symbol: B3GLCT; MIM:610308; CAZy family GT31), localised on the ER membrane, glucosylates O-fucosylated proteins. The resultant glc-beta-1,3-fuc disaccharide modification on thrombospondin type 1 repeat (TSR1) domain-containing proteins is thought to assist in the secretion of many of these proteins from the ER lumen, and mediate an ER quality-control mechanism of folded TSRs (Vasudevan et al. 2015). Defects in B3GALTL can cause Peters plus syndrome (PpS; MIM:261540), an autosomal recessive disorder characterised by anterior eye chamber defects, short stature, delay in growth and mental developmental and cleft lip and/or palate (Heinonen    Maki 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis140">
 <bp:controlled rdf:resource="#BiochemicalReaction150" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway87">
 <bp:pathwayOrder rdf:resource="#PathwayStep188" />
 <bp:pathwayOrder rdf:resource="#PathwayStep198" />
 <bp:pathwayOrder rdf:resource="#PathwayStep186" />
 <bp:pathwayOrder rdf:resource="#PathwayStep196" />
 <bp:pathwayOrder rdf:resource="#PathwayStep184" />
 <bp:pathwayOrder rdf:resource="#PathwayStep194" />
 <bp:pathwayOrder rdf:resource="#PathwayStep182" />
 <bp:pathwayOrder rdf:resource="#PathwayStep192" />
 <bp:pathwayOrder rdf:resource="#PathwayStep190" />
 <bp:pathwayComponent rdf:resource="#Pathway91" />
 <bp:pathwayComponent rdf:resource="#Pathway90" />
 <bp:pathwayComponent rdf:resource="#Pathway93" />
 <bp:pathwayComponent rdf:resource="#Pathway92" />
 <bp:pathwayComponent rdf:resource="#Pathway95" />
 <bp:pathwayComponent rdf:resource="#Pathway94" />
 <bp:pathwayComponent rdf:resource="#Pathway96" />
 <bp:pathwayComponent rdf:resource="#Pathway88" />
 <bp:pathwayComponent rdf:resource="#Pathway89" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence182" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with O-glycosylation of proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation is the most abundant modification of proteins, variations of which occur in all living cells. Glycosylation can be further categorized into N-linked (where the oligosaccharide is conjugated to Asparagine residues) and O-linked glycosylation (where the oligosaccharide is conjugated to Serine, Threonine and possibly Tyrosine residues). Within the family of O-linked glycosylation, the oligosaccharides attached can be further categorized according to their reducing end residue: GalNAc (often described as mucin-type, due to the abundance of this type of glycosylation on mucins), Mannose and Fucose. This section reviews currently known congenital disorders of glycosylation associated with defects of protein O-glycosylation (Cylwik et al. 2013, Freeze et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis142">
 <bp:controlled rdf:resource="#BiochemicalReaction152" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway89">
 <bp:pathwayOrder rdf:resource="#PathwayStep185" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction97" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence185" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective C1GALT1C1 causes TNPS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1; MIM:610555) mediates the transfer of Galactose (Gal) from UDP-galactose to single O-linked GalNAc residues (Tn antigens) to form Core 1 structures on glycoproteins. C1GALT1 is active when in complex with the molecular chaperone C1GALT1C1 (aka COSMC; MIM:300611) which assists the folding and/or stability of C1GALT1. Defects in C1GALT1C1 causes somatic Tn polyagglutination syndrome (TNPS; MIM:300622), characterised by the polyagglutination of erythrocytes by naturally occurring anti-Tn antibodies following exposure of the Tn antigen on their surface. Defects in C1GALT1C1 render C1GALT1 inactive and results in the accumulation of the incompletely glycosylated Tn antigen. The Tn antigen is tumour-associated, found in a majority of human carcinomas, and is not normally expressed in peripheral tissues or blood cells (Crew et al. 2008, Ju et al. 2014). C1GALT1 and C1GALT1C1 belong to the CAZy family GT31 (www.cazy.org).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis141">
 <bp:controlled rdf:resource="#BiochemicalReaction151" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis38">
 <bp:controlled rdf:resource="#BiochemicalReaction43" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis144">
 <bp:controlled rdf:resource="#BiochemicalReaction154" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis37">
 <bp:controlled rdf:resource="#BiochemicalReaction42" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis143">
 <bp:controlled rdf:resource="#BiochemicalReaction153" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis146">
 <bp:controlled rdf:resource="#BiochemicalReaction157" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis39">
 <bp:controlled rdf:resource="#BiochemicalReaction44" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis145">
 <bp:controlled rdf:resource="#BiochemicalReaction156" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis89">
 <bp:controlled rdf:resource="#BiochemicalReaction99" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis88">
 <bp:controlled rdf:resource="#BiochemicalReaction98" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis85">
 <bp:controlled rdf:resource="#BiochemicalReaction95" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis84">
 <bp:controlled rdf:resource="#BiochemicalReaction94" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis87">
 <bp:controlled rdf:resource="#BiochemicalReaction97" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis86">
 <bp:controlled rdf:resource="#BiochemicalReaction96" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis81">
 <bp:controlled rdf:resource="#BiochemicalReaction91" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis80">
 <bp:controlled rdf:resource="#BiochemicalReaction90" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis83">
 <bp:controlled rdf:resource="#BiochemicalReaction93" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis82">
 <bp:controlled rdf:resource="#BiochemicalReaction92" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence208">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence209">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence206">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence207">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence200">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence201">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence204">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence205">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence202">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence203">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis99">
 <bp:controlled rdf:resource="#BiochemicalReaction109" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis96">
 <bp:controlled rdf:resource="#BiochemicalReaction106" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis95">
 <bp:controlled rdf:resource="#BiochemicalReaction105" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis98">
 <bp:controlled rdf:resource="#BiochemicalReaction108" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis97">
 <bp:controlled rdf:resource="#BiochemicalReaction107" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis92">
 <bp:controlled rdf:resource="#BiochemicalReaction102" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis91">
 <bp:controlled rdf:resource="#BiochemicalReaction101" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis94">
 <bp:controlled rdf:resource="#BiochemicalReaction104" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis93">
 <bp:controlled rdf:resource="#BiochemicalReaction103" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis90">
 <bp:controlled rdf:resource="#BiochemicalReaction100" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence219">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence217">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence218">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence211">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence212">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence210">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence215">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence216">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence213">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence214">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis67">
 <bp:controlled rdf:resource="#BiochemicalReaction77" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis66">
 <bp:controlled rdf:resource="#BiochemicalReaction76" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis69">
 <bp:controlled rdf:resource="#BiochemicalReaction79" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis68">
 <bp:controlled rdf:resource="#BiochemicalReaction78" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis63">
 <bp:controlled rdf:resource="#BiochemicalReaction68" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis62">
 <bp:controlled rdf:resource="#BiochemicalReaction67" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis65">
 <bp:controlled rdf:resource="#BiochemicalReaction71" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis64">
 <bp:controlled rdf:resource="#BiochemicalReaction69" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis61">
 <bp:controlled rdf:resource="#BiochemicalReaction66" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis60">
 <bp:controlled rdf:resource="#BiochemicalReaction65" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis78">
 <bp:controlled rdf:resource="#BiochemicalReaction88" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis77">
 <bp:controlled rdf:resource="#BiochemicalReaction87" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis79">
 <bp:controlled rdf:resource="#BiochemicalReaction89" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis74">
 <bp:controlled rdf:resource="#BiochemicalReaction84" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis73">
 <bp:controlled rdf:resource="#BiochemicalReaction83" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis76">
 <bp:controlled rdf:resource="#BiochemicalReaction86" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis75">
 <bp:controlled rdf:resource="#BiochemicalReaction85" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis70">
 <bp:controlled rdf:resource="#BiochemicalReaction80" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis72">
 <bp:controlled rdf:resource="#BiochemicalReaction82" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis71">
 <bp:controlled rdf:resource="#BiochemicalReaction81" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPC causes SMDP2 and RDS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pulmonary surfactant-associated protein C (SFTPC), amongst other roles, is a component of surfactant, a surface-active film that helps reduce surface tension in alveoli. Defects in the SFTPC gene result in protein misfolding, misrouting and/or misprocessing resulting in accumulation of partially-processed, inactive pro-SFTPC in alveoli causing cell toxicity. Defects in SFTPC can cause pulmonary surfactant metabolism dysfunction 2 (SMDP2; MIM:610913), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Cellular responses to the misfolded pro-SFTPC products include ER stress, the activation of reactive oxygen species and autophagy. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450) (Thomas et al. 2002, Mulugeta et al. 2005, Thurm et al. 2013, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A2 causes PALM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC34A2 encodes NaPi-2b which is abundantly expressed in lung and to a lesser degree in epithelia of other tissues including small intestine, pancreas, prostate, and kidney. In the lung, SLC34A2 is expressed only in alveolar type II cells, which are responsible for surfactant production, so it is proposed that it uptakes liberated phosphate from the alveolar fluid for surfactant production. SLC34A2 cotransports divalent phosphate (HPO4(2-)) with three Na+ ions (electrogenic transport) from the extracellular region into alveolar type II cells. Defects in SLC34A2 can cause pulmonary alveolar microlithiasis (PALM; MIM:265100), a rare disease characterised by the deposition of calcium phosphate microliths (tiny, roundish corpuscles) throughout the lung. Most patients remain asymptomatic for years or decades, the disease following a long-term, progressive course resulting in slow deterioration of lung functions. PALM can result in a potentially lethal disease (Yin et al. 2013, Ferreira Francisco et al. 2013, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RB causes SMDP5</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Surfactant catabolism by alveolar macrophages plays a small but critical part in surfactant recycling and metabolism. Upon ligand binding, granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), a heterodimer of alpha (CSF2RA) and beta (CSF2RB) subunits, initiates a signalling process that not only induces proliferation, differentiation and functional activation of hematopoietic cells but can also determine surfactant uptake into alveolar macrophages and its degradation via clathrin-coated vesicles. Defects in human CSF2RB can cause pulmonary surfactant metabolism dysfunction 5 (SMDP5; MIM:614370, aka pulmonary alveolar proteinosis 5, PAP5), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material causing respiratory failure (Greenhill    Kotton 2009, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA3 causes SMDP3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family A member 3 (ABCA3) plays an important role in the formation of pulmonary surfactant, probably by transporting phospholipids such as phosphatidylcholine (PC) and phosphatidylglycerol (PG) from the ER membrane to lamellar bodies (LBs). PC and PG are the major phospholipid constituents of pulmonary surfactant. LBs are the surfactant storage organelles of type II epithelial cells from where phospholipids can be secreted together with surfactant proteins (SFTPs) into the alveolar airspace. Defects in ABCA3 can cause pulmonary surfactant metabolism dysfunction type 3 (SMDP3; MIM:610921), resulting in respiratory distress in newborns and interstitial lung disease (ILD) in children (Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPB causes SMDP1 and RDS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pulmonary surfactant-associated protein B (SFTPB), amongst other roles, is a component of surfactant, a surface-active film that helps reduce surface tension in alveoli. Defects in the SFTPB gene result in loss-of-function SFTPB proteins and accumulation of partially-processed , inactive pro-SFTPC in alveoli. Defects in SFTPB can cause pulmonary surfactant metabolism dysfunction 1 (SMDP1; MIM:265120), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450) (Vorbroker et al. 1995, Li et al. 2004, Wert et al. 2009, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RA causes SMDP4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Surfactant catabolism by alveolar macrophages plays a small but critical part in surfactant recycling and metabolism. Upon ligand binding, granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), a heterodimer of alpha (CSF2RA) and beta (CSF2RB) subunits, initiates a signalling process that not only induces proliferation, differentiation and functional activation of hematopoietic cells but can also determine surfactant uptake into alveolar macrophages and its degradation via clathrin-coated vesicles. Defects in human CSF2RA can cause pulmonary surfactant metabolism dysfunction 4 (SMDP4; MIM:300770, aka congenital pulmonary alveolar proteinosis, (PAP)), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Cellular responses to the misfolded pro-SFTPC products include ER stress, the activation of reactive oxygen species and autophagy. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450) (Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SFTPA2 causes IPF</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">One function of the pulmonary collectins, surfactant proteins A1, A2, A3 and D (SFTPAs, D), is that they influence surfactant homeostasis, contributing to the physical structures of lipids in the alveoli and to the regulation of surfactant function and metabolism. They are directly secreted from alveolar type II cells into the airway to function as part of the surfactant. The mechanism of secretion is unknown. Mutations in SFTPA2 disrupt protein structure and the defective protein is retained in the ER membrane causing idiopathic pulmonary fibrosis (IPF; MIM:178500). IPF is one of a family of idiopathic pneumonias sharing clinical features of shortness of breath, formation of scar tissue and varying degrees of inflammation and/or fibrosis on lung biopsy. IPF is typically progressive, leading to death from respiratory failure within 2-5 years of diagnosis in the majority of instances (Meltzer    Noble 2008, Noble    Barkauskas 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep136" />
 <bp:pathwayOrder rdf:resource="#PathwayStep345" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep134" />
 <bp:pathwayOrder rdf:resource="#PathwayStep132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep275" />
 <bp:pathwayOrder rdf:resource="#PathwayStep120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep138" />
 <bp:pathwayComponent rdf:resource="#Pathway160" />
 <bp:pathwayComponent rdf:resource="#Pathway66" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway65" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway68" />
 <bp:pathwayComponent rdf:resource="#Pathway45" />
 <bp:pathwayComponent rdf:resource="#Pathway67" />
 <bp:pathwayComponent rdf:resource="#Pathway58" />
 <bp:pathwayComponent rdf:resource="#Pathway128" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Metabolic processes in human cells generate energy through the oxidation of molecules consumed in the diet and mediate the synthesis of diverse essential molecules not taken in the diet as well as the inactivation and elimination of toxic ones generated endogenously or present in the extracellular environment. Mutations that disrupt these processes by inactivating a required enzyme or regulatory protein, or more rarely by changing its specificity can lead to severe diseases. Metabolic diseases annotated here involve aspects of carbohydrate, glycosylation, amino acid (phenylketonuria), surfactant and vitamin metabolism, and biological oxidations. One somatic mutation that affects cytosolic isocitrate metabolism, often found in glioblastomas and some lymphoid neoplasms, is also annotated. Also described are mutated forms of adrenocorticotropic hormone (ACTH) that can lead to obesity, resulting in excessive accumulation of body fat. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with surfactant metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The reactions annotated here describe genetic defects in genes regulating surfactant homeostasis which are associated with severe acute and chronic lung diseases in newborns and older infants (Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence291">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence292">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence290">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence295">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence296">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence293">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence294">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence288">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence289">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence286">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence287">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence299">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence297">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence298">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence270">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence273">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence274">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence271">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence272">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence266">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence267">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence264">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence265">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence268">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence269">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence280">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence281">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence284">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence285">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence282">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence283">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence277">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence278">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence275">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence276">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence279">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence251">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence252">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence250">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep282">
 <bp:stepProcess rdf:resource="#Pathway131" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep281">
 <bp:stepProcess rdf:resource="#Catalysis142" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction152" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep280">
 <bp:stepProcess rdf:resource="#Pathway130" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction200">
 <bp:evidence rdf:resource="#Evidence373" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAA does not protect MUT</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep289">
 <bp:stepProcess rdf:resource="#BiochemicalReaction156" />
 <bp:stepProcess rdf:resource="#Catalysis145" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction201">
 <bp:evidence rdf:resource="#Evidence376" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective mitochondrial BTD does not hydrolyse BCTN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep288">
 <bp:stepProcess rdf:resource="#Pathway134" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction202">
 <bp:evidence rdf:resource="#Evidence377" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective extracellular BTD does not hydrolyse BCTN</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep287">
 <bp:stepProcess rdf:resource="#BiochemicalReaction155" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction203">
 <bp:evidence rdf:resource="#Evidence379" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate 6x(PCCA:PCCB)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep286">
 <bp:stepProcess rdf:resource="#Pathway133" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction204">
 <bp:evidence rdf:resource="#Evidence380" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate PC:Mn2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep285">
 <bp:stepProcess rdf:resource="#Catalysis144" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction154" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction205">
 <bp:evidence rdf:resource="#Evidence381" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate 6xMCCC1:6xMCCC2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep284">
 <bp:stepProcess rdf:resource="#Pathway132" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction206">
 <bp:evidence rdf:resource="#Evidence382" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate ACACA:Mn2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep283">
 <bp:stepProcess rdf:resource="#BiochemicalReaction153" />
 <bp:stepProcess rdf:resource="#Catalysis143" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence244">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence245">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence242">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence243">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence248">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence249">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence246">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence247">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence262">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence263">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence260">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence261">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep271">
 <bp:stepProcess rdf:resource="#Pathway126" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep270">
 <bp:stepProcess rdf:resource="#BiochemicalReaction146" />
 <bp:stepProcess rdf:resource="#Catalysis136" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep279">
 <bp:stepProcess rdf:resource="#BiochemicalReaction151" />
 <bp:stepProcess rdf:resource="#Catalysis141" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep278">
 <bp:stepProcess rdf:resource="#Catalysis140" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep277">
 <bp:stepProcess rdf:resource="#Catalysis139" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction149" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep276">
 <bp:stepProcess rdf:resource="#Pathway129" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep275">
 <bp:stepProcess rdf:resource="#Pathway128" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep274">
 <bp:stepProcess rdf:resource="#BiochemicalReaction148" />
 <bp:stepProcess rdf:resource="#Catalysis138" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep273">
 <bp:stepProcess rdf:resource="#Pathway127" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep272">
 <bp:stepProcess rdf:resource="#Catalysis137" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction147" />
</bp:PathwayStep>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Evidence rdf:ID="Evidence255">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence256">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence253">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence254">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence259">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence257">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence258">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence230">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence228">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence229">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence222">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence223">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence220">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence221">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence226">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence227">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence224">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence225">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence240">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence241">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep293">
 <bp:stepProcess rdf:resource="#Catalysis147" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction158" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep292">
 <bp:stepProcess rdf:resource="#Pathway136" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep291">
 <bp:stepProcess rdf:resource="#BiochemicalReaction157" />
 <bp:stepProcess rdf:resource="#Catalysis146" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep290">
 <bp:stepProcess rdf:resource="#Pathway135" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence239">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep299">
 <bp:stepProcess rdf:resource="#Catalysis150" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep298">
 <bp:stepProcess rdf:resource="#Pathway139" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep297">
 <bp:stepProcess rdf:resource="#Catalysis149" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep296">
 <bp:stepProcess rdf:resource="#Pathway138" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep295">
 <bp:stepProcess rdf:resource="#Catalysis148" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep294">
 <bp:stepProcess rdf:resource="#Pathway137" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence233">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence234">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence231">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence232">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence237">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence238">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence235">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence236">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
 <bp:stepProcess rdf:resource="#Catalysis5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
 <bp:stepProcess rdf:resource="#Catalysis6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
 <bp:stepProcess rdf:resource="#Catalysis7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep246">
 <bp:stepProcess rdf:resource="#Pathway114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep245">
 <bp:stepProcess rdf:resource="#Pathway113" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep244">
 <bp:stepProcess rdf:resource="#BiochemicalReaction133" />
 <bp:stepProcess rdf:resource="#Catalysis123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep243">
 <bp:stepProcess rdf:resource="#Catalysis122" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep242">
 <bp:stepProcess rdf:resource="#BiochemicalReaction131" />
 <bp:stepProcess rdf:resource="#Catalysis121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep241">
 <bp:stepProcess rdf:resource="#Pathway112" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep240">
 <bp:stepProcess rdf:resource="#Catalysis120" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction130" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#Catalysis8" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#Pathway20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#Catalysis9" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep249">
 <bp:stepProcess rdf:resource="#BiochemicalReaction135" />
 <bp:stepProcess rdf:resource="#Catalysis125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#Catalysis10" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep248">
 <bp:stepProcess rdf:resource="#Pathway115" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep247">
 <bp:stepProcess rdf:resource="#BiochemicalReaction134" />
 <bp:stepProcess rdf:resource="#Catalysis124" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction14" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep235">
 <bp:stepProcess rdf:resource="#Catalysis117" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction127" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction13" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep234">
 <bp:stepProcess rdf:resource="#BiochemicalReaction126" />
 <bp:stepProcess rdf:resource="#Catalysis116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep233">
 <bp:stepProcess rdf:resource="#Catalysis115" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep232">
 <bp:stepProcess rdf:resource="#BiochemicalReaction124" />
 <bp:stepProcess rdf:resource="#Catalysis114" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction10" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep231">
 <bp:stepProcess rdf:resource="#Pathway109" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction9" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep230">
 <bp:stepProcess rdf:resource="#BiochemicalReaction123" />
 <bp:stepProcess rdf:resource="#Catalysis113" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction12" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction11" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction3" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction8" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction5" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep239">
 <bp:stepProcess rdf:resource="#Pathway111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep238">
 <bp:stepProcess rdf:resource="#Catalysis119" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction129" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#Catalysis4" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep237">
 <bp:stepProcess rdf:resource="#BiochemicalReaction128" />
 <bp:stepProcess rdf:resource="#Catalysis118" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep236">
 <bp:stepProcess rdf:resource="#Pathway110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep260">
 <bp:stepProcess rdf:resource="#Pathway121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep268">
 <bp:stepProcess rdf:resource="#BiochemicalReaction145" />
 <bp:stepProcess rdf:resource="#Catalysis135" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep267">
 <bp:stepProcess rdf:resource="#Pathway124" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep266">
 <bp:stepProcess rdf:resource="#BiochemicalReaction144" />
 <bp:stepProcess rdf:resource="#Catalysis134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep265">
 <bp:stepProcess rdf:resource="#Pathway123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep264">
 <bp:stepProcess rdf:resource="#Catalysis133" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction143" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep263">
 <bp:stepProcess rdf:resource="#BiochemicalReaction142" />
 <bp:stepProcess rdf:resource="#Catalysis132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep262">
 <bp:stepProcess rdf:resource="#Pathway122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep261">
 <bp:stepProcess rdf:resource="#Catalysis131" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction141" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep269">
 <bp:stepProcess rdf:resource="#Pathway125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep257">
 <bp:stepProcess rdf:resource="#BiochemicalReaction139" />
 <bp:stepProcess rdf:resource="#Catalysis129" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep256">
 <bp:stepProcess rdf:resource="#Pathway119" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep255">
 <bp:stepProcess rdf:resource="#Catalysis128" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction138" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep254">
 <bp:stepProcess rdf:resource="#Pathway118" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep253">
 <bp:stepProcess rdf:resource="#BiochemicalReaction137" />
 <bp:stepProcess rdf:resource="#Catalysis127" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep252">
 <bp:stepProcess rdf:resource="#Pathway117" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep251">
 <bp:stepProcess rdf:resource="#Catalysis126" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction136" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep250">
 <bp:stepProcess rdf:resource="#Pathway116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep259">
 <bp:stepProcess rdf:resource="#BiochemicalReaction140" />
 <bp:stepProcess rdf:resource="#Catalysis130" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep258">
 <bp:stepProcess rdf:resource="#Pathway120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#Pathway32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep202">
 <bp:stepProcess rdf:resource="#BiochemicalReaction105" />
 <bp:stepProcess rdf:resource="#Catalysis95" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep201">
 <bp:stepProcess rdf:resource="#Pathway98" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep200">
 <bp:stepProcess rdf:resource="#Pathway97" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#Catalysis34" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#Catalysis35" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#Pathway33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#Catalysis36" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep209">
 <bp:stepProcess rdf:resource="#Catalysis100" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#Pathway34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep208">
 <bp:stepProcess rdf:resource="#Pathway100" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
 <bp:stepProcess rdf:resource="#Catalysis37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep207">
 <bp:stepProcess rdf:resource="#Catalysis99" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction109" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#Pathway35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep206">
 <bp:stepProcess rdf:resource="#Catalysis98" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction108" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#Pathway36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep205">
 <bp:stepProcess rdf:resource="#BiochemicalReaction107" />
 <bp:stepProcess rdf:resource="#Catalysis97" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
 <bp:stepProcess rdf:resource="#Catalysis38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep204">
 <bp:stepProcess rdf:resource="#Pathway99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#Pathway37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep203">
 <bp:stepProcess rdf:resource="#Catalysis96" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction106" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
 <bp:stepProcess rdf:resource="#Catalysis26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
 <bp:stepProcess rdf:resource="#Catalysis27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
 <bp:stepProcess rdf:resource="#Catalysis28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#Pathway29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
 <bp:stepProcess rdf:resource="#Catalysis29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#Catalysis30" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#Pathway30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
 <bp:stepProcess rdf:resource="#Catalysis31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#Pathway31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#Catalysis32" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#Catalysis33" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
 <bp:stepProcess rdf:resource="#Catalysis19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#Pathway25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
 <bp:stepProcess rdf:resource="#Catalysis20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep224">
 <bp:stepProcess rdf:resource="#BiochemicalReaction119" />
 <bp:stepProcess rdf:resource="#Catalysis109" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep223">
 <bp:stepProcess rdf:resource="#Pathway106" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep222">
 <bp:stepProcess rdf:resource="#Catalysis108" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction118" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep221">
 <bp:stepProcess rdf:resource="#Pathway105" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep220">
 <bp:stepProcess rdf:resource="#BiochemicalReaction117" />
 <bp:stepProcess rdf:resource="#Catalysis107" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#Catalysis21" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#Pathway26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#Catalysis22" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#Catalysis23" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep229">
 <bp:stepProcess rdf:resource="#Pathway108" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#Pathway27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep228">
 <bp:stepProcess rdf:resource="#BiochemicalReaction122" />
 <bp:stepProcess rdf:resource="#Catalysis112" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#Catalysis24" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep227">
 <bp:stepProcess rdf:resource="#Catalysis111" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#Catalysis25" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep226">
 <bp:stepProcess rdf:resource="#BiochemicalReaction120" />
 <bp:stepProcess rdf:resource="#Catalysis110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#Pathway28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep225">
 <bp:stepProcess rdf:resource="#Pathway107" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#Catalysis12" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#Catalysis13" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#Pathway21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#Catalysis14" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep213">
 <bp:stepProcess rdf:resource="#Pathway101" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep212">
 <bp:stepProcess rdf:resource="#BiochemicalReaction113" />
 <bp:stepProcess rdf:resource="#Catalysis103" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep211">
 <bp:stepProcess rdf:resource="#BiochemicalReaction112" />
 <bp:stepProcess rdf:resource="#Catalysis102" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep210">
 <bp:stepProcess rdf:resource="#BiochemicalReaction111" />
 <bp:stepProcess rdf:resource="#Catalysis101" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#Pathway22" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#Pathway23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep219">
 <bp:stepProcess rdf:resource="#Pathway104" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
 <bp:stepProcess rdf:resource="#Catalysis15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep218">
 <bp:stepProcess rdf:resource="#Catalysis106" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
 <bp:stepProcess rdf:resource="#Catalysis16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep217">
 <bp:stepProcess rdf:resource="#Pathway103" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
 <bp:stepProcess rdf:resource="#Catalysis17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep216">
 <bp:stepProcess rdf:resource="#BiochemicalReaction115" />
 <bp:stepProcess rdf:resource="#Catalysis105" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#Pathway24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep215">
 <bp:stepProcess rdf:resource="#Pathway102" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
 <bp:stepProcess rdf:resource="#Catalysis18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep214">
 <bp:stepProcess rdf:resource="#Catalysis104" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#Pathway42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#Catalysis45" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#Pathway43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#Catalysis46" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#Pathway44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#Catalysis47" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#Pathway45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#Pathway46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
 <bp:stepProcess rdf:resource="#Catalysis48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#Pathway47" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
 <bp:stepProcess rdf:resource="#Catalysis39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#Pathway38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
 <bp:stepProcess rdf:resource="#Catalysis40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#Catalysis41" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#Pathway39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
 <bp:stepProcess rdf:resource="#Catalysis42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#Pathway40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#Catalysis43" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#Pathway41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#Catalysis44" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence329">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence327">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence328">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence321">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence322">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence320">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence325">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence326">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence323">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence324">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence340">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence338">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence339">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence332">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence333">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence330">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence331">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence336">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence337">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence334">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence335">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction190">
 <bp:evidence rdf:resource="#Evidence354" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TCII does not bind Cbl in the circulation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction191">
 <bp:evidence rdf:resource="#Evidence356" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAB does not transfer adenosyl group from ATP to B12s</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence307">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction189">
 <bp:evidence rdf:resource="#Evidence352" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTR does not transfer CH3 group from MTHF to cob(I)alamin</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence308">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence305">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence306">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence309">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction181">
 <bp:evidence rdf:resource="#Evidence336" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26C1 does not 4-hydroxylate 9cRA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence300">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction182">
 <bp:evidence rdf:resource="#Evidence338" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACY1 does not hydrolyse mercapturic acids</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction183">
 <bp:evidence rdf:resource="#Evidence340" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GSS does not synthesize GSH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction184">
 <bp:evidence rdf:resource="#Evidence342" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP1B1 does not 4-hydroxylate EST17b</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence303">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction185">
 <bp:evidence rdf:resource="#Evidence344" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A1 does not transfer GlcA from UDP-GlcA to BMG</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence304">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction186">
 <bp:evidence rdf:resource="#Evidence345" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A1 does not transfer GlcA from UDP-GlcA to BIL</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence301">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction187">
 <bp:evidence rdf:resource="#Evidence349" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CD320 does not transport extracellular TCII:Cbl to endosome</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence302">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction188">
 <bp:evidence rdf:resource="#Evidence351" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTR does not transfer CH3 group from MeCbl to HCYS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence318">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence319">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence316">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence317">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence310">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction192">
 <bp:evidence rdf:resource="#Evidence358" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTRR does not convert cob(II)alamin to MeCbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence311">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction193">
 <bp:evidence rdf:resource="#Evidence360" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCD4:LMBRD1 does not transport Cbl from lysosomal lumen to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction194">
 <bp:evidence rdf:resource="#Evidence362" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AMN does not transport GIF:Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction195">
 <bp:evidence rdf:resource="#Evidence364" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CUBN does not transport GIF:Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence314">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction196">
 <bp:evidence rdf:resource="#Evidence366" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMADHC does not bind MMACHC:B12r</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence315">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction197">
 <bp:evidence rdf:resource="#Evidence368" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CBLIF does not bind Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence312">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction198">
 <bp:evidence rdf:resource="#Evidence370" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMACHC does not decyanate CNCbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence313">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction199">
 <bp:evidence rdf:resource="#Evidence371" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMACHC does not reduce Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction167">
 <bp:evidence rdf:resource="#Evidence310" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP21A2 does not 21-hydroxylate PROG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction168">
 <bp:evidence rdf:resource="#Evidence312" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35D1 does not transport UDP-GlcA, UDPGlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction169">
 <bp:evidence rdf:resource="#Evidence314" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 does not hydrolyse GSH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction160">
 <bp:evidence rdf:resource="#Evidence298" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26B1 does not 4-hydroxylate atRA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction161">
 <bp:evidence rdf:resource="#Evidence300" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27B1 does not hydroxylate CDL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction162">
 <bp:evidence rdf:resource="#Evidence302" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 does not oxidise 18HCORST</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction163">
 <bp:evidence rdf:resource="#Evidence303" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 does not oxidise CORST</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction164">
 <bp:evidence rdf:resource="#Evidence304" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 does not oxidise 11DCORST</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction165">
 <bp:evidence rdf:resource="#Evidence306" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP2U1 does not omega-hydroxylate ARA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction166">
 <bp:evidence rdf:resource="#Evidence308" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP24A1 does not 24-hydroxylate CALTOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction180">
 <bp:evidence rdf:resource="#Evidence334" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP4F22 does not 20-hydroxylate TrXA3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction178">
 <bp:evidence rdf:resource="#Evidence330" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPLAH does not hydrolyse OPRO</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction179">
 <bp:evidence rdf:resource="#Evidence332" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPMT does not transfer CH3 from AdoMet to 6MP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction170">
 <bp:evidence rdf:resource="#Evidence316" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B1 does not oxidise 11DCORT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction171">
 <bp:evidence rdf:resource="#Evidence318" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A4 does not transfer GlcA from UDP-GlcA to BIL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction172">
 <bp:evidence rdf:resource="#Evidence319" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A4 does not transfer GlcA from UDP-GlcA to BMG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction173">
 <bp:evidence rdf:resource="#Evidence321" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective FMO3 does not N-oxidise TMA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction174">
 <bp:evidence rdf:resource="#Evidence323" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AHCY does not hydrolyse AdoHcy</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction175">
 <bp:evidence rdf:resource="#Evidence325" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CYP27A1 does not 27-hydroxylate 5bCHOL3a,7a,12a-triol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction176">
 <bp:evidence rdf:resource="#Evidence326" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27A1 does not 27-hydroxylate 5&#946;-CHOL3&#945;,7&#945;,24(s)-triol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction177">
 <bp:evidence rdf:resource="#Evidence328" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GCLC does not ligate L-Glu to L-Cys</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction145">
 <bp:evidence rdf:resource="#Evidence269" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALE does not epimerise UDP-Gal to UDP-Glc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction146">
 <bp:evidence rdf:resource="#Evidence271" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM3 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction147">
 <bp:evidence rdf:resource="#Evidence273" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PGM1 does not isomerise G6P to G1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction148">
 <bp:evidence rdf:resource="#Evidence275" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GFPT1 does not transfer an amino group from L-Gln to F6P to form GlcN6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction149">
 <bp:evidence rdf:resource="#Evidence278" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 does not cleave 17aHPROG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction140">
 <bp:evidence rdf:resource="#Evidence260" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DHDDS does not elongate E,E-FPP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction141">
 <bp:evidence rdf:resource="#Evidence262" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALT does not transfer UMP to Gal1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction142">
 <bp:evidence rdf:resource="#Evidence264" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE does not phosphorylate ManNAc to ManNAc-6-P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction143">
 <bp:evidence rdf:resource="#Evidence265" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE does not hydrolyse UDP-GlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction144">
 <bp:evidence rdf:resource="#Evidence267" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALK1 does not phosphorylate Gal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction156">
 <bp:evidence rdf:resource="#Evidence290" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 does not hydrolyse glutamate from AFXBO-SG, AFNBO-SG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction157">
 <bp:evidence rdf:resource="#Evidence292" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TBXAS1 does not isomerise PGH2 to TXA2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction158">
 <bp:evidence rdf:resource="#Evidence294" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP7B1 does not 7-hydroxylate 25OH-CHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction159">
 <bp:evidence rdf:resource="#Evidence296" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAOA does not oxidatively deaminate 5HT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction150">
 <bp:evidence rdf:resource="#Evidence279" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 does not 17-hydroxylate P4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction151">
 <bp:evidence rdf:resource="#Evidence280" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 does not 17-hydroxylate PREG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction152">
 <bp:evidence rdf:resource="#Evidence282" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP19A1 does not convert ANDST to E1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction153">
 <bp:evidence rdf:resource="#Evidence284" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAT1A does not transfer Ado from ATP to L-Met</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction154">
 <bp:evidence rdf:resource="#Evidence286" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP2R1 does not 25-hydroxylate vitamin D</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction155">
 <bp:evidence rdf:resource="#Evidence288" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11A1 does not cleave 20a,22b-DHCHOL</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>